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ABSTRACT 
Hepatitis B virus (HBV) is a major pathogen that induces chronic hepatitis in 
approximately 400 million people worldwide frequently leading to liver cirrhosis and 
hepatocellular carcinoma. Woodchucks infected with woodchuck hepatitis virus 
(WHV) demonstrate virological and immunological profiles of infection and liver 
disease patterns highly comparable to those seen in human hepatitis B. Many 
attributes of HBV and the immune system interactions remain unknown, particularly 
how HBV persists and causes chronic liver disease. In the current studies, we 
investigated several aspects of the hepadnavirus-host immune system interaction 
and examined a role in these interactions of interferon gamma (IFNy), which is 
known to be a potent antiviral and immune system regulatory cytokine. The 
specific objectives of our studies were to: (1) clone and express woodchuck IFNy 
and tumor necrosis factor alpha (TNFa) in the baculovirus and Escherichia coli (E. 
coli) expression systems; (2) establish an in vitro model in which the effect of WHV 
genome expression on the hepatocyte surface presentation of the class I major 
histocompatibility complex (MHC) molecules can be investigated and, by using this 
system, to determine which WHV translation product interferes with the class I 
antigen display and whether this interference can be reversed by hepatocyte 
treatment with IFNy, and (3) investigate the modulator effect of IFNy on a DNA 
vaccine in preventing WHV infection. In the course of these studies, we have 
successfully produced biologically active recombinant woodchuck IFNy and TNFa. 
The data showed that the baculovirus-derived IFNy and TNFa had considerably 
II 
greater biological potency than the same cytokines produced in E. coli. In a 
subsequent study, we established an in vitro model to examine hepadnavirus 
interference with hepatocyte class I MHC expression. The results revealed that the 
class I antigen presentation was significantly inhibited on hepatocytes transcribing 
the complete WHV genome, similarly as it was previously reported by this 
laboratory for hepatocytes in chronic WHV hepatitis. WHV envelope preS2 protein 
was found to be responsible for the class I MHC antigen suppression, while 
transcription of WHV X gene significantly augmented the class I antigen display on 
the hepatocytes surface. This defect in class I MHC presentation may diminish the 
susceptibility of hepatocytes to virus-specific T cell-mediated elimination, hamper 
·"' 
hepadnavirus clearance, and contribute to the establishment of chronic hepatitis. 
Importantly, we also demonstrated that IFNy, a stimulator of class I MHC 
expression, can reverse this WHV-induced inhibitory effect and restore class I MHC 
presentation on hepatocytes, suggesting that the same could be true for 
hepatocytes in chronic hepadnaviral hepatitis. Further, our results demonstrated 
that DNA vaccination with combined WHV core gene and IFNy DNA provided 
significantly better protection against serologically evident WHV infection and 
hepatitis than WHV core DNA vaccine alone. However, our study revealed that 
protection against the virus is never complete. The data also showed that IFNy can 
serve as an adjuvant and can augment immune response against hepadnavirus, as 
well as possibly clear infection in a non-cytopathic manner. In summary, the results 
and the investigative tools generated should advance our understanding of the 
iii 
complexity of molecular interactions occurring between hepadnavirus, hepatocytes 
and the host immune system which govern development of HBV persistence and 
chronic hepatitis. They may also aid in the development of novel more effective 
therapies against HBV. 
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CHAPTER 1. INTRODUCTION 
1.1 Epidemiology of hepatitis 8 virus infection 
Viral hepatitis is a liver inflammatory disease caused by hepatotropic DNA 
or RNA viruses. The disease is characterized by intrahepatic 
lymphomononuclear cell infiltrations, hepatocellular injury, liver regeneration and 
it may, in consequence, compromise liver functions. There are at least six known 
hepatitis viruses, named from A to G which appear to primarily target the liver. 
Other viruses, such as Epstein-Barr virus, cytomegalovirus and yellow fever virus, 
can also induce hepatitis-like illness. Among these six main types of viruses 
causing hepatitis in humans, only the B, C and D viruses would lead to life long 
disease, i.e. chronic hepatitis (CH). 
It has been well recognized that hepatitis B is one of the most common 
and serious human infectious diseases worldwide, although the availability of 
protective vaccines, as well as the introduction of vigorous blood screening 
programs, have dramatically lowered the risk of hepatitis B virus (HBV) infection 
in the last two decades. Nevertheless, It is estimated that about 30% of the 
world population, or an estimated 1.8 billion people, have been exposed to HBV 
(Fact Sheet WH0/204, 2000). Among these people, approximately 350 million 
have serologically evident, i.e., HBV surface antigen (HBsAg)-positive, chronic 
infection and at least 1 million chronically infected persons die each year from 
HBV-associated cirrhosis, hepatocellular carcinoma (HCC) or liver failure (Block 
et a/., 2003). However, the geographical distribution of HBV infection varies 
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greatly across the world. In western countries, although HBV incidence in the 
general population is less than 1%, certain high-risk groups, such as drug 
abusers and sexually promiscuous persons, have higher rates of HBV infection 
(Hollinger and Liang, 2001 ). In endemic areas, such as Subsaharan Africa and 
South-East Asia, up to 10% of the population are serum HBsAg-positive chronic 
HBV carriers (Chisari and Ferrari, 1997). In these regions, the vertical 
transmission from mother to baby and close contact within a family are major 
routes of HBV transmission. In Canada, incidence of serologically diagnosable 
acute hepatitis 8 (AH) is calculated as 2.3 per 100 000 (Zhang et a/., 2001 a). 
Chronic HBV carriage rate in Canada varies due to heterogeneity of the 
population. It has been reported to be 6.9% in the lnnuit population (Baikie eta/., 
1989), 7.4% in immigrants from Asia and Africa (Delage et a/., 1 986), and 0.2-
0.5% in non-immigrants (Zhang eta/., 2001a). 
1.2 HBV structure and molecular organization 
HBV is a 42-nm diameter enveloped DNA virus, also known as Dane 
particle named after the discoverer of the complete virion by electron microscopy 
(Dane et a/., 1970). This virus has an envelope composed of three related 
surface proteins named as large (L), middle (M), and small (S) or major surface 
proteins. These surface proteins are inserted into a lipid bi-layer derived from the 
host cell. Inside the virion, the 21-nm diameter core is constituted by an 
icosahedral nucleocapsid containing a copy of the HBV genome, which occurs in 
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the form of partially double-stranded DNA molecule (Onodera et a/., 1982). In 
addition, the nucleocapsid contains HBV DNA polymerase which is attached to 
the HBV genome. In the circulation of HBV-infected individuals, there are large 
quantities of subviral spherical and filamentous particles, 22 nm in diameter, 
which are constituted by envelope proteins. The amount of these subviral 
particles is usually 1 00-fold greater than that of Dane particles and could be as 
high as 200 j..Jg/ml or more (Hollinger and Liang, 2001; Zoulim eta/., 1992). This 
large excess of virus envelope material carrying HBs antigenic reactivity can bind 
and exhaust antibodies directed against HBsAg (anti-HBs) which are considered 
to be able to neutralize the virus. 
1.2.1 Genome organization 
The HBV genome contains about 3.2 kilo-base pairs (Kb) of nucleotides 
forming a partially double-stranded circular form (see Figure 1.1 ). The minus-
strand DNA is a full size virus genome with the HBV DNA polymerase covalently 
linked to its 5'-end. The positive strand has a variable length and is always 
shorter than the negative strand. At the 5'-end of the positive strand, there is a 
capped short oligoribonucleotide which was generated during HBV genome 
replication. The circularity of HBV DNA is maintained by cohesive and 
complementary 5'-ends. The HBV genome has four overlapping open reading 
frames (ORF) encoding both structural proteins (core and envelope proteins) and 
non-structural proteins (viral DNA polymerase and X protein) (Figure 1.1 ). 
Figure 1.1. Schematic presentation of HBV and WHV genome structures. 
Partially double stranded DNA (black bold-line circles) which encodes viral 
proteins are shown as black arrows. The name, length, and corresponding 
nucleotide positions of each viral protein are marked. These viral proteins are 
translated from 4 viral mRNA transcripts (colored lines at outer circle) which were 
generated during viral replication by corresponding viral endogenous promoters 
presented as colored-filled eclipses. Other regulatory viral sequences such as 
enhancers (open color eclipse) and direct repeats (DR1 and DR2, purple 
rectangles) are presented in the diagram as well. All nucleotide positions are 
relative to the unique EcoRI site which was arbitrarily set as 1. 
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Besides the ORFs, the HBV genome also contains regulatory DNA sequences to 
control the transcription of viral RNAs. Four promoters (i.e., preC promoter, preS 
promoter, S promoter and X promoter) and two enhancers (enh1 and enh2) have 
been identified within HBV genome (Figure 1.1 ). In addition, a polyadenylation 
sequence located within the core gene provides the transcription termination 
signal. 
1.2.2 Proteins and their functions 
Depending on the size, the HBV transcripts can be divided into two 
classes: a genome-size transcript (3.5 Kb) and subgenomic transcripts (2.4, 2.1 
and 0.7 Kb). The subgenomic transcripts serve as mRNA templates for the 
translation of viral proteins including envelope proteins (L, M, S) and the X 
protein; whereas the genomic transcripts function not only as mRNA for the 
translation of pre-core (preC), core (C) and polymerase (Couillin eta/.), but also 
as the template for reverse transcription of the HBV minus-strand DNA. 
The three envelope proteins (L, M, S) are type II transmembrane proteins 
that share the same carboxy-terminus but have different amino-terminal 
extensions due to the different use of a within frame start codon. L protein is the 
largest envelope protein and is probably responsible for binding to the cellular, 
not yet identified, receptor/s. It also interacts with the nucleocapsid to facilitate 
the enveloping of the core particles and formation of virions (Bruss eta/., 1996a). 
The function of M protein is not clear and it seems dispensable for HBV. S 
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protein, the major component of both Dane particles and subviral, freely 
circulating envelope particles, is the smallest and also the most abundant 
envelope protein. Although both glycosylated and non-glycosylated enveloped 
proteins exist, HBV infectivity seems to be independent of glycosylation, but 
requires myristylation of L protein (Bruss eta/., 1996b ). 
Core protein is encoded by a 3.5-Kb genome size transcript. Its arginine-
rich domain, located at the carboxyl terminus, can bind to the negatively charged 
HBV nucleotides, whereas its amino-terminal domain can mediate assembly of 
the core particles. After forming the core particle, reverse transcription is initiated 
by the attached HBV polymerase using the 3.5-Kb genome size HBV RNA as the 
template. Using the same ORF but an upstream start codon, the preC can be 
translated into a protein. The protein, referred as HBV e antigen (HBeAg), is a 
form of the preC product protein which is truncated at both signal peptide, as well 
as the arginine-rich domain at the carboxyl terminal. HBeAg is secreted and may 
serve as a tolerogen to the host immune system and is dispensable for HBV 
replication and infection (Milich and Liang, 2003). Clinically, HBeAg has been 
used as a serological marker of actively progressing HBV infection. Clearance of 
HBeAg and the appearance of antibodies to HBeAg (anti-HBe) are considered to 
be an indicator of suppressed HBV replication (Milich and Liang, 2003). 
The largest protein of HBV is HBV DNA polymerase, which is encoded by 
the 3.5-Kb pregenomic RNA. It overlaps with C, S, and X ORFs. The HBV 
polymerase has three enzyme activities including: DNA-dependent DNA 
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polymerase, reverse transcriptase, and RNase H. Its amino-terminal domain can 
also serve as a protein primer for the initiation of reverse transcription of HBV 
negative strand DNA. Heat shock protein 90, a cellular chaperon molecule, is 
also believed to facilitate reverse transcription by mediating the formation of a 
ribonucleoprotein complex between HBV polymerase and an RNA ligand (Hu 
and Seeger, 1996). 
The HBV X is a multifunctional protein that can interact with transcriptional 
factors and tumor suppressor p53 protein, as well as influence a variety of signal 
transduction pathways (Elmore eta/., 1997). Not only viral genes, but also host 
genes can be regulated by the X protein. Recent evidence suggested that X may 
regulate HBV replication through targeting mitochondria calcium release 
(Bouchard et a/., 2001 ). In addition, it can activate proliferation and induce 
apoptosis of the infected cells (Gottlob eta/., 1998). The development of HCC 
due to chronic HBV infection is considered to be, at least to some degree, a 
consequence of the activity of X protein (Diao eta/., 2001; Wang eta/., 1990). 
The requirement of X for HBV replication is disputable due to the contradictory 
results reported by different groups, all using woodchucks infected with 
woodchuck hepatitis virus (WHV) as the animal model of hepatitis B (Zhang eta/., 
2001b; Zoulim eta/., 1994). 
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1.3 HBV replication cycle 
Although the liver is the site of the most active virus replication, HBV also 
propagates in the lymphatic system (Michalak, 2000). In the liver, the infectious 
Dane particles first bind to the yet unknown receptor on hepatocytes. 
Subsequently, HBV enters the cell and the nucleocapsid delivers virus-relaxed 
circular DNA (rcDNA) into the nucleus. Within the nucleus, the synthesis of HBV 
DNA positive strand is completed by the attached HBV polymerase using the 
genome-size HBV DNA minus-strand as the template. The gaps of both strands 
are then repaired, yielding a covalently closed circular double-stranded DNA, 
referred to as cccDNA. Using the RNA polymerase from the infected cell, four 
different lengths of HBV mRNA are transcribed from the HBV cccDNA template 
(as indicated in Section 1.2.2). These transcripts are then polyadenylated and 
transported into the cytoplasm. HBV proteins are translated from the respective 
viral transcripts as described in Section 1.2.2. Subsequently, the genome-size 
HBV RNA and the associated HBV DNA polymerase are packaged into the 
assembled virus nucleocapsids through the interaction between the core protein 
and the polymerase. The reverse transcription of the negative strand HBV DNA 
starts within the capsid and leads to the synthesis of the less than full-length 
positive DNA strand. The mature capsid can follow two intracellular pathways. 
One pathway leads to assembly of Dane particles, which bud into the lumen of 
the endoplasmic reticulum (ER) and are then secreted from the cell through the 
Golgi complex. In another pathway, matured HBV capsids can re-enter the 
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nucleus and initiate a new round of virion replication without superinfecting the 
cell (Seeger and Mason, 2000). 
1.4 Natural history of HBV infection 
The course and symptoms of H8V infection can be extremely variable. It 
depends on the age of the host at the time of infection, the dose of virus at its 
entry, as well as the status of the host's immune system. Clinically, liver disease 
caused by HBV infection can be divided into several categories: acute hepatitis 
(AH), fulminant hepatitis, CH and a "healthy" serum HBsAg-positive chronic 
carrier state (Hollinger and Liang, 2001). In addition, subclinical, serologically 
evident H8V infection and occult, asymptomatic, serological undetectable 
infections are also recognized (Michalak et a/., 2004). 
The incubation time of hepatitis 8 is between 6 to 24 weeks (wks). There 
are no specific symptoms in this period other than fatigue, nausea, anorexia and 
slight fever. Some patients may develop jaundice and some may not feel any 
obvious unwellness. The diagnosis is based on the detection of H8V-specific 
serological markers, such as HBsAg, HBeAg, antibodies to hepatitis 8 core (anti-
H8c), and molecular markers, i.e. H8V DNA. Also, biochemical indicators of liver 
injury are tested, such as elevated levels of serum aspartate aminotransferase 
(AST), alanine aminotransferase (AL T) and bilirubin. 
Approximately 1% of acute H8V infections will progress to a usually fatal, 
severe (fulminant) hepatitis. This form is due to the massive, rapid destruction of 
11 
hepatocytes and loss of liver function, and is characterized by the development 
of hepatic encephalopathy associated with coma. 
Usually, more than 90% of adult patients with AH type B will recover from 
the disease and become serum-negative for HBsAg. However, 5-10% of the 
acutely infected patients progress to CH. This form of hepatitis is diagnosed 
when serum HBsAg-positive infection lasts more than 6 months (mo). In contrast 
to HBV infection in adults, more than 90% of neonatally acquired HBV infection 
will result in CH with mild symptoms or in asympomatic HBV carriage (Hollinger 
and Liang, 2001 ). In general, the frequency of clinically evident acute disease 
increases, whereas the percentage of chronic HBV carriers decreases with age 
at infection. 
There is a clear correlation between chronic HBV infection and the 
development of HCC. The risk of developing HCC is almost 1 00-times greater in 
chronic HBV carriers than in uninfected individuals (Beasley eta/., 1981). The 
persistence of liver inflammation and continued hepatocyte regeneration may 
induce the malignant transformation of hepatocytes. Also, the postulated 
oncogenic potential of HBV X protein may contribute to HCC development 
through either modulating cells' susceptibility to apoptosis or inducing 
uncontrolled cell growth (Chirillo eta/., 1997; Gottlob eta/., 1998). Integration of 
HBV genome or its fragments into the host hepatocyte genome could be another 
important factor for the increased incidence of HCC. This integration may either 
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disrupt the function of cell cycle regulatory proteins or activate pre-oncogenes, 
such as N-myc2 oncogene (Bruni et a/., 1 999). 
HBV can also induce extrahepatic disorders through the deposition of the 
immune complexes of viral antigens and their specific antibodies. The 
pathogenic role of HBsAg-anti-HBs immune complexes has been documented in 
glomerulonephritis, polyarteritis nodosa, acute vasculitis and arthritis (Gocke, 
1975; Michalak, 1978; Michalak eta/., 1976; Slusarczyk eta/., 1980). 
1.5 Hepadnavirus family 
HBV is the prototypic virus of the hepadnavirus family. This family is 
divided into two genera: Orthohepadnaviridae (mammalian viruses) and 
Avihepadnaviridae (avian viruses). Key members of the mammalian genus are 
HBV, WHV (Summers eta/., 1978), and ground squirrel hepatitis virus (GSHV) 
(Marion et a/., 1 980). The best characterized member of the avian 
hepadnaviruses is the duck hepatitis B virus (DHBV) (Mason et a/., 1 980). The 
following common features are shared by viruses belonging to this family: (1) 
Similar genome organization, viral RNA transcripts, and replication strategy; (2) 
Enveloped virions contain 3-3.3 Kb partially double-stranded rcDNA; (3) Virion 
contains a viral DNA polymerase which is able to repair the DNA gap; (4) Large 
amounts of circulating genome-free lipoprotein particles constituted by viral 
envelope proteins; (5) Narrow host range; (6) Frequently occurring life-long 
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persistent infection, and (7) Induction of similar courses of infection and 
pathological forms of virus-induced liver disease (Tiollais et a/., 1985). 
However, mammalian and avian hepadnaviruses also display important 
differences. The avian hepadnavirus genome does not contain the X gene and it 
encodes two instead of three envelope proteins (pre-S and S). Furthermore, liver 
disease induced by avian hepadnaviruses seemingly does not progress to HCC 
(Cava eta/., 1993). 
1.6 Animal models of HBV infection 
1.6.1 Woodchuck hepatitis model 
WHV was the first non-human hepadnavirus that was identified. It was 
originally discovered in a woodchuck colony at the Philadelphia Zoological 
Garden (Summers et a/., 1978). WHV is morphologically indistinguishable from 
HBV. Viral genome analysis indicates overall more than 60% homology in 
nucleotide seque[lce between HBV and WHV (Galibert eta/., 1982). Among all 
the members of the hepadnavirus family, infection of woodchucks with WHV is 
accepted as the most suitable model to study HBV pathobiology. This is based 
on the fact that WHV and HBV share significant similarities with regards to 
ultrastructure, genomic organization, antigenic cross-reactivity of gene translation 
products, range of targeted organs (liver and lymphatic system), course of 
infection, the immunovirological and pathological features of the virus-induced 
liver disease, and the development of HCC (Michalak, 1998a). 
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Like HBV infection in humans, persistent WHV infection is common in 
some woodchuck populations, where it is frequently associated with CH and 
development of HCC. Similar to HBV, neonatal WHV infection causes serum 
WHsAg-positive infection in >90% of animals, while the same form of the 
infection is observed only in 5-10% of adult woodchucks. Vertical transmission of 
WHV from mother to babies has also been verified with the woodchuck model 
(Coffin and Michalak, 1999). 
Woodchucks chronically infected with WHV have been extensively used 
for pre-clinical evaluations of antiviral drugs. The woodchuck model also 
provides valuable pharmacodynamic and pharmacokinetic information on novel 
anti-HBV agents before clinical trials. Toxicity and hepatic injuries have been 
shown in woodchucks treated with certain test antiviral nucleotide analogues to 
be similar to those observed in treated humans (Korba et a/., 2000; Le Guerhier 
eta/., 2001). In summary, using the woodchuck-WHV model it is possible to 
study almost any aspect of the pathogenesis of HBV infection, anti-HBV 
therapeutic and preventive strategies. 
1.6.2 Other natural models 
Due to the narrow host range, chimpanzees and some higher primates are 
the only animals able to be infected with HBV. However, the chimpanzee is an 
endangered species and its availability, cost, and breeding are the major 
obstacles in laboratory usage. Certain strains of ducks, such as Peking ducks, 
15 
are susceptible to DHBV. Although DHBV lacks the X gene and it encodes only 
two surface proteins (as mentioned in Section 1.5), the ability of DHBV to 
propagate in primary duck hepatocyte cultures significantly contributed to the 
recognition of the replication cycle of hepadnaviruses. Also, these animals are 
easy and inexpensive to breed. Viral hepatitis can be induced after inoculation 
with DHBV, but it remains inconclusive whether chronic DHBV infection is 
associated with HCC development. Extrahepatic DHBV replication, such as in 
the lymphatic system and pancreas, has also been documented (Hosoda eta/., 
1990; Walter eta/., 1991). However, the avian immune system considerably 
differs from the mammalian counterparts. Therefore, ducks infected with DHBV 
are not being frequently used as a model to study the immunopathogenesis of 
HBV. 
Advances in molecular biology led to the discovery of new members of the 
Hepadnaviridae family. They have been found in a variety of animals, such as 
Beechey ground squirrels (Ganem eta/., 1982), arctic ground squirrels (Tennant 
eta/., 1991), wild herons (Sprengel eta/., 1988), tree squirrels (Feitelson eta/., 
1986), wild and domestic geese, marsupials, orangutans (Marion et a/., 1987), 
and woolly monkeys (Lanford et a/., 1998). So far, no detailed immunological or 
molecular studies have been carried out using these species. 
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1.6.3 HBV transgenic mice 
Because of the absence of an inbred animal model susceptible to HBV 
infection, and the inability of HBV to efficiently propagate in in vitro culture 
systems, a number of researchers have generated transgenic mice that express 
a single virus gene or the complete genome of HBV. The well characterized 
mouse immune system, homogenous genetic background, low cost, as well as 
the availability of commercial reagents and assays facilitate effective usage of 
HBV transgenic mouse models (Chisari and Ferrari, 1995). 
One of the first HBV transgenic mice expressing the HBV envelope 
proteins was created using constructs containing liver-specific promoters or the 
endogenous virus promoters (Babinet eta/., 1985; Burk eta/., 1988; Chisari eta/., 
1985). It has been demonstrated that the liver, as well as other organs (i.e., 
kidney) are the place of HBV envelope protein production driven by an 
endogenous viral promoter (Deloia et a/., 1989). In the case when the L 
envelope protein expression was controlled by the exogenous albumin promoter, 
the intracellular accumulation of HBsAg has been found within hepatocytes. This 
defect in secretion resulted in the expansion of ER and induction of hepatocyte 
injury, which is similar to 'ground glass' hepatocytes observed in patients 
chronically infected with HBV (Chisari eta/., 1987). Moreover, adoptive transfer 
of HBsAg-specific, cloned CDS+ cytotoxic T lymphocytes (CTL) induced an acute 
necroinflammatory liver disease in these mice, similar to that occurring in HBV 
infection in humans (An do et a/., 1994; Moriyama et a/., 1990). A three-step 
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process has been proposed to cause liver damage due to this adoptive transfer. 
The first step supposedly involves the flush of HBsAg-specific CTL into the liver, 
whereby apoptosis of hepatocytes expressing envelope protein is induced by 
direct contact with transferred CTL. The second step occurs between 4 and 12 h 
after CTL injection. The CTL recruit host non-specific inflammatory cells to the 
liver and these cells amplify the effects of CTL. An extensive necrosis of liver 
parenchyma beyond the site of CTL infiltration has been observed, suggesting 
that hepatocytes are killed by host-derived inflammatory cells other than CTL. 
The third step, histologically comparable to fulminant hepatitis in human, 
happened within 24-72 h of CTL transfer to half of the transgenic mice with a 
high-level HBsAg display in hepatocytes. At this stage, liver failure causes death 
of the host, which is marked by diffuse infiltration of inflammatory cells, massive 
destruction of liver structure, and hyperplasia of Kupffer cells (An do et a/., 1994; 
Ando eta/., 1993; Moriyama eta/., 1990). 
HBV nucleocapsid protein and HBeAg have also been successfully 
expressed in transgenic mice. HBcAg was accumulated in the nucleus and 
HBeAg was found in the circulation (Milich et a/., 1994; Reifenberg et a/., 1997; 
Takashima et a/., 1992). Adoptive transfer of HBe/HBcAg-specific CD4+ T 
helper (Th) cells has been shown to induce liver injury in mice expressing 
HBe/HBcAg (Chen eta/., 2000). It has also been demonstrated that HBeAg is 
able to pass through the placenta and that in utero exposure to HBeAg can lead 
to T cell tolerance to HBe/HBcAg in the neonates (Milich eta/., 1990). It appears 
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that the circulating HBeAg can also modify the host immune response by 
depletion of HBeAg-specific Th1 cells, but not HBeAg-specific Th2 population, 
through a Fas-mediated mechanism (Milich eta/., 1998). 
The nonstructural HBV X protein has also been expressed in transgenic 
mice (Koike et a/., 1994; Lee et a/., 1990). Because of its transactivation 
property, it has been suggested that expression of X protein might induce HCC. 
In support of this hypothesis, two groups have shown the development of HCC in 
some strains of X gene transgenic mice (Kim eta/., 1991; Koike eta/., 1994). 
However, other investigators have not observed this association in independently 
derived X transgenic mice (Lee eta/., 1990). 
Several groups have expressed the entire HBV genome in the mice under 
the control of endogenous viral promoters (Araki eta/., 1989; Burk eta/., 1988; 
Chao eta/., 1991; Farza eta/., 1988; Guidotti eta/., 1995). Similar to CH in 
humans, large amounts of HBV virions were found in the circulation of these 
mice. Liver, as well as kidney, were the sites of production of the engineered 
viral particles (Araki eta/., 1989; Burk eta/., 1988; Chao eta/., 1991; Farza eta/., 
1988; Guidotti eta/., 1995). However, HBV cccDNA, the replication form of HBV 
genome, was not found in these mice. Furthermore, the high-level HBV 
production is not associated with liver pathology. On the other hand, one group 
has successfully infected chimpanzees with viral particles derived from HBV 
transgenic mice (Heise et a/., 1999), proving their biological competency. By 
using the HBV transgenic mouse models, a number of factors, such as HBV-
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specific CTL (Guidotti eta/., 1996b), cytokines (Gilles eta/., 1992; Guidotti eta/., 
1994a; Guidotti eta/., 1994b), and co-infection with lymphocytic choriomeningitis 
virus (LCMV) (Guidotti et a/., 1996a), have been shown to inhibit HBV replication 
in these mice. Based on these studies, several mechanisms of HBV elimination 
from the infected liver have been proposed. The potential mechanisms include 
elimination of HBV nucleocapsid particles in the cytoplasm of infected cells and 
post-transcriptional degradation of cytoplasmic HBV mRNA (Guilhot eta/., 1993; 
Heise eta/., 1999). 
HBV transgenic mice provided a significant amount of data regarding HBV 
biology, host immune responses against HBV proteins, and HBV oncogenic 
potential. However, there are also numerous limitations of this model. First, this 
is not an infective model of HBV-induced liver disease and transgenic mice 
support only HBV replication and virus assembly, but not the pre-transcription 
stages of the virus infection. Second, the replication scheme of HBV in 
transgenic mice is different from that occurring in nature where episomal HBV 
genome, but not the integrated HBV genome, is the main template. Third, HBV 
cccDNA is absent. Fourth, the HBV nucleocapsids assembled within the mouse 
hepatocytes were unable to re-enter into the nucleus. Fifth, the virus is not able 
to spread through re-infection of hepatocytes. Recenly, the development of 
chimeric mice transplanted with human liver provide a new tool to study HBV in 
mice (Mercer eta/., 2001; Petersen eta/., 2004). 
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1.7 Cell cultures for hepadnaviral propagation 
One of the obstacles to study HBV is the lack of an in vitro cell culture 
system able to support efficient propagation of HBV. So far, using primary 
hepatocytes as targets, de novo hepadnavirus infection has been successful only 
in duck primary hepatocytes (Tuttleman et a/., 1986b). It was estimated that 
around 10% of primary duck hepatocytes are usually being infected. DHBV 
cccDNA and single-strand DHBV DNA were detected in these cells. Newly 
synthesized viral structural antigens were also identified in the infected duck 
hepatocytes. Interestingly, the susceptibility window for in vitro DHBV infection 
was only within 4 days after isolation of hepatocytes. Nevertheless, with the help 
of this cell culture system, it was found that hepadnaviral cccDNA is amplified 
within the infected hepatocytes from rcDNA prior to virion assembly (Tuttleman et 
a/., 1986a). Therefore, amplification of virus does not require the newly produced 
virions to re-infect liver cells or integration of virus DNA into the host genome. 
Although no conclusion regarding the receptors for HBV has been drawn, several 
candidate receptors for DHBV have been identified (reviewed in Chisari, 2000). 
Establishment of equivalent culture systems for the propagation of other 
mammalian hepadnaviruses has proven to be much more difficult. This is mainly 
because of difficulties in maintaining differentiated mammalian hepatocytes in 
culture. In general, using primary human hepatocytes and infectious HBV 
inocula derived from chronically infected patients, only very limited propagation of 
HBV has been documented in some studies (Gripon eta/., 1988; Rumin eta/., 
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1996). It has been shown that chemical agents, such as dimethyl sulfoxide 
(DMSO) (Gripon eta/., 1988; Paran eta/., 2001; Rumin et a/., 1996) and a 
mixture of DMSO and polyethylene glycol (PEG) (Gripon et a/., 1993) can 
enhance HBV synthesis in cultured primary human hepatocytes. However, the 
underlying mechanisms for DMSO treatment are not clear. 
Due to the difficulties in obtaining primary human hepatocytes, the human 
hepatoma HepG2 cells have been widely used as a HBV infection target. It has 
been demonstrated that this cell line is susceptible, to some degree, to infection 
with serum-derived HBV (Bchini et a/., 1990). These cells were kept for several 
months after inoculation with HBV and were able to express low levels of HBV 
cccDNA and mRNA, as well as HBsAg. Furthermore, complete viral particles 
containing HBV DNA and DNA polymerase activity were secreted. By infecting 
HepG2 cells with serum-derived HBV, a cell line, which secretes a high level of 
HBsAg due to the integration of HBV genome into the HepG2 chromosome, was 
derived (Mabit eta/., 1994). Recently, a human hepatocyte cell line HepaRG has 
been generated. It has been shown that these cells after treatment with 
hydrocortisone and DMSO become susceptible to HBV infection (Gripon eta/., 
2002). 
With advances in molecular biology techniques, cloned HBV sequences 
have been introduced into HepG2 and Huh7 human hepatocarcinoma cell lines. 
Various constructs containing more than full-length HBV genome have been 
transfected into these cells (Bouchard eta/., 2001). This led to the release of 
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Dane-like particles in the culture medium (Chang eta/., 1987; Sureau eta/., 1986; 
Yaginuma eta/., 1987). Besides HBV virions, HBV replicative intermediates, as 
well as viral proteins were detected in these cell culture systems. This suggests 
that human hepatoma cells transfected with more than full-length HBV genomes 
are able to support replication of HBV in spite of low susceptibility to infection 
with serum-derived HBV particles. In the latter situation, poor binding or entry of 
HBV into the hepatoma cells could be a possible explanation. 
Similar to HBV, WHV and GSHV were found to infect, with limited success, 
primary woodchuck hepatocytes (Aldrich et a/., 1989). In our laboratory, the 
WCM-260 woodchuck hepatocyte cell line derived from a healthy animal was 
established a few years ago (Diao eta/., 1998). These cells have been shown to 
be susceptible to infection with both serum and lymphoid cell-derived WHV 
inocula (Lew and Michalak, 2001 ). Expression of WHsAg and WHcAg has been 
detected in in vitro infected WCM-260 cells by flow cytometry. The presence of 
WHV cccDNA was also identified beginning from 3 days post infection. WHV 
serially transmitted by de novo infection in WCM-260 hepatocytes proved to be 
infectious to healthy woodchucks and able to induce classical acute hepatitis 
(Lew and Michalak, 2001). These data clearly documented that WCM-260 
hepatocytes can support the complete cycle of replication of biologically 
competent WHV. 
Cell culture systems capable of supporting replication of HBV or other 
hepadnaviruses would provide a simple model to examine virus-target cell 
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interactions without involvement of other cell types or soluble factors, as it 
happens in vivo. By studying HBV in cell cultures, the replication strategy of HBV 
and identification of potential receptors could eventually be achieved. 
Furthermore, the cell culture system may provide useful information regarding 
mechanisms of antiviral function of cytokines, as well as help in evaluating and 
screening of new antiviral agents (Deres eta/., 2003; Lu eta/., 2002; Pasquetto 
eta/., 2002; Suri eta/., 2001). 
However, the common shortfall of all current in vitro infection systems is a 
relatively low level of virus propagation. As a consequence, the use of highly 
sensitive detection methods to assess virus presence and its replication status is 
required. 
1.8 Host immune responses against HBV infection. 
It is generally accepted that HBV is essentially not cytopathic to the 
infected liver cells (Chisari and Ferrari, 1995; Lee, 1997). In fact, the immune 
responses mounted against HBV antigens are mainly responsible for the liver 
damage as well as the virus clearance. There are two major types of immune 
activities against any microbial infection, referred to as innate immunity and 
adaptive immunity. Within the innate immune response, which is the first line of 
host defense against pathogens, both cellular and soluble factors are involved. 
Cellular constituents of this system include: monocytes, macrophages, dendritic 
cells (DC), natural killer cells (NK), natural killer T cells (NK T), and 
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polymorphonuclear cells. Activation of these cells can lead to the production of 
anti-viral cytokines which may directly inhibit viral replication, i.e., interferon alp 
(IFNa/p), interferon y (IFNy), and tumor necrosis factor a (TNFa). Furthermore, 
secretion of chemokines by these cells contributes to the recruiting of 
inflammatory cells to the site of infection. More importantly, the processing and 
presentation of viral antigens by macrophages and DCs are key steps in the 
activation of the host's adaptive immunity (Bohm et a/., 1995; Freigang et a/., 
2005). 
Adaptive immunity involves two types of specific responses, humoral 
response, which normally targets extracellular pathogens, and cellular immune 
response, which deals with intracellular infections. Pathogen-specific cellular 
immunity is mediated by two main groups of effector cells: CD4+ T helper cells, 
which provide help to B lymphocytes and to other immune effector cells, and 
CDS+ CTL, whose main function is elimination of infected cells. In many 
infections with noncytopathic viruses, the clinical symptoms are a result of the 
host's immune responses against virally infected cells and the subsequent 
destruction of these cells. 
1.8.1 Antibody responses 
Antibodies to HBsAg (anti-HBs) are considered to be virus neutralizing 
and their generation is a T cell-dependent process (Milich and Mclachlan, 1986). 
It is presumed that these antibodies are able to inhibit the attachment and entry 
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of HBV to target cells, and to facilitate removal of the virus by macrophages. 
Induction of anti-HBs alone due to prophylactic vaccination, using either serum-
derived HBsAg or yeast-produced recombinant HBsAg, is normally sufficient to 
protect the host from HBV infection (Stephenne, 1 988). Also, the recovery from 
acute HBV infection is usually accompanied by the seroconversion from HBsAg 
to anti-HBs. 
Unlike antibodies to HBsAg, antibodies against HBV core antigen, i.e., 
anti-HBc, have been normally explored as a diagnostic marker of progressing or 
past HBV infection. The presence of a high titer anti-HBc of lgM class can be 
used to distinguish between a recent onset of HBV infection and chronic HBV 
infection. However, in some patients with CH, lgM anti-HBc is detectable due to 
reactivation of HBV infection (Hollinger and Liang, 2001 ). 
On the other hand, there is substantial experimental evidence indicating 
that induction of anti-core antibodies is associated with protection against 
hepadnavirus infection (see Chapter 6). In this regard, it was reported that 
immunization of two chimpanzees with liver-derived or recombinant HBcAg led to 
the generation of anti-HBc and protection of the animals from HBV infection 
(!warson et a/., 1985). In the same study, a third chimpanzee which was 
immunized with liver-derived HBcAg developed hepatitis following HBV challenge. 
A similar observation was reported in the woodchuck model of hepatitis B 
(Schodel et a/., 1 993). Thus, it has been shown that woodchucks immunized 
with recombinant WHcAg produced anti-core antibodies and were apparently not 
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susceptible to infection after challenge with an infectious WHV dose (Schadel et 
a/., 1993). In the same study, when woodchucks were immunized with HBcAg, 4 
out of 6 woodchucks were protected from challenge with WHV. Since the elicited 
anti-HBc antibodies showed little cross-reactivity with WHcAg, it was 
hypothesized that the T cell responses, rather than anti-HBc antibodies, were 
playing a pivotal role in the protection of the woodchucks immunized with HBcAg 
(Schadel eta/., 1993). However, in the above studies, the presence of virus post 
challenge was not examined by sensitive detection techniques, making the 
conclusions less convincing. Therefore, it is not clear whether such an 
immunization strategy in fact is capable of rendering a sterile immunity against 
the virus, i.e., completely protect the host from viral infection. If this would be the 
case, there is also the question whether protective immunity induced by 
immunization with hepadnavirus core antigen can be enhanced. 
The anti-HBe has also been routinely monitored in clinical situations. 
Similar to anti-HBc, the anti-viral and pathogenic significance is not clear. 
Induction of anti-HBe alone does not protect from HBV infection (Milich and Liang, 
2003). However, the seroconversion from HBeAg to the anti-HBe-positive status 
has been associated with a decrease in activity of HBV replication and a milder 
progression of liver disease (Maruyama eta/., 1993). 
Although it has been reported that antibodies to the carboxyl-end of HBV 
polymerase, especially the RNaseH domain, can be used as an indicator of HBV 
infection (Weimer et a/., 1989), little is known about biological significance of 
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these antibodies. The origin of these antibodies is unknown and they are not 
tested in clinical situations. 
1.8.2 Cellular responses 
1.8.2.1 Innate responses 
The first line of immune defense is innate immunity, which provides rapid, 
non-specific protection against a variety of pathogens without establishing long-
term memory. This innate immunity not only renders the host immediate 
protection but also initiates the development of pathogen-specific, adaptive 
immune responses. As mentioned at the beginning of Section 1.8, the cells 
maintaining the innate response include monocytes/macrophages, DC, NK, NK T 
and polymorphonuclear cells (reviewed by Basset eta/., 2003). 
Macrophages can eliminate pathogenic invaders by phagocytosis before 
they can spread, and stimulate adaptive immune responses. After activation of 
these cells, cytokines, such as interleukin-1 ~ (IL-1 ~). TN Fa, IFNy and 
chemokines are released into the environment. The recruitment of other 
inflammatory cells, such as neutrophils, can also contribute to elimination of 
pathogens, as well as to the local tissue damage via oxidative and non-oxidative 
stress mechanisms (Burg and Fillinger, 2001 ). Interestingly, when neutrophils 
were depleted in the HBV transgenic mice before the adoptive transfer of HBV-
specific CTL, the degree of liver damage was significantly reduced, although the 
anti-viral effect of CTL was not influenced (Sitia et a/., 2002). Recently, it was 
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found that the activation of toll-like receptors is able to initiate IFNa/~-mediated 
suppression of HBV in transgenic mice (lsogawa eta/., 2005). 
DCs arise from the bone marrow and are widely distributed in both 
lymphoid and non-lymphoid tissues. They guard the sites against pathogen entry 
and are able to capture and process invading microbes. Upon recognition and 
appropriate activation, which includes processing and loading of peptides into 
major histocompatibilty complex (MHC) molecules, up-regulating co-stimulatory 
molecules, and secreting of cytokines, DC maturation is triggered. The cells 
migrate to lymphoid organs where they stimulate a primary or memory immune 
response. Interference with DC antigen presenting may, therefore, benefit virus 
by inhibiting induction of anti-viral immunity. It has been reported that HBV can 
inhibit function of monocyte-derived DCs by compromising antigen presentation 
and by reducing the production of Th1 cytokines (Beckebaum eta/., 2003). In 
addition, DC derived from patients with CH type B showed impaired abilities to 
stimulate HBV-specific T cells compared to DCs from patients who resolved AH 
and to those from healthy individuals (Lohr eta/., 2002). Addition of IL-12 was 
able to restore function of DCs derived from patients chronically infected with 
HBV (Lohr et a/., 2002). Furthermore, activation of intrahepatic antigen 
presenting cells (APCs), which may include DC, by injection of anti-CD40 
antibodies has been shown to inhibit HBV replication in HBV transgenic mice 
(Kimura eta/., 2002a). This effect is mediated by IL-12 and TNFa produced by 
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activated APCs and by NK cells secreting IFNy. The NK cells are triggered by 
IL-12 which is secreted by activated APCs (Kimura eta/., 2002a). 
NK cells are derived from the lymphoid cell precursors residing in the bone 
marrow (Biron eta/., 1996). Unlike T cells, NK cells lack antigen specificity and 
they do not have immunological memory. They contain perforin and granzymes, 
which are released following cell to cell contact, and are able to kill virally 
infected cells or tumor cells (Biron eta/., 1999). Their rapid response (0-5 days) 
after infection with pathogenic micro-organisms provides immediate protection 
before the induction of an adaptive immune response (reviewed by Biron eta/., 
1996). The function of NK cells is determined by the balance between their 
activation and inhibition signals transduced through NK cell surface receptors. 
These receptors include CD94/NKG2 heterodimers, NKG20, Ly49H, NKp30, 
NKp44, NKp46 and CD16, which belong to two distinct receptor categories, killer 
lg-like receptors (KIR) and lectin-like receptors (reviewed by Mandelboim and 
Porgador, 2001 ). Although the natural ligands for the activation of these 
receptors are not well recognized, it has been shown that NKp46 is able to bind 
hemagglutinin of influenza virus and hemagglutinin-neuraminidase of 
parainfluenza virus and render resistance to these viruses (Mandelboim et a/., 
2001 ). In addition to a direct stimulation through the activation receptors, NK 
cells can be activated during the initial stages of viral infection by cytokines and 
chemokines. For example, IFNa/p, IL-12, IL-15 and IL-18, produced by viral 
infected cells or by macrophages and OCs, can stimulate NK cells to secrete 
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IFNy, TNFa and macrophage inflammatory protein (MIP) (reviewed by Biron et 
a/., 1999). Therefore, NK cells can control the virus infection both in a non-
cytopathic manner and by killing virus-infected cells. 
It has been suggested that cytokines secreted by NK cells (i.e., IFNy and 
TNFa) might inhibit HBV replication through a non-cytopathic mechanism 
(Kimura et a/., 2002a), which possibly involves disruption of assembly of virial 
nucleocapsid (Biermer eta/., 2003). However, the exact mechanism by which 
NK cells may control HBV infection is still not clear. HBV constituents that 
potentially activate NK cells have not yet been identified. 
NK T cells are a sub-population ofT cells expressing T cell receptor (TCR) 
a~ that share some characteristics with NK cells (Bendelac eta/., 1997). They 
are CD4-positive or CD4/8-negative cells which possess some surface receptors 
(i.e., NK1.1 and Ly49A) found on NK cells. They have a restricted TCR 
repertoire, which use Va14Ja28.1 and V~8 in mice. TCR of NK T cells can 
interact with glycolipids presented in the context of non-polymorphic class I MHC 
molecules which are composed of CD1d and beta-2-microglobulin (~2M) 
(reviewed by Bendelac et a/., 1997). In mice, NK T cells can be detected 
wherever conventional T cells are found, although the ratio of NK T to T cells 
varies widely in a tissue-specific manner, i.e., 30-50% of mature T cells in liver, 
20-30% in bone marrow, and 10-20% in thymus are NK T cells (Bendelac eta/., 
1997). In other tissues and organs, they represent a smaller percentage of T 
cells, such as in spleen (3%) and blood (4%) (Eberl et a/., 1999). Without 
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knowing the natural ligands which activate NK T cells, it has been found that a-
galactosylceramide, derived from a marine sponge, binds CD1d and strongly 
stimulates both CD4+ and CD4- NK T cells (Kawano et a/., 1997). Once 
activated, NK T cells can produce a high level of immunoregulatory cytokines, 
such as IL-4, IFNy and TNFa. In addition to the cytokine production, NK T cells 
can exhibit a potent lytic activity against CD4/CD8-double positive thymocytes 
through Fasl-Fas pathway (Arase eta/., 1994) or kill tumor cells in a perforin-
dependent manner (Smyth eta/., 2000). 
Regarding a role of NK T cells in the control of HBV replication, it has 
been reported that a single injection of a-galactosylceramide was able to strongly 
inhibit HBV replication in the liver of transgenic mice within 24 h (Kakimi et a/., 
2000). This effect was preceded by rapid production of IFNa/~ and IFNy, and 
followed by recruitment of NK cells to the liver. IFNa/~ or IFNy receptor 
deficiency, but not depletion of CD4/CD8+ T cells, interfered with a-
galactosylceramide-mediated HBV inhibition (Kakimi eta/., 2001). Activated NK 
T cells can also stimulate hepatocytes to produce CXC chemokines and recruit 
lymphomononuclear inflammatory cells into the liver (Kakimi eta/., 2001). The 
inflammatory cells infiltrating the liver seem not to be responsible for the inhibition 
of HBV replication in transgenic mice, but they may contribute to the severity of 
hepatitis by damaging hepatocytes in a virus non-specific manner (Kakimi et at., 
2001 ). Furthermore, there is also some evidence indicating that some 
populations of NK T cells in the liver can be activated by HBV envelope antigens 
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but not by a-galactosylceramide in HBV S gene transgenic mice generated on 
the recombinase-activated gene deficient (RAG-1·'-) background (Baron et a/., 
2002). 
1.8.2.2 Adapative immune responses: 
1.8.2.2.1 CDS+ T cell response 
CDS+ T cells recognize pathogen-derived peptides presented by class I 
MHC molecules on the surface of the infected cells (see Fig. 1.2). Peptides 
generated by proteasome-mediated protein degradation are transported to the 
ER, bound by newly synthesized class I molecules MHC and transported to the 
cell surface. Since most peptides bound by class I MHC are derived from 
endogenously synthesized, cytosolic proteins, CDS+ T cells principally defend 
against microbes that replicate within infected cells (Pamer and Cresswell, 199S). 
Classically, class I MHC-bound peptides are generated in the cytosol 
through a stepwise process involving the ubiquitin-proteasome system (Gramme 
and Neefjes, 2002). In this pathway, newly synthesized proteins are released 
from ER and tagged with ubiquitin by E3 ubiquitin ligase. Then, the ubiquitin 
tagged protein is directed to the barrel-like proteasome which is composed of a 
and f3 subunits. The peptidase activity resides in f3 subunits. The proteasome's 
constitutive~ subunits can be replaced by IFNy-induced ~subunits, i.e., low 
molecular weight protein 2 (LMP2), LMP7 and multicatalytic endopeptidase 
Figure 1.2. Class I MHC antigen processing and presentation pathway. Several 
steps are involved in the class I MHC antigen processing and presentation. The 
majority of class I MHC binding peptides are generated by proteasome-mediated 
degradation. The peptides are transported into the lumen of ER by the TAP1 
and TAP2 complex. Then, translocated peptides are selectively loaded to the 
class I MHC heavy chain (MHCI-hc)-b2m complex within the ER with the help of 
chaperones such as, tapasin, calreticulin and the thiol oxidoreductase ERp57. 
Finally, the peptide-MHCI-hc-~2m complex is transported to the cell surface for 
recognition of CD8+ T cells via the Golgi apparatus. 
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complex 1 (MECL 1) subunits. Such a newly formed proteasome with new [3 
subunits is called immuno-proteasome. This results in different peptidase activity 
which cleaves the poly-peptides differently from the proteasome with constitutive 
[3 subunits. The proteasome-generated peptides are trimmed further to fit into 
the class I MHC complex by aminopeptidases which reside in either cytosol or in 
the ER. In order to be loaded to the class I MHC complex, peptides need to be 
translocated from cytosol to the lumen of the ER, where the actual loading 
happens. This process is mediated by transporters associated with antigen 
presentation 1 (TAP1) and TAP2 complex located on the membrane of the ER 
and requires ATP (Androlewicz et a/., 1993). Subsequently, with the help of 
chaperon molecules, such as tapasin, peptides are loaded to the class I MHC 
heavy chain which has been pre-complexed with [32m. The final complex leaves 
the ER via the Golgi apparatus and is displayed on the cell surface, as 
schematically shown in Fig. 1.2. 
In some situations, an exogenous protein can be phagocytosed and 
processed in the lysosome to generate class I MHC-bound peptides which then 
enter the ER by the TAP-dependent transport mechanisms. Although its 
physiological significance remains unknown, this non-classical pathway, referred 
to as cross presentation, adds a broader peptide spectrum to the class I MHC 
presentation. 
Several mechanisms are proposed to explain the anti-viral function of 
CDS+ T cells (reviewed by Harty eta/., 2000). First, upon activation of CDS+ T 
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cells by interaction of TCR with MHC class 1-peptide complex, granules 
containing perforin and granzyme B are released toward the target cell. 
Assembled perforin can punch holes in the membrane of the target cell and 
deliver granzyme B, an apoptosis inducing enzyme, and cause death of target 
cells. Second, Fas ligand (CD95L)/Fas(CD95) interaction is also able to cause 
cell apoptosis. The Fasl protein, expressed on the activated CD8+ T cells, 
interacts with Fas protein on the target cell, initiating an intracellular signaling 
cascade which leads to apoptosis of target cells. Third, in addition to production 
of chemokines attracting other inflammatory cells to the site of infection, CD8+ T 
cells can also secrete cytokines, such as INFy and TNFa, which can be cytotoxic 
as well as having direct anti-viral effects without killing target cells (Nakamoto et 
a/., 1997). 
The anti-HBV effect of CD8+ T cells has been extensively studied in the 
HBV transgenic model. Adoptive transfer of HBV-specific CD8+ T cells into HBV 
transgenic mice resulted in a transient, mild hepatitis and in a significant drop in 
the HBV genome transcripts in the liver (Tsui eta/., 1995). It has been estimated 
that no more than 1 0% of hepatocytes had been lysed by transferred CTL in a 
perforin and Fasl-dependent manner (Guidotti eta/., 1996b; Nakamoto eta/., 
1997). Therefore, other factors have to contribute to the elimination of HBV in 
the liver, since almost all hepatocytes are infected in advanced CH. It has been 
suggested that cytokines, such as IFNy and TNFa actually mediate inhibition of 
HBV replication (Guidotti eta/., 1996b). 
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In HBV-infected patients, multi-specific antiviral CD4+ and CD8+ T cell 
responses were found in the PBMC from patients with a self-limited AH (Bertoletti 
eta/., 1991; Ferrari eta/., 1990; Jung eta/., 1991; Rehermann eta/., 1995). 
These responses were significantly stronger than those found in patients with CH 
(Rehermann eta/., 1996b). A recent study of patients with well-defined time of 
exposure to HBV has indicated that HBV-specific CD8+ and CD4+ T cell 
responses occur before symptomatic disease (Webster et a/., 2000). 
Consequently, maximal reduction of HBV DNA load has been observed before 
the appearance of hepatitis (Webster et a/., 2000). Quantification of the liver 
infiltrating HBV-specific CD8+ T cells using tetramer staining and flow cytometry 
has shown an equivalent number of HBV-specific CD8+ T cells in the liver of 
patients with active chronic HBV hepatitis accompanied by high serum ALT 
levels as in those with low HBV replication without hepatitis and with normal 
serum AL T levels. This may suggest that inhibition of virus replication by CD8+ T 
cells is independent of the severity of liver damage (Maini et a/., 2000). 
Antibody-mediated depletion of CD8+ or CD4+ T cells after HBV infection in 
chimpanzees indicated that HBV-specific CD8+ T cells are a major contributor to 
inhibition of HBV replication in the liver (Thimme eta/., 2003). 
1.8.2.2.2 CD4+ T cell response 
CD4+ T cells recognize peptide in the context of class II MHC on the 
surface of APC. The major function of CD4+ T cells is helping CTL immunity or 
in production of antibodies by 8 cells. There are two subsets of CD4+ T cells, 
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referred to as T helper 1 (Th1) and T helper 2 (Th2). Th1 CD4+ T cells are 
characterized by producing cytokines such as IL-2, TNFa and IFNy, which mainly 
stimulate cellular immune response. Th2 cells are able to secrete IL-4, IL-5, IL-6, 
and IL-10 to favour the humoral immune responses. Although some CD4+ T 
cells are able to kill target cells through cell contact (Hahn eta/., 1995), cytokine 
production and immunoregulation are the main functions of these cells. 
Therefore, the antiviral effect of CD4+ T cells is achieved by either helping other 
immune effector cells to proliferate and differentiate or by releasing cytokines to 
inhibit directly virus replication. 
In contrast to the relatively well-recognized role of CDS+ T cells in HBV 
infection, CD4+ T cell contribution is much less characterized. In the transgenic 
mouse model, it has been found that adoptive transfer of a HBV envelope-
specific CD4+ Th1 cell line induces transient liver injury and inhibition of HBV 
replication (Franco eta/., 1997). This effect is mediated by production of IFNy, 
but not by the direct killing of hepatocytes by CD4+ T cells (Mancini eta/., 199S). 
Consistent with the finding that a higher number of HBV-specific CDS+ CTL 
accompanies AH but notCH, a stronger Th1 CD4+ T cell response against HBV 
was observed in AH, but not in CH (Lohr et a/., 199S). Long-lasting CD4+ T 
memory cells specific for HBV nucleocapsid protein were found in patients with a 
past history of resolved acute HBV infection (Penna et a/., 1996; Rehermann et 
a/., 1996a). Surprisingly, in these convalescent patients, the strength and 
breadth ofT cell responses directed against HBV epitopes are similar to those 
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observed in the acute phase of HBV infection. Since low levels of HBV DNA and 
HBV RNA are detectable in individuals who recovered from AH type B by 
sensitive polymerase chain reaction (PCR) assays (Michalak et a/., 1994), it has 
been suggested that trace amounts of replicating HBV might help maintain the 
virus-specific T cells responses. These active HBV-specific T cell reactivities are 
believed to play an important role in restricting the recurrence of HBV infection 
(Penna eta/., 1996; Rehermann eta/., 1996a). On the other hand, in spite of the 
presence of anti-HBV T cell responses, continued low level of HBV replication 
seems persistent for life. 
In chronically HBV infected patients, it has been found that Th1 type CD4+ 
T cells directed against the virus envelope proteins can be induced by 
vaccination with HBsAg and they may, to some extent, control the level of HBV 
viremia (Couillin et a/., 1999). This suggests that the HBV induced immune 
tolerance in CH can be broken if an efficient immunization strategy can be 
applied. In general, HBV-specific CD4+ T cells can, to some degree, inhibit HBV 
replication directly and, more importantly, provide the necessary help for the 
generation of a strong anti-HBV CTL response. 
In the woodchuck model, it has been found that there is a strong T cell 
proliferative response to the WHV core antigen (WHcAg), as measured using 
PBMC from acutely infected animals (Menne eta/., 1997b). Immunization with a 
synthetic dominant T cell epitope of WHcAg, constituted by WHcAg amino acids 
located in the positions 97-11 0 (WHc 97-11 0), can apparently completely protect 
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woodchucks from challenge with WHV, suggesting that a specific T cell response 
was playing an important role for defense against WHV (Menne eta/., 1997b). 
Deficiency in T cell response to WHcAg, as well as to other WHV antigens in the 
acute phase of hepatitis was associated with the progression to CH in 
woodchucks infected in the neonatal period (Menne eta/., 2002b). 
1.9 Cytokines and HBV replication 
Cytokines are small soluble proteins that can alter the function of the cells 
which display appropriate receptors. Most cytokines perform multiple biological 
functions, and some of the functions can also be mediated by several different 
cytokines. Many cytokines are directly or indirectly involved in the host's antiviral 
immunity. In this section, I will mainly focus on the group of antiviral cytokines 
designated as interferons and will only briefly describe TNFa, whose antiviral 
activity is much less understood. 
1.9.1 Interferons 
Interferons are a family of functionally related cytokines that induce a 
range of molecular and cellular responses, including antiviral, antiproliferative, 
antitumor and immunomodulatory activities (Pestka et a/ .. 1987). According to 
the structural and functional properties, they are classified as type I (IFNa/~, K, w 
etc.) and type II (IFNy) interferons. IFNa/~ are produced by many types of cells 
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upon virus infection, whereas IFNy is mainly secreted by immune cells, such as 
Th1 CD4+ T cells, CTL, NK and NK T cells. Although there are many members 
of the type I IFN family, they bind to the same receptor and signal through the 
same signal transducer and activator of transcription (STAT1/2) complex (Smith 
et a/., 2005). They activate transcription of a series of genes containing 
interferon stimulated regulatory element (ISRE) (Stark et a/., 1998), while IFNy, 
the only member in the type II family, binds to a distinct receptor and signals 
through STAT1 homodimers. Once dimerized, the STAT1 translocates to the 
nucleus and binds to the gamma-activated sequence (GAS) element and initiates 
nearby gene transcription (Stark eta/., 1998). 
Several IFN-induced antiviral effector molecules have been identified. 
One of them is the virus double strand RNA (ds-RNA)-activated, IFN-induced 
protein kinase R (PKR), which can phosphorylate the translation initiation factor 
eiF-2a. This results in the rapid inhibition of protein translation and leads to 
inhibition of viral replication (Williams, 1999). Other molecules are the IFN-
inducible 2'-5' oligoadenylate synthetases (OAS), which are stimulated by virus 
ds-RNA and lead to the generation of 2',5'-oligoadenylates. Subsequently, latent 
RNase (RNase L) is activated by 2',5'-oligoadenylates and mediates degradation 
of RNA and inhibition of viral replication (Rebouillat and Hovanessian, 1999). 
Another molecule is the IFN-inducible Mx protein, a member of the GTPase 
superfamily. It has been suggested that Mx protein interferes with replication of 
the influenza virus and bunyavirus family via direct binding to viral 
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ribonucleoprotein complex and by blocking their entry into the nucleus (Haller et 
a/., 1998). Other genes induced by IFNs include: (1) adenosine deaminases that 
act on RNA (ADAR), an RNA editing enzyme which modifies the sequence of 
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viral and cellular RNA through binding to ds-RNA, leading to the generation of 
mutant proteins in virus-infected cells (Liu and Samuel, 1996; Sc:·unders and 
Barber, 2003); (2) P56, an inhibitor of protein translation due to its ability to bind 
the translation factor eiF-3 (Guo et a/., 2000), and (3) inducible nitric oxide 
synthase (iNOS), which has been shown to inhibit the growth of ectromelia, 
vaccinia, and herpes simplex virus 1 (HSV-1) in mouse macrophages (Karupiah 
et a/., 1993). Among these effector molecules, PKR, ADAR and Mx genes are 
induced by type I IFNs, whereas 2'-5' OAS and RNase L by both types of IFNs. 
iNOS is induced by IFNy, but not by type I IFNs (Stark eta/., 1998). Mice triply 
deficient for RNase L, Mx1, and PKR are still partially resistant to 
encephalomyocarditis virus (ECMV), indicating that multiple, functionally 
overlapping anti-viral molecules are responsible for antiviral activities (Zhou et a/., 
1999). 
1.9.2 lmmunomodulatory effect of IFNs 
Besides the fact that IFNs can activate intracellular antiviral molecules 
which directly inhibit virus replication, they also play key roles in the regulating of 
immune responses against viruses. First, IFNs are able to upregulate expression 
of class I MHC and enhance the effectiveness of the endogenous antigen 
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presentation pathway (Fruh and Yang, 1999; Kloetzel and Ossendorp, 2004). As 
a result, the virus-infected cells might be able to better process and present viral 
peptides in the context of class I MHC complexes on the cell surface, which are 
then recognized by specific CD8+ CTL. In consequence, the activated virus-
specific CD8+ CTL could either eliminate infected cells by inducing apoptosis or 
inhibit virus replication in a non-cytopathic manner. Second, IFNy is a strong 
stimulator of gene transcription for class II MHC as well as co-stimulatory 
molecules in APCs (Boehm et a/., 1997). The activated APCs could further 
promote anti-viral humoral and cellular immunity (see Section 1.8.2.2). Third, 
IFNy is secreted by CD4+ Th1 T cells and is necessary for the skewing of the 
immune response toward the antiviral favorable CTL immunity (Farrar and 
Schreiber, 1993). 
It was first found in HBV transgenic mice that adoptive transfer of HBV-
specific CTL could inhibit virus replication through secreting IFNy and TNFa 
without killing the infected hepatocytes (Guidotti eta/., 1996b). It was proposed 
that two independent antiviral pathways are involved in this noncytopathic 
process. One is related to the disruption of HBV nucleocapsid structure and 
another to the degradation of HBV RNA transcripts (Guidotti et a/., 1996b). 
Recent data indicated that nitric oxide (NO) is one of the antiviral mediators of 
IFNy activity (Guidotti et a/ .. 2000). Further experiments suggested that even 
induction of IFNa/~ and INFy in the liver of HBV transgenic mice through 
infection with unrelated hepatotropic LCMV (Guidotti eta/., 1996a), adenovirus or 
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mouse cytomegalovirus (MCMV) (Cavanaugh et a/., 1998) can inhibit HBV 
replication. Systemic administration of IFNy stimulating cytokines, such as IL-12 
and IL-18, which can activate IFNy production by APCs, NK, and T cells, has 
shown a similar HBV inhibitory effect in transgenic mice (Cavanaugh eta/., 1997; 
Kimura et a/., 2002b). A single dose of a-galactosylceramide, which can be 
presented by non-classical CD1d molecules to the NK T cells, is able to stimulate 
the rapid secretion of IFNy by NK T cells (as mentioned in Section 1.8.2.1 ). 
Consequently, replication of HBV in the transgenic mice is inhibited by 
degradation of viral RNA. A similar HBV susceptibility has also been observed 
after induction of IFNa/~ by injection of HBV transgenic mice with polyinosinic-
polycytidylic acid complex, which mimics ds-RNA (Guidotti eta/., 2000). In spite 
of the transient viral inhibition at the RNA level, HBsAg and HBV DNA in the 
circulation, as well as in the liver, did not decrease. Moreover, there is no 
evidence that an anti-HBV T cell immune response was induced in these 
transgenic mice. 
Finally, investigations of the natural course of experimental AH in 
chimpanzees have validated the findings in HBV transgenic mice described 
above (Guidotti et a/., 1999). It has been found that the appearance of intra-
hepatic IFNy is associated with the apparent complete elimination of HBV 
replication intermediates and cccDNA before the onset of liver injury. As a result, 
the level of HBV in serum and liver was greatly reduced prior to the appearance 
of hepatitis in these chimpanzees (Guidotti eta/., 1999). 
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1.9.3 Tumor necrosis factor alpha 
TNF-related cytokines, including TNFa and lymphotoxin a/~ etc, are type II 
transmembrane glycoproteins that signal through cognate receptors. The 
trimeric ligands cluster the receptor, initiating signal tranduction which regulate 
cell survival and death (Beutler and Cerami, 1989; Locksley et a/., 2001 ). 
Although apoptosis induced by TNFa can be an effective strategy for the 
elimination of viral-infected cells, it does not seem to be beneficial due to the 
severe cost to the host, especially in HBV infection, where the whole liver is 
infected by the virus. Unlike IFNs, the effector molecules responsible for TNF's 
noncytopathic inhibition of virus replication have not been identified. Indeed, 
synergized with IFNy, TNFa secreted by CTL has been shown to inhibit HBV 
replication without apparent destruction of hepatocytes in both mouse (Guidotti et 
a/., 1996b) and chimpanzee models of HBV infection (Guidotti eta/., 1999). It 
has been suggested that disruption of HBV nucleocapsid formation is probably 
one of the strategies used by TNFa to noncytopathically inhibit HBV replication 
(Biermer eta/., 2003). Recent data also suggest that TN Fa might be required to 
elicit and maintain HBV-specific CTL induced by DNA immunizations (Kasahara 
et a/., 2003). In addition, since TNFa is also involved in promoting NK and 
lymphocyte differentiation (locksley et a/., 2001 ), this cytokine can indirectly 
assist immunological defense against viral and other pathogen infections. 
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1.10 Strategies of virus escape from host immune responses 
The host's immune system employs a variety of strategies to eliminate the 
invading virus. On the other hand, the virus has developed multiple evasion 
mechanisms to avoid being cleared by the host's immune system. The balance 
between the strength of immune response and the virus escape strategies 
determine the outcome of infection, i.e., virus clearance or its persistence. This 
section will briefly outline the mechanisms employed by virus to evade the host's 
immune system. However, particular emphasis will be placed on delineations of 
the class I MHC-related escape mechanisms. 
1.1 0.1 General considerations 
1.1 0.1.1 Infection of immune-privileged sites 
For the benefit of the host, certain areas of the body are not subject to 
immune surveillance. One such place is the central nervous system (CNS) 
which has a blood-brain barrier and, under normal circumstances, antibodies and 
T cells can not penetrate this barrier. Infection of the CNS with viruses, such as 
HSV, LCMV, varicella zoster virus (VZV) and measles virus, will usually prevent 
the virus from being seen and cleared by the immune system (Oidstone and Rail, 
1993). 
Another example is the infection of lymphocytes which themselves 
contribute to clearance of virus. By using this strategy, virus may compromise 
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the function of cells of the immune system and, sometimes, lead to a general 
immune suppression. For example, human immunodeficiency virus (HIV), which 
mainly infects CD4+ T cells and macrophages, leads to decline of CD4+ T cells 
and, in consequence, to severe cellular immune deficiency (Embretson et a/., 
1993). Another example is the measles virus which targets lymphoid tissues and 
causes general immuno-suppression. Although the detailed mechanism is not 
clear, primary and secondary T cell proliferation has been found to be inhibited in 
measles virus infected hosts (Niewiesk eta/., 1997). 
1.1 0.1.2 Antigenic variation 
Due to the lack of proof-reading capabilities of viral polymerases, 
genomes of certain viruses, such as HIV, hepatitis C virus (HCV) and HBV, are 
highly prone to mutations. This may lead to variations in their proteins. As a 
result, the newly developed virus may no longer be recognized by the parental 
virus-specific 8 and T cell-mediated responses. 
For example, influenza virus is an enveloped virus with a protein shell 
composed of hemagglutinin (HA) and neuraminidase (N). These envelope 
proteins are responsible for the virus attachment and entry into cells. The host is 
able to mount humoral immunity characterized by production of neutralizing 
antibodies targeting specific HA and N epitopes. Upon binding to virus, the 
antibodies can block the viruses' attachment to the cells. However, subtle 
changes in the HA and N protein sequences resulting from mutations in the virus 
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genome can lead to the alteration of antigenic B epitopes on the surface of virion 
particles, while preserving its infectivity. In consequence, the pre-existing 
neutralizing antibodies cannot recognize the mutated epitopes (Treanor, 2004). 
Virus antigenic variation also has an impact on the cellular immune 
responses. Presentation of endogenous peptides to .class I MHC is influenced 
not only by the amino acid constitution of the epitope, but also by the surrounding 
amino acid residues. Therefore, variation in the viral protein can lead to an 
alteration of the CTL-recognized epitope, causing diminished antigenicity or 
reduction in the affinity of peptide-MHC interaction. It has been shown in HIV-
infected patients, that novel epitopes generated from mutated variants can 
function as antagonists to silence HIV-specific T lymphocytes (Kienerman et a/., 
1995). 
1.10.1.3 Inhibition of class II MHC antigen presentation 
C04+ T cells play a key role in the activation of CD8+ CTL, differentiation 
and development of B cells, and secretion of antiviral cytokines. The activation 
of CD4+ T cells requires the interaction between the TCR on T cells and the 
peptide-MHC class II complex presented on the APCs. Viruses have been using 
different mechanisms to avoid CD4+ T cell activation by interfering with the class 
II MHC presentation pathway. 
Signalling through the JAK-STAT pathway, IFNy (as indicated in Section 
1. 9.1) can up regulate the transcription of class It MHC molecules. It was found 
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that cells infected with human cytomegalovirus (HCMV) did not respond to IFNy 
stimulation as shown by failure of class II MHC up-regulation (Miller eta/., 199S). 
This effect is due to the rapid degradation of Janus kinase 1 (JAK1) by the virus 
(Miller et a/., 199S). Similarly, vaccinia and HSV have evolved mechanisms to 
modulate phosphorylation and dephosphorylation of STAT1 to impede its entry 
into the nucleus or the recycling of STAT1 back to the cytoplasm (reviewed by 
Goodbourn et a/., 2000; Gotoh et a/., 2002). Consequently, class II MHC 
expression failed to increase upon IFNy stimulation. 
MHC class II a~ dimers assemble with the invariant chain (li) in the ER 
and the complexes are sorted to the MHC class 11-loading compartment, where 
loading of peptides occurs with the aid of OM molecules. The expression of 
HCMV protein US2 causes rapid proteasome-mediated degradation of two 
essential proteins in the class II presentation pathway, i.e., the HLA-DM-a and 
HLA-DR-a chains, preventing antigen presentation to CD4+ T cells (Tomazin et 
a/., 1999). 
1.10.1.4 Inhibition of class I MHC pathway 
The CDS+ CTL response is believed to be responsible for the clearance of 
the majority of virus infections (Wong and Pamer, 2003). The interaction 
between TCR on CDS+ CTL and virus peptide-MHC class I complex on the 
infected cells provides the primary activation signal to the CTL. Therefore, 
interfering with the MHC class I presentation pathway may facilitate the 
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persistence of viral infection. As many reported studies have shown, the viral 
interference may happen at almost any step of the class I MHC presentation 
pathway (see Section 1.8.2.2). 
1.1 0.1.4.1 Interference with proteasome degradation 
Most class I peptides are generated by proteasomes in the cytosol (review 
by Gramme and Neefjes, 2002) (see Fig. 1.2). Proteasomal degradation is 
dependent on the recognition and cleavage of specific peptide sequences within 
a protein. Modification of viral protein can interfere with proteasomal processing 
and lead to deficiency in generation of certain peptides. It has been reported that 
a single amino acid change in a proteolytic cleavage site of a murine leukemia 
virus has abolished productive processing of an immunodominant CTL epitope 
(Ossendorp eta/., 1996). On the other hand, some viral proteins can deliberately 
inhibit activity of the proteasome by interfering with transcription of its subunits. 
For example, LMP2 and LMP7, two subunits of the proteasome, are 
transcriptionally inhibited in cell lines transformed by adenovirus 12 (Rotem-
Yehudar eta/., 1996). As a result, class I MHC display is compromised. 
1.1 0.1.4.2 Inhibition of TAP1 and TAP2-mediated peptide transport 
Peptides generated in the cytosol are loaded to the MHC class I complex 
in the ER via TAP1 and TAP2 molecules located on the ER (see Section 1.8.2.2). 
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HCMV encoded US6 protein binds the TAP1 molecule and disables its ability to 
bind ATP, which is a prerequisite for active peptide transport (Hewitt eta/., 2001). 
In another example, the ICP47 protein produced by HSV type 1 and 2 has also 
been found to inhibit the formation of the peptide-MHC class I complex by 
competitive blocking of the peptide-TAP1/2 binding sites (Ahn eta/., 1996). 
1.10.1.4.3 Retention and degradation of MHC class I molecules 
The HCMV encoded US3 protein is able to bind to the ~2m-class I heavy 
chain complex prior to peptide loading in the ER. Although it does not prevent 
peptide binding, the peptide-MHC class I complex is unable to leave the ER, 
resulting in the absence of class I MHC display on the cell surface (Jones eta/., 
1996). In the presence of HCMV US2 or US11 protein, it has been found that the 
class I MHC molecules were transported from the ER back into the cytosol, 
where they were degraded by the proteasome with a half-life less than 1 min 
(Wiertz eta/., 1996). Gp48, a protein of MCMV, binds class I MHC molecules 
and redirects their transport into lysosomes, where the class I MHC complexes 
are degraded (Reusch eta/., 1999). Another example is the Nef protein encoded 
by HIV. After binding to class I MHC displayed on the cell surface, Nef is able to 
trigger the endocytosis process which leads to the intracellular degradation of 
class I MHC complexes (Mangasarian and Trone, 1997; Schwartz eta/., 1996). 
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1.1 0.1.4.4 Oownregualtion of MHC class 1-related gene transcription 
By reducing the mRNA transcription of class I MHC and related genes, 
virus may suppress the display of class I MHC antigens on the cell surface. For 
example, the level of class I MHC-related {i.e., TAP1, TAP2, class I heavy chain 
and 132m) mRNA levels were found to have a 2-100 fold reduction in Ad12-
transformed cell lines compared to non-transformed cells (Rotem-Yehudar eta/., 
1996). This inhibition of transcription by Ad12 was due to the reduction in 
formation of active transcription complex (Hou eta/., 2002). 
1.1 0.1.4.5 Inhibition of MHC class I chaperone molecules 
Adenoviral gene product E19 has been found to bind to TAP and class I 
MHC heavy chain independently, acting as a competitive inhibitor for tapasin, a 
chaperone molecule which helps in transporting the peptide from TAP to the 
class I MHC complex in the ER (Bennett eta/., 1999). Therefore, E19 interrupts 
the relay of peptides from TAP to class I MHC complex and delays the 
presentation of MHC class !-peptide complexes on the cell surface. 
1.1 0.1.5 Inhibition of NK cell-mediated killing 
In accordance with the "missing self' hypothesis, down regulation of class 
MHC molecules may render the virus infected cells susceptible to NK cell-
mediated killing (Ljunggren and Karre, 1990). In order to avoid NK killing, one of 
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the mechanisms used by virus is the expression of viral gene encoded MHC 
class I heavy chain analogs. UL 18 and m144, proteins of HCMV and mouse 
CMV (MCMV), respectively, share tertiary homology to class I MHC heavy chain. 
Consequently, it has been shown that these proteins can replace the heavy chain 
of class I MHC and assemble with j32m to form surrogate, class I MHC-Iike 
complexes on the surface of the infected cells. Accordingly, an inhibitory signal 
is delivered to the NK cells, preventing the killing of virus-infected cells by these 
effector cells (Farrell et a/., 1 997). Another strategy used by virus to avoid 
activation of NK cells is the up-regulation of non-classical class I MHC. For 
example, HLA-E, an inhibitor of NK-mediated cytolysis, is up-regulated by HCMV 
(Tomasec et a/., 2000). Furthermore, down-regulation of ligands capable of 
activating NK cells has also been discovered in MCMV infection. A MCMV gene 
product, m152/gp40, is able to suppresses the expression of heat shock protein 
(Hsp)-60, which is a high-affinity ligand for the NKG20 receptor. This prevents 
activation of NK cells (Karre, 2002; Krnipotic eta/., 2002). 
1.1 0.1.6 Inhibition of cytokine function 
Cytokines are mediators which regulate immune responses and some of 
them can directly inhibit virus replication. IL-10, a Th2 cytokine, which is able to 
inhibit T cell proliferation and IL-2 production, is a negative regulator of antiviral T 
cell responsiveness. Virus can express a biologically functional IL-10 analogue 
and inhibit the host's antiviral responses. For example, EBV synthesizes the 
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BCRF1 protein, which is the homologue of IL-10 (Zdanov eta/., 1997). A similar 
IL-1 0-like protein has also been identified in HCMV (Kotenko et a/., 2000). 
Additional interference with cytokine functioning may occur at the level of 
cytokine receptors. For instance, a secreted protein, M-T7, encoded by myxoma 
virus, was found to function as a soluble IFNy receptor (Upton et a/., 1992). 
Release of the receptor homologues in a soluble form seems to compete with 
binding of IFNy to the cell surface, which compromises the cytokine function. 
Viral products can also interfere with cytokine activity by inhibiting the 
downstream signal transduction pathway, as discussed above in Section 1.9.1. 
1.1 0.2 Immune escape mechanisms by hepadnavirus 
As indicated in Section 1.1 0.1.1, although the liver is the main target of 
HBV infection, HBV also replicates in lymphoid tissue, which serves as a 
reservoir of persistent HBV infection (Fe ray eta/., 1990; Lew and Michalak, 2001; 
Michalak, 2000; Michalak eta/., 1994). Hiding of HBV in the lymphatic system 
may also compromise immunological functions of the infected cells. Under 
certain conditions, like organ transplantation and chemotherapy, it is possible 
that the virus residing in the lymphatic system may re-establish symptomatic 
infection in the context of weakened immune surveillance (Abdelmalek et a/., 
2003; Berger eta/., 2005; Knoll eta/., 2004; Lau eta/., 1997b). 
HBV DNA and RNA have been detected in monocyte-derived DCs 
obtained from patients with CH (Tavakoli eta/., 2004). In addition, these HBV 
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infected DCs have shown reduced capacity to stimulate lymphocytes in allogenic 
mixed lymphocyte reactions (Beckebaum et a/., 2003). The level of IL-12 
secreted by these OCs was also significantly lower than that secreted by DC 
from healthy controls (Arima eta/., 2003). This suggests that not only DCs were 
infected by HBV, but also that their functions were impaired. 
HBV may also persist by generation of immune escape mutants. It has 
been reported that a naturally occurring mutant within HBcAg located between 
residues 18-27 in patients with CH can serve as antagonists for TCR recognition 
of the wild-type virus epitope (Bertoletti et a/., 1994). The presence of the 
mutated epitope was able to inhibit the HBV-specific CTL response against the 
wild-type epitope. Therefore, in this situation, not only the mutated virus, but also 
the wild-type HBV can evade specific CTL recognition due to the active 
suppression of anti-HBV CTL. 
It has been reported that HBV pol gene transfection resulted in the non-
responsiveness of transfected cells to IFNa (Foster et a/., 1991 ). The precise 
mechanism is not clear, but it seems that the binding of IFNa to the target cells 
was not influenced (Foster eta/., 1991). This finding may partially explain why 
the majority of CH patients do not respond to IFNa therapy. It also suggests that 
HBV might use this strategy to avoid being eliminated by the innate immune 
response. 
In the woodchuck model of HBV infection, the down-regulation of class I 
MHC heavy chain presentation on hepatocytes has been demonstrated in 
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animals chronically infected with WHV but not in acute WHV hepatitis (Michalak 
et a/., 2000). In spite of the difference in class I MHC protein display between 
CH and AH, the level of class I MHC-related gene expression, such as class I 
MHC heavy chain, ~2m, TAP1 and TAP2, in the liver was found to be similar in 
CH and AH, and transcription of all these genes was elevated compared to the 
levels detected in healthy animals. Furthermore, the level of IFNy mRNA, the 
cytokine which is a potent stimulator of class I MHC expression, was also found 
to be up-regulated in hepatic tissues to a similar extent in both CH and AH. 
Based on the above findings, a post-transcriptional interference with hepatocyte 
class I MHC presentation in chronic WHV hepatitis has been proposed. However, 
a molecular mechanism of this interference was not investigated. It was 
postulated that a difference in class I MHC protein display may contribute to the 
persistence of WHV infection, since a decreased class I MHC expression could 
be associated with inhibition of HBV-specific CTL recognition of infected 
hepatocytes and lead to failure of eliminating this virus. 
1.11 HBV Vaccines and antiviral therapy 
1.11.1 Current anti-HBV agents 
For the treatment of chronic hepatitis B, three drugs are currently licensed 
by Food and Drug Administration (FDA), USA, i.e., IFNa, lamivudine (3TC), and 
adefovir dipivoxil. Clinical studies indicated that IFNa monotherapy is associated 
with loss of serum HBeAg in 30-40% of the patients (van Nunen eta/., 2001) and 
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clearance of serum H BsAg in 5-1 0% (Perrillo et a/., 1990). It was also concluded 
that the patients with elevated transaminases, low serum HBV DNA level, and 
active liver histology without cirrhosis benefit the most from IFNa therapy (lau et 
a/., 1997a; Wong eta/., 1993). However, the permanent loss of serum HBsAg is 
only approximately 6% greater in IFNa-treated than in non-treated patients, and 
even in the IFNa-susceptible patients, serum HBV DNA is still detectable by 
sensitive PCR assays (Wong eta/., 1993). This suggested that IFNa therapy is 
able to suppress HBV replication only to some degree and in a limited number of 
patients, and is unable to eliminate HBV completely. Systemic administration of 
comparable doses of mouse IFNa into the HBV transgenic mice did not show any 
effect on HBV replication in the liver (Guidotti and Chisari, 2001). However, 
induction of IFNa/~/y production in the liver of HBV transgenic mice was effective 
in HBV inhibition (Guidotti and Chisari, 2001 ). This suggests that a local high 
concentration of IFNa probably has a stronger anti-viral effect than a high level of 
IFNa in the circulation. Side effects of interferon treatment are frequent and 
include constitutional symptoms such as: bone marrow suppression; 
neuropsychiatric effects; and the occurrence of autoimmune disease, especially 
thyroiditis (Hollinger and Liang, 2001 ). Subcutaneous or parental injection of 
IFNa is a major inconvenience to the treated patients. Nevertheless, patients 
responding to the therapy have a survival advantage over nonresponders. 
One type of promising anti-HBV agents are nucleoside or nucleotide 
analogs that target the virus-encoded reverse transcriptase, inhibiting its activity 
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and terminating DNA chain extension. Lamivudine is a cytosine nucleoside 
analog that is phosphorylated by intracellular kinases to the active compound 
(Hanazaki, 2004). Treatment of HBV patients with lamivudine is followed by a 
rapid and profound reduction of serum HBV DNA load and aminotransferase 
levels (Dienstag et a/., 1995; Lai et a/., 1998). After a one year treatment period 
with lamivudine, HBeAg seroconversion occurs in about 20% of the patients 
versus 6-7% in controls (Dienstag eta!., 1999; Lai eta/., 1998). Similarly to IFNa 
therapy, patients with elevated AL T and a greater histological activity index of 
liver injury before treatment are prone to have a higher HBeAg conversion rate 
(Chien et a/., 1999; Perrillo et a/., 1999). Lamivudine is given orally and is well 
tolerated with few side effects. Therefore, long-term therapy is possible with this 
drug and it can be given in situations where IFNa is not appropriate, such as 
decompensated cirrhosis, after liver transplantation, and during 
immunosuppressed states (Bain et a/., 1996; Perrillo et a/., 1999). The major 
problem with lamivudine treatment is the induction of drug-resistant HBV mutants 
due to the selection pressure on the virus reverse transcriptase. One of the most 
common lamivudine-resistant HBV mutations is in the YMDD motif which is part 
of the catalytic site of the reverse transcriptase (Allen eta/., 1998). The mutation 
usually happens with 14-39% of the patients after 8-1 0 months lamivudine 
therapy (Honkoop eta/., 1997) and can reach up to 66% after 4 years of therapy 
(Leung, 2000). The appearance of the YMDD mutant can be associated with 
elevation of serum HBV DNA and liver enzymes (Liaw eta/., 1999). Termination 
59 
of lammivudine treatment is usually accompanied by recurrence of wild-type HBV 
and a flare-up of hepatitis (liaw et a/., 1999). 
Another newly approved acyclic nucleotide analog is adefovir dipivoxil, 
which exhibits a broad-spectrum of antiviral activity in HBeAg-positive, HBeAg-
negative and HIV-HBV coinfected patients (Rivkin, 2004). More importantly, 
adefovir dipivoxil alone appears to be able to inhibit HBV lamivudine-resistant 
YMDD mutants (Peters et a/., 1999). As with lamivudine, it is an oral agent with 
even fewer side effects in a short-term study (reviewed by Marcellin, 2002). 
Recent clinical observations indicate that about 1.6% of patients develop HBV 
mutants within 2 years of adefovir dipivoxil treatment (Dando and Plosker, 2003). 
If lamivudine and adefovir dipivoxil were given to patients in sequence or 
combined together, this could avoid mutant generation to each drug (Villeneuve 
eta/., 2003). 
1.11.2 Current HBV vaccines 
In spite of the relative limited success in treatment of CH type B discussed 
above (see Section 1.11.1 ), the effective prevention of HBV infection can be 
achieved by administration of HBV subunit vaccines consisting of 22-nm subviral 
particles composed solely of HBV envelope proteins. Initially these particles 
were purified from individuals chronically infected with HBV, but their usage was 
restricted by safety concerns. Most HBV vaccines used today are recombinant 
yeast-derived HBsAg vaccines which include only major S envelope proteins 
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(McAleer eta/., 1984 ). Although a small percentage of healthy individuals do not 
produce high titer protective antibodies, triple immunization with this vaccine is 
generally sufficient to render apparently life-long protection against HBV (Lemon 
and Thomas, 1997). Unfortunately, this protein-based HBV vaccine is not able to 
exert a therapeutic effect in already established HBV infection. This is probably 
because it induces almost entirely humoral immune responses whose presumed 
action is to bind and block the cell entry of HBV particles. In the case of already 
established HBV infection, a CTL response is required to recognize and to 
eliminate intracellular viruses, as discussed in Sections 1.8 and 1.9. 
1.11.3 Experimental HBV vaccines 
It has been found that clearance of HBV infection in AH is normally 
accompanied by a strong, multi HBV-specific CTL response, which is barely 
detectable in chronic HBV infection (see Section 1.8.2.2). Therefore, strategies to 
alter the quality and quantity of HBV-specific cellular immune responses might be 
a promising avenue for treatment of chronic HBV infection. 
DNA immunization has been shown to elicit both humoral and cellular 
immunity against virus-encoded proteins in various animal models (review by 
Encke eta/., 1999; Wands eta/., 1997). DNA immunization with HBV C and 
HBV S DNA plasmids have been studied in mice (Geissler eta/., 1997). It was 
shown that after 1-4 times repeated intramuscular DNA injection, high titers of 
anti-HBc and anti-HBs were readily detectable, respectively. More importantly, 
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immunized-mice also developed an antigen-specific, class II MHC-restricted CD4 
T cell response (Sallberg et a/., 1997). Similar to what was observed in patients 
acutely infected with HBV, production of Th1 cytokines was seen with HBsAg-
stimulated T cells from DNA-immunized mice (Whalen eta/., 1995). Furthermore, 
HBV-specific, long lasting CTL response against HBsAg was also found after 
DNA immunization with plasmids containing the HBV S gene (Whalen et a/., 
1995). Similar effects were observed in the duck model of hepatitis B (Triyatni et 
a/., 1998) and in woodchucks infected with WHV (Lu et a/., 1999; Menne et a/., 
2002a). 
The therapeutical potential of genetic immunization has been validated 
with the HBV transgenic mouse model (Mancini et a/., 1996). The clearance of 
HBsAg as well as the inhibition of S gene transcription were observed after 
immunization with plasmids encoding the HBV S gene. It has been shown that 
these effects were mediated by both neutralizing antibodies and T cell responses. 
These experiments suggest that DNA immunization can break the immune 
tolerance which accompanies chronic HBV infection. 
One of the concerns with the treatment of chronic HBV infection by DNA 
immunization is that the elicited HBV-specific CTL might kill the hepatocytes 
presenting HBV epitopes and lead to exacerbation of hepatitis due to the immune 
attack. In HBV transgenic mice, it has been shown that adoptive transfer of 
HBsAg-specific CTL can cause liver damage if the mouse liver has been 
engineered to express high level HBsAg (Chisari, 1995) (see Section 1.6.3). 
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However, in another study, where HBsAg-specific CTL were transferred into mice 
with progressive HBV replication, no severe inflammation was observed (Sette et 
a/., 2001). In woodchucks chronically infected with WHV, WHsAg immunization 
was able to induce antibodies to WHsAg (anti-WHs) and resulted in severe 
damage of the livers expressing WHsAg (Hervas-Stubbs et a/., 1997). The 
discrepancy between these studies needs to be further investigated before this 
strategy can be tested in a human disease situation. At the present time, it is 
assumed that the best regime for the treatment of chronic HBV patients might be 
a combination therapy, where a potent antiviral agent is combined with 
immunization with HBV antigens to elicit a strong anti-HBV cellular and humoral 
immunity, as has been seen in natural acute HBV infection progressing to 
recovery. 
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CHAPTER 2. GENERAL MATERIALS AND METHODS 
2.1 Animals 
2.1.1 Woodchucks 
All woodchucks (Marmota monax) used in this study were maintained by 
the Molecular Virology and Hepatology Research Laboratory at the Health 
Sciences Centre, Memorial University, St. John's, Newfoundland under 
environmental and biosafety conditions specifically established for this species. 
Animals were fed a herbivore diet supplemented with fresh vegetables and given 
water ad libitum, as reported previously (Diao et a/., 1998; Michalak and Bolger, 
1989; Michalak and Churchill, 1988; Michalak eta!., 1990; Michalak eta/., 1994). 
Animals infected with WHV were housed separately from healthy 
woodchucks. Healthy woodchucks had no serological markers of current or past 
exposure to WHV, i.e., they were negative for serum WHsAg, anti-WHc and anti-
WHs antibodies (see Sections 2.3.2 and 2.3.3). In addition, DNA extracted from 
sera, PBMC, and liver biopsies from these animals were WHV DNA non-reactive 
by specific nested PCR (Section 2.8.2) and subsequent Southern blot analysis of 
the resulting PCR products (see Section 2.9.3). 
The beginning of WHV infection was considered to be at the time of the 
first appearance of detectable WHV DNA in the circulation (i.e., serum and/or 
PBMC) when assayed by PCR/Southern blot hybridization assays. The initiation 
of the acute phase of WHV infection was diagnosed when WHsAg was detected 
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for the first time in serum. The presence of AH was verified by histological 
examination of liver biopsies obtained by laparotomy after WHsAg appearance 
(see Section 2.5). Recovery from AH was diagnosed when serum WHsAg 
permanently cleared and anti-WHs usually, but not always, appeared. 
Chronically infected animals were defined as those having the continuous 
presence of circulating WHsAg, anti-WHc antibodies, and WHV DNA for at least 
6 months (mo). Diagnosis of CH was confirmed by histological examination of 
liver biopsies that demonstrated typical features of protracted necroinflammatory 
liver injury (see Section 2.5). 
2.1.2 Other species 
Other animal species were used for control experiments or to produce 
polyclonal antibodies in this study. These species included rabbit, mouse and 
guinea pig. All animals were housed in the Animal Care facility at Memorial 
University of Newfoundland. 
2.2 Sample collection 
2.2.1 Blood sampling 
Blood was obtained from the digitalis vein of woodchucks under 
isofluorane induced anaesthesia (CDMV Inc., St. Hyacinthe, Quebec). The blood 
was collected into tubes with no additives (red top Vacutainer; Becton Dickinson, 
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Franklin Lakes, NJ) for serum isolation (see Section 2.2.2) or into tubes 
containing sodium ethylenediamine tetra-acetic acid (EDTA; lavender top 
Vacutainer; Becton Dickinson) for plasma and PBMC isolation (see Section 
2.2.3). 
2.2.2 Serum isolation. 
Blood was allowed to clot at room temperature for approximately 1 h. The 
tube was then centrifuged at 720 x g for 10 min. The isolated serum was 
aseptically aliquoted in small volumes and stored at -70 oc until use. 
2.2.3 Isolation of peripheral blood mononuclear cells 
Approximately 4 ml of EDT A-treated blood was gently overlaid on 4 ml of 
Ficoii-Paque (Pharmacia Biotech, Baie d'Urfe, Quebec) and centrifuged at 330 x 
g for 30 min. The plasma layer was collected and stored at -70 °C. The 
interface containing PBMC was removed and diluted with 10 ml of sterile 
phosphate buffered saline, pH 7.4, with EDTA (PBS-EDTA; Appendix A), and 
centrifuged at 330 x g for 10 min. Left over red blood cells remaining in the 
PBMC pellet were lysed with 3 ml of buffered ammonium chloride solution (ACK; 
Appendix A) for 10 min at room temperature with occasional shaking, then 
washed with PBS-EDT A under the same conditions as indicated above. 
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Viable cells were counted with a hematocytometer using a trypan blue 
exclusion assay. Approximately 107 cells were pelleted by centrifugation under 
the conditions described above and frozen in a mixture of 90% heat-inactivated 
(at 56 oc for 1 h) fetal calf serum (FCS-HI; Gibco BRL, Gaithersburg, MD) and 
10% DMSO (Sigma Chemical Co., St. Louis, MO) at -70 °C. The cells were 
transferred to liquid nitrogen the next day for long-term storage. Frozen cells 
were used to isolate nucleic acid (see Section 2.6). 
2.2.4 Liver biopsies 
Liver biopsies were obtained by surgical laparotomy under sterile 
conditions, as described elsewhere (Michalak et a/., 1 999). Each animal was 
sedated by an intramuscular injection of ketamine (23 mg/kg; Ketaset; CDMV 
Inc., St. Hyacinthe, Quebec) and xylazine ( 10 mg/kg; Lloyd Laboratories, 
Shenandoah, Iowa), and then anaesthetised with 2-4% isofluorane (CDMV Inc.). 
Each biopsy was divided aseptically into several portions. Some of these 
fragments (1-2 mm3 each) were immediately frozen in liquid nitrogen for future 
nucleic acid analyses. Other tissue fragments (about 5 mm3 each) were fixed in 
10% buffered formalin (Fisher Scientific ltd., Nepean, Ontario) for histological 
examination or embedded in HistoPrep (Fisher Scientific ltd.) and frozen in 
isopentane alcohol cooled in liquid nitrogen for immunofluorescent examinations. 
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2.2.5 Collection of specimens at autopsy 
For autopsy, animals were injected with an overdose of ketamine:xylazine 
mixture. Blood was collected by cardiac puncture and used for isolation of serum 
(Section 2.2.2), plasma, and PBMC (Section 2.2.3). The liver, spleen, kidneys, 
pancreas, lymph nodes, bone marrow, and portions of the small intestine and 
skeletal muscle were removed aseptically. Tissue samples were preserved for 
further investigations as described in Section 2.2.4. 
2.3 Cell cultures 
2.3.1 Woodchuck WCM-260 hepatocytes 
The WCM-260 hepatocyte cell line used in this study was established 
previously in our laboratory (Diao et a/., 1998; Lew and Michalak, 2001 ). The 
hepatocyte culture medium for WCM-260 cells consists of 80% (vollvol) Hepato-
STIM™ medium (Becton Dickinson) supplemented with 10 ng/ml epidermal 
growth factor (EGF; Becton Dickinson), 2 mM L-glutamine (ICN Pharmaceuticals, 
Montreal, Quebec), 50 units/ml penicillin (Gibco BRL) and 50 jJg/ml streptomycin 
sulfate (Gibco BRL). The medium also contained 20% (vol/vol) of filtered, culture 
supernatant obtained from 90% confluent HepG2 cells (see Section 2.3.2). This 
enriched medium was called a conditioned hepatocyte medium (Diao et a/., 
1998). WCM-260 hepatocytes were either seeded in T-25 culture flask (Corning; 
Corning Costar Corp., Cambridge, MA) or in the wells of a 12-well culture plate 
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(Corning; Corning Costar Corp.). They were maintained in a humidified tissue 
culture incubator with 5% C02 (Forma Scientific, Marietta, Ohio) at 37 oc. The 
medium was replaced every 2 to 3 days until cells become confluent. WCM-260 
cells were detached by trypsinization. For this purpose, cells were incubated 
with 2 ml trypsin solution consisting of 0.25% (wt/vol) trypsin and 0.02% (wt/vol) 
EDTA (Trypsin-EDTA; Gibco BRL) at 37 oc for 5 min. Then, 10 ml of Hank's 
balanced salt solution (HBSS) was added and the cells were transferred to a 15-
ml centrifuge tube and pelleted at 45 x g for 5 min at room temperature. 
Recovered hepatocytes were resuspended in 1 ml of fresh, conditioned 
hepatocyte medium. Ten IJI of this mixture was diluted 1:2 with 0.1% trypan blue 
and cells counted in a hematocytometer. Samples containing approximately 1 x 
106 hepatocytes in 1 ml of 90% FCS-HI/1 0% DMSO were frozen in liquid nitrogen 
for long-term storage. Hepatocytes were maintained in culture through repeated 
passage by re-seeding at 6 x 104 cells/ml at approximately weekly intervals. 
2.3.2 Other cells 
HepG2 cell line (ATCC number HB-8065; American Tissue Culture 
Collection, Rockville, MD) and L cells (ATCC number CCL-1) were cultured in 
Dulbecco's-modified Eagle medium (D-MEM; Gibco BRL) supplemented with 1.5 
g/1 sodium bicarbonate, 1 mM sodium pyruvate (Gibco BRL), 0.1 mM non-
essential amino acids (Gibco BRL), 50 U/ml penicillin, 50 j..Jg/ml streptomycin 
sulfate (Gibco BRL), and 10% FCS-HI (Gibco BRL), under conditions 
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recommended by the supplier, i.e. ATCC. To detach and passage these two cell 
lines, they were treated in a similar way as WCM-260 hepatocytes (described in 
Section 2.3.1 ). 
2.4 Nucleic acid isolations 
2.4.1 DNA isolation 
DNA was extracted from approximately 5 x 1 06 hepatocytes or frozen 
PBMCs, or from 1 00 !JI of serum or culture supernatant, or from 50 mg of 
homogenized tissues. All tissue fragments predestined for DNA isolation were 
washed with HBSS by centrifugation at 1,000 x g prior to homogenization in a 
final volume of 100 !JI of HBSS. Cells used for DNA extraction were 
resuspended in 100 !JI of HBSS. Then, the samples were incubated with 200 1-11 
of lysis buffer (Appendix A) containing 50 !Jg of proteinase K (Sigma Chemical 
Co.) at 42 oc for 16 h. The digest was supplemented with 300 !JI of phenol 
equilibrated in 0.1 M Tris-HCI buffer, pH 8.0, containing 0.1% (wt/vol) 
hydroxyquinilone (Sigma Chemical Co.), mixed for 15 min at ambient 
temperature, and centrifuged at 18,000 x g for 5 min to separate the aqueous 
and organic phases. The upper aqueous layer was removed and transferred to a 
new 1.5-ml tube containing 300 !JI chloroform:isoamyl alcohol (24: 1, vol/vol; 
Sigma Chemical Co.). The mixture was rotated for 10 min and then centrifuged 
for 5 min at 10,000 x g at room temperature. The aqueous layer containing DNA 
was transferred to a 1.5-ml Eppendorf tube and precipitated with 750 !JI of cold 
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100% ethanol (Sigma Chemical Co.) with 30 1-11 of 3 M sodium acetate (pH 5.2) 
and kept for 16 hat -20 °C. DNA was recovered by centrifugation at 20,000 x g 
for 30 min at 4 °C. The resultant pellet was washed by centrifugation with 600 1-11 
of room temperature 70% ethanol. The DNA was then air-dried for 5 min and 
resuspended in 40 1-11 (cell or tissue DNA) or in 10 1-11 (DNA from serum, culture 
supernatant or cell washes) of either TE buffer (1 mM EDTA in 10 mM Tris-HCI 
buffer, pH 8.0) or autoclaved double-distilled water. 
2.4.2 RNA isolation 
Total RNA was isolated from tissue samples, frozen cells or cultured cells, 
as well as from naive and mitogen-stimulated PBMC using TRizol reagent (Gibco 
BRL), according to the manufacturer's instruction. Briefly, tissues or cells were 
homogenized in 1 ml of TRizol reagent (Gibco BRL) and mixed for 30 min. After 
the addition of 200 1-11 chloroform, the tubes were shaken vigorously for 15 sec 
and the samples centrifuged at 12,000 x g for 15 min at 4 oc. RNA was 
precipitated from the aqueous upper phase with 500 1-11 of isopropanol (Sigma 
Chemical Co.) for 10 min at ambient temperature and collected by centrifugation 
at 12,000 x g for 10 min at 4 °C. The RNA pellet was washed in 1 ml of RNase-
free 75% ethanol. The final RNA pellet was briefly air-dried and resuspended in 
RNase-free water prepared by treatment with diethyl pyrocarbonate (DEPC; 
Sigma Chemical Co.). RNA was quantitated as described in Section 2.4.3 and 
used immediately for reverse transcription reaction or stored at -70 °C. 
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2.4.3 Quantitation of nucleic acids 
DNA, RNA and synthetic oligonucleotide primers or probes used in these 
studies were quantitated based on the ultraviolet (UV) absorbance at 260 nm 
using a DU 530 spectrophotometer (Beckman Instruments, Inc., Fullerton, CA). 
DNA and oligonucleotides were read after a 1 :50 dilution in TE buffer. The 
concentration of RNA was estimated assuming an optical density of 1 
corresponded to 40 mg RNA/mi. The actual calculation used was as follows: 
RNA (mg/ml) = (00260 nm - OD320 nm) X dilution factor X 40 mg/ml. DNA 
concentrations were determined as above except that an optical density of 1 
corresponded to 50 mg DNA/mi. The concentration of oligonucleotides was 
determined using the specific weight per 00 obtained in the certificate of 
analysis from the manufacturer (Gibco BRL). The estimation of the purity of the 
nucleic acid preparations was based on the 260:280 nm absorbance ratio. Only 
RNA preparations with a OD26o nm to OD2ao nm ratio of greater than 1.8 and DNA 
greater than 1.6 were used. 
2.5 Reverse trancription reaction 
The reverse transcription (RT) reaction was applied to convert total RNA 
to single stranded eDNA. Possible genomic DNA contamination during RNA 
extraction was eliminated by digestion with DNAse I (2 U/20 1-11; Ambion, Auxtin, 
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TX) at 37 oc in the presence of 10 mM Tris-HCI buffer, at pH 7.5 with 2.5 mM 
MgCh and 0.1 mM CaCI2 . The inactivation of DNAse I was achieved by adding 5 
~I of a chelate reagent from a DNAse-free kit (Ambion). After reacting for 2 min, 
samples were briefly spun down and RNA present in supernatant was transferred 
to another tube as DNA-free RNA sample. One to two ~g of RNA in 10 ~I of 
RNase-free water was added to 1.5 ~I of random primers (1 00 ng/~1) and 
incubated for 4 min at 75 oc, then chilled on ice. RT reaction was completed in a 
20 ~I reaction volume by mixing RNA random primer mixture, 4 ~I of 5 x RT 
buffer (375 mM KCI, 15 mM MgCI2 in 250 mM Tris-HCI buffer, pH 8.3; Gibco 
BRL), 2 ~I of dithiothreitol (OTT; 0.1 M; Gibco BRL), 2 ~I of deoxynucleotide 
triphosphate (dNTP) mixture (1 0 mM of each nucleotide; Promega Corp., 
Madison, WI), 10 U of RNase inhibitor (RNasin; 40 U/~1; Promega Corp.) and 200 
U of reverse transcriptase from Moloney murine leukemia virus (Gibco BRL). In 
a control reaction, reverse transcriptase was replaced with RNase-free distilled 
water. After incubation at 37 oc for 1 h and then at 95 oc for 5 min, the samples 
were stored at -70 oc for future PCR amplification (see Section 2.6). 
2.6 Polymerase chain reaction 
In this study, nucleic acid amplifications by PCR were used for two 
different purposes. First, to detect the presence of WHV DNA in serum, PBMC, 
and liver of WHV-infected animals and, secondly, to amplify cDNAs for cloning 
woodchuck gene sequences not identified prior to this work. 
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2.6.1 General criteria for designing oligonucleotide primers 
Since many of the woodchuck eDNA sequences required in this study 
were never determined previously, the PCR primers initially used for amplification 
were based on the consensus of the respective published human, mouse and rat 
sequences. At this initial stage, most of the oligonucleotide primers contained at 
least one degenerate base (referred to as degenerate primers). As the study 
progressed, the woodchuck specific sequences were established in our 
laboratory or by other groups (Lohrengel et a/., 1998; Nakamura et a/., 1997), 
and the primer sequences were modified accordingly. 
In order to ensure efficient amplification of the target sequences, each 
primer pair was matched according to GC content (approximately 50%), length 
(18-25 bases) and melting temperature (± 5 °C). Matching was done by using 
PC/Gene software (lntelligenetics, Geneva, Switzerland) and the BLAST search 
engine software (http://www.ncbi.nlm.nih.gov/BLAST; National Centre for 
Biotechnology Information, National Library of Medicine, National Institute of 
Health, Bethesda, MD). All oligonucleotides were commercially synthesized by 
Gibco BRL (Gaithersburg, MD), lOT DNA Technologies (Coralville, lA) or Qiagen 
(Mississauga, Ontario). Primers used for the initial amplification and cloning of 
particular woodchuck genes are outlined in the respective chapters. 
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2.6.2 Standard PCR conditions for WHV DNA detection 
Three sets of primers specific for non-overlapping regions of WHV DNA, 
i.e., C, S and X genes, were used for the detection of virus genome by direct 
PCR. In addition, 3 other primers pairs, internal to those mentioned above, were 
used for nested PCR when the results of the direct PCR were negative. 
Sequences of these primers and their location in the WHV genome have been 
outlined in previous studies from our laboratory (Coffin and Michalak, 1 999; 
Michalak eta/., 1 999). 
In general, direct PCR detection of WHV utilized 2 IJg of total DNA as 
template. The final reaction conditions consisted of 200 IJM of each dNTP, 10 
pmol of each oligonucleotide primer, 1 X reaction buffer comprising 1.5 mM 
MgCI2 with 50 mM KCI in 20 mM Tris-HCI buffer, pH 8.4, and 2.5 U of Taq DNA 
polymerase (all from Gibco BRL) in a 100 IJI total volume. The reaction mixture 
was layered with 100 IJI of mineral oil (Sigma Chemical Co.) to inhibit evaporation. 
DNA amplification proceeded in a programmable thermal cycler (TwinBiock 
System; Ericomp Inc., San Diego, CA) using the following program: 94 oc for 5 
min as the first step, then 94 oc for 30 sec, 52 oc for 30 sec, and 72 oc for 30 
sec for 30 cycles. A final extension step was performed at 72 oc for 10 min. For 
each thermocycling reaction, recombinant WHV DNA (Galibert et a/., 1 982; 
Pardoe and Michalak, 1 995) and liver DNA from a WHsAg-positive, chronically 
infected animal were used as positive controls. In addition, both a water and a 
mock sample, containing all reagents used during the DNA extraction and PCR 
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but not test DNA, were included as negative controls. For nested PCR, 10 1-11 of 
the direct PCR mixture was reamplified under the same conditions as the direct 
reaction with nested primers specific for appropriate WHV genes. PCR 
amplifications were performed under conditions limiting the possibility of 
contamination, as outlined in detail in our previous studies (Coffin and Michalak, 
1999; Michalak eta/., 1999). 
2.6.3 Amplification of eDNA for cloning of woodchuck genes 
All PCR using degenerate primers were performed under lenient PCR 
conditions and using 1-5 1-11 of eDNA (see Section 2.5) as the amplification 
template. The 1 00-1-JI final reaction mixture was the same as for WHV DNA 
amplification (see Section 2.6.2) except it contained 40 pmol of each synthetic 
oligonucleotide primer and high fidelity Taq polymerase Pwo (Boehringer 
Mannheim, Laval, Quebec) with exonuclease activity. The following program 
was employed for PCR using degenerate primer pairs: 94 oc for 10 sec, 52 oc 
for 10 sec, and 72 oc for 2 min for 35 cycles. The products were analyzed by 
agarose gel electrophoresis. If the size of the product matched the deduced size 
from relevant human, mouse and rat gene fragments, gel purification was 
performed which was followed by cloning (see Section 2.8). 
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2. 7 Detection of amplified DNA 
2. 7.1 Agarose gel electrophoresis 
Ten ~I final PCR product was mixed with 2 ~I of 6 x blue/orange loading 
dye (Promega Corp.) prior to loading on a 1% agarose gel containing 0.5 ~g/ml 
ethidium bromide (EB). In addition, 0.25 ~g of <pX174 DNNHae Ill molecular 
weight standards (Promega Corp.) was also loaded in a parallel well. The gel 
was run at 120 V for 30 min in TAE buffer (1 mM EDTA in 40 mM Tris-HCI buffer, 
pH 8.0). DNA bands were visualized by UV and the images were preserved 
using GeneGenius, a gel documenting system (Syngene, Cambridge, UK). 
2.7.2 Southern blot hybridization 
2. 7 .2.1 Blotting of DNA onto nylon membrane 
Following electrophoresis and documentation of the UV-visualized DNA 
bands, the gel predestined for Southern blot analysis was soaked in denaturing 
solution (1.5 M NaCI and 0.5 M NaOH) for 30 min and then rocked in neutralizing 
buffer (1.5 M NaCI in 1 M Tris-HCI buffer, pH 8.0) for 1 h. 
Transfer of DNA from the gel to a nylon membrane was done using 
capillary transfer. A glass platform was set up in a dish containing 10 x standard 
saline citrate (SSC, diluted from 20 X sse constituted by 3 M NaCI in 0.3 M 
Na2Cit.2H20, pH 7.0). A Whatman (3MM) filter paper wick was soaked in 10 x 
SSC and mounted on this platform. The gel was placed upside down on the wick 
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and parafilm was used to surround the gel. A piece of nylon membrane 
(Hybond-N; Amersham, Piscataway, NJ) and 2 pieces of filter paper cut to size 
and briefly soaked in 6 X SSe were laid on top of the gel, followed by 5 em high 
stack of paper towel trimmed to size. A glass weight of approximately 500 g was 
placed on top to facilitate the 16 h-capillary transferring. The next day, the 
membrane was dried between sheets of filter paper for 30 min at room 
temperature, and then baked at 80°e in a vacuum oven for 2 h. 
2. 7 .2.2 Hybridization 
The baked nylon membrane with blotted test DNA was put into a 
hybridization tube with 6 ml of hybridization buffer (6 X sse, 0.5% SDS, 5 X 
Denhardts' solution made from 50 x Denhardts' solution (1% [wt/vol] Ficoll, 1% 
[wt/vol] polyvinylpyrrolidone, 1% [wt/vol] bovine serum albumin), and 100 IJg/ml 
sonicated salmon sperm DNA). The membrane was prehybridized in a 65 oe 
hybridization oven for 1.5 h. Subsequently, 6 x 106 counts per minute (cpm) of 
32P-Iabelled DNA probe, which was previously boiled for 5 min and then chilled 
on ice for 2 min, was added into the hybridization tube. After hybridization at 65 
oe for 16 h, the buffer containing probe was removed and the membrane was 
washed twice at 65 oe in 50 ml of pre-warmed 2 X sse with 0.1% SDS for 10 
min each. This was followed by 2 washes with 50 ml of 0.1 x SSe, 0.05% SDS 
for 15 min each at ambient temperature. The membrane was then rinsed in 0.1 x 
sse and dried briefly on paper towels. It was then covered in plastic wrap and 
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exposed on a phosphor screen for phosphorimaging (Cyclone™; Canberra-
Packard, Meriden, CT) or on an X-ray film (XRP-1; Kodak, Toronto, Ontario). For 
autoradiography, cassettes equipped with intensifying screens were exposed at-
70°C. 
2.7.2.3 Recombinant WHV DNA probe 
Recombinant WHV DNA used for the Southern blot detection of amplified 
WHV DNA sequence was derived from the pSP65 plasmid vector containing the 
EcoRI fragment of the full WHV genome (Galibert eta/., 1982). This plasmid was 
kindly provided by Dr. J. Summers from the University of New Mexico, 
Albuquerque, New Mexico (Pardoe and Michalak, 1995). The construct was 
digested with EcoRI and separated by electrophoresis in 1% low melting point, 
ethidium bromide-agarose (Gibco BRL). The band containing the linear, cloned 
WHV DNA (rWHV DNA) was excised from the gel and isolated using the 
Wizard™ PCR Prep DNA Purification System (Promega Corp.), as per 
manufacturer's instruction. DNA concentration was determined based on its 
absorbance at 260 nm, as described above (see Section 2.4.3). 
This rWHV DNA was labelled with 32P-dCTP using the Rediprime TM DNA 
labelling system (Amersham) following manufacturer's instructions. Briefly, 25 ng 
of rWHV DNA was made up to 45 1-JI in TE buffer, boiled for 5 min, and chilled on 
ice for about 2 min. The DNA mixture was added to the Rediprime™ reaction 
tube. Then, 5 IJI of a-32P-dCTP (10 1JCii1JI; Amersham) was added and the tube 
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was flicked a few times to resuspend the lyophilized mixture which consisted of 
dATP, dGTP, dTTP, Klenow enzyme, and 9-mer random primers. The labelling 
reaction was incubated for 1 h at 37 °C. 
The 32P-Iabelled probe was purified from unincorporated 32P-dCTP by 
fractionation on a NICK™ column (Amersham), as described in the 
manufacturer's instruction sheet. The column was washed with 3 ml of TE buffer 
and inserted in a 15-ml disposable centrifuge tube. Fifty !JI of the probe mixture 
was applied onto the column, followed by 400 !JI of TE buffer. The eluent was 
discarded and 450 !JI of TE buffer was applied to the column. This eluted fraction 
containing the labelled probe was collected and a 2-!JI sample was used for 
radioactivity counting in a scintillation counter. The cpm per !JI of the aliquot was 
determined. The probe was stored at 4 oc prior to being used for Southern blot 
hybridization analysis (see Section 2.7.2.2). 
2.8 DNA cloning 
2.8.1 Purification of PCR-amplified DNA 
PCR products destined for cloning were purified using the Wizard PCR 
preps DNA purification system (Promega Corp.). After electrophoresis on a 1% 
low melting point agarose gel, the band containing the PCR product of interest 
was excised, placed in a 1.5-ml micro-tube and melted at 65 oc. One ml of 
purification resin was added to the tube, mixed briefly, and filtered under vacuum 
through a Wizard minicolumn. The column was washed twice with 80% 
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isopropanol, and then centrifuged at 12,000 x g for 20 sec. The collected 
isopropanol was discarded. TE buffer (50 1-JI) prewarmed to 65 oc was added to 
the column and left for 1 min at room temperature. The minicolumn was 
centrifuged at 12,000 x g for 20 seconds and the elutant containing the DNA 
saved. The DNA concentration was determined by spectrophotometric analysis 
at 1:10 dilution in TE buffer, as described in Section 2.4.3. 
2.8.2 Cloning 
Gel purified DNA was cloned using a dual promoter TOPO-TA Cloning Kit 
(Invitrogen, Carlsbad, CA). The final cloning mixture consisted of 4 1-JI purified 
PCR product, 1 1-JI NaCI and 1 1-JI of TOPO pCRII vector in a total volume of 6 1-JI. 
After incubating at room temperature for 30 min, 2 1-JI of the reaction mixture was 
added to 50 1-JI of ice-cold, competent TOP1 0 bacterial cells (Invitrogen). The 
mixture was further chilled for 30 min on ice, heat shocked for 30 sec at 42 °C, 
and placed on ice for 2 min. Subsequently, 500 1-JI of SOC medium (Appendix A) 
was added and the cells were incubated at 37 oc for 1 h in a rotary shaker at 200 
rpm. A 1 00-1-JI aliquot of each transformation reaction mixture was then spread 
onto 1.5 % Bacto-Agar (Difco Laboratories, Detroit, Ml) coated with 40 1-JI of X-
Gal (Sigma Chemical Co.; Appendix A) in a 10-cm Petri dish. Cells were then 
incubated at 37 oc for 16 h and white colonies obtained were screened further 
(see Section 2.8.3). 
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2.8.3 Plasmid DNA preparation 
Individual bacterial colonies were collected and inoculated into 5 ml of 
sterile LB medium supplemented with 50 ~g/ml kanamycin (Sigma Chemical Co.). 
Bacteria were grown overnight at 37 oc with 250 rpm shaking. For preparation of 
small amounts of plasmid DNA predestined for preliminary testing, a 1.5-ml 
aliquot of transformed bacterial cells were pelleted at 20,000 x g for 20 sec. The 
cells were resuspended in 100 1-11 of glucose Tris-EDTA (GTE; Appendix A) and 
left for 5 min at ambient temperature. The bacteria were lysed with 100 1-11 of 
freshly prepared solution of 0.2 N NaOH/1% SDS for 5 min at room temperature. 
To neutralize the solution and aid in the removal of chromosomal DNA and 
proteins, 100 1-11 of prechilled 3 M potassium acetate, pH 5.5, was added to the 
tube, and the mixture was kept on ice for 5 min. Then, the mixture was 
centrifuged at 20,000 x g for 5 min to pellet cell debris and chromosomal DNA. 
The supernatant was transferred to a 1.5-ml Eppendorf tube and the nucleic 
acids were precipitated with 1 ml of 95% ethanol for 10 min at room temperature. 
Plasmid DNA was pelleted by centrifugation at 15,000 x g for 5 min. The pellet 
was washed with 1 ml of 70% ethanol, air-dried, and resuspended in 30-50 1-11 of 
TE buffer. Plasmid mini-preparations were analyzed for the presence of the 
proper DNA inserts, as described in Section 2.8.4. 
A large-scale plasmid DNA preparation (maxi or midi preparations) was 
produced by using a Maxi/Midi plasmid preparation kit from Qiagen, according to 
manufacture's instruction. Briefly, 50 1-11 bacterial aliquot containing the proper 
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plasmid insert, as judged by miniprep analysis described above, was grown to 
saturation in 200 ml of LB medium supplemented with 50 1-Jg/ml of the 
appropriate antibiotic (kanamycin or ampicillin). The bacteria were collected by 
centrifugation at 6,000 x g for 15 min at 4 °C. The pellet was resuspended in 10 
ml of P1 solution (Appendix A) supplemented with 100 1-Jg/ml RNase A. Bacteria 
were lysed with 1 0 ml of P2 solution (Appendix A) for 5 min at room temperature 
followed by neutralizing with 10 ml of ice-old P3 solution (Appendix A) on ice for 
30 min. Chromosomal DNA and bacterial protein were removed by passing 
through a filter cartridge provided with the kit. The cleared solution was then 
applied to the column filled with DNA binding resin pre-equilibrated with QBT 
buffer (Appendix A). After twice washing with QC buffer (Appendix A}, DNA was 
eluted with 15 ml of QF buffer (Appendix A). Plasmid DNA was precipitated by 
adding 10.5 ml of isopropanol (Sigma Chemical Co.) and incubation at room 
temperature for 5 min followed by centrifugation at 20,000 x g for 30 min. The 
pellet was washed with 70% ethanol and resuspended in 500 1-11 of TE buffer. 
The DNA was quantitated, as described in Section 2.4.3, and stored at -20 oc. 
2.8.4 Digestion with restriction enzymes 
For the purpose of either releasing the DNA fragment of interest from the 
vector or to examine the specificity of the DNA sequence, restriction enzyme 
digestion was performed with appropriate enzymes, following the instruction 
provided by the manufacture of a particular enzyme. Briefly, for single restriction 
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enzyme digestion, a 20-!JI reaction mixture with 0.5-1 !Jg plasmid DNA, 10 U 
enzyme and the appropriate buffer was incubated at 37 oc for 1-2 h. Digestions 
with two enzymes were done in a 30-!JI reaction containing 0.5-1 !Jg plasmid 
DNA, 10 U of each restriction enzyme, and the appropriate buffer compatible with 
both enzymes. Incubation was performed at 37 oc for 2-4 h. Agarose gel 
electrophoresis (see Section 2.7.1) was used to determine the size of the inserts 
obtained after the digestion. 
2.9 DNA sequencing 
2.9.1 End-labelling of oligonucleotide probes 
Synthetic oligonucleotides were labelled with 32P-ATP using T 4-kinase 
(Gibco BRL) following manufacturer's instruction. The final reaction mixture 
consisted of 10 pmol of template, 3 !JI of 32P-ATP (Amersham), 1 x forward 
reaction buffer (Appendix A), and 10 U of T4 kinase in a total volume of 10 !JI. 
The tube contents were mixed gently and incubated for 1 h at 37 °C. 
2.9.2 PCR amplification 
Final confirmation of the identity of a particular DNA fragment was done by 
nucleotide sequence analysis using the fmol DNA cycle sequencing system 
(Promega Corp.). Briefly, a cocktail containing approximately 40 fmol of 
recombinant plasmid DNA or a PCR product, 1.5 pmol of a sequencing primer 
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end-labelled with 32P-ATP (Amersham) (Section 2.9.1), 2 mM of MgCI2 in 50 mM 
Tris-HCI buffer, pH 9.0 (supplied as a 5 x buffer), and 5 U of sequencing grade 
Taq DNA polymerase (Promega Corp.) were prepared. The cocktail was divided 
equally into each of 4 tubes containing 2 1-11 of either the G (guanine), A (adenine), 
T (thymine) or C (cytosine) terminating nucleotide mixture. Cycle sequencing 
was conducted using the following program: 95 oc for 2 min, then 30 cycles 
consisting of 95 oc for 30 sec, 42 oc for 30 sec, and 70 oc for 1 min. Upon 
completion, 3 1-11 of formam ide stop solution (Appendix A) was added to each tube 
and the tubes were stored on ice until electrophoresis in a sequencing 
polyacrylamide gel (Jung eta/.) (see Section 2.9.3). 
2.9.3 Sequencing PAGE 
Prior to loading on the sequencing gel each sample was heat-denatured 
for 5 min at 70 °C, then chilled on ice. The DNA samples were separated on an 
8% denaturing polyacrylamide gel containing 7 M urea (Gibco BRL). After 
electrophoresis at 50 oc (monitored by a thermal probe) at 50 W, the gel was 
fixed with a 10% methanol, 10% acetic acid solution and dried at 80 oc in a slab 
gel dryer. Subsequently, the gel was exposed briefly to a multipurpose storage 
phosphor screen and the image analyzed using the Cyclone system (Canberra 
Packard). Final documentation was performed by overnight exposure of the gel 
to X-ray film (Kodak). 
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The identity of the nucleotide sequences was confirmed by comparison 
with published sequences in GenBank library (National Centre for Biotechnology 
Information, National Library of Medicine, National Institute of Health, Bethesda, 
MD) using the BLAST search engine software (http://www.ncbi.nlm.nih.gov 
/BLAST). Once confirmed, the complete sequences of the cloned woodchuck 
DNAs were determined by employing a commercial fluorescence-based 
automated DNA sequence analyzer (LI-COR; LiCor Inc., Lincoln, NB) (service 
provided by Department of Genetics, Hospital for Sick Children, Toronto, Ontario). 
2.10 Expression and purification of woodchuck recombinant proteins 
2.1 0.1 Expression of protein in E. coli system 
An E. coli expression system, pET41 (Novagen, Madison, WI), was used 
to express the following WHV proteins, i.e., recombinant preS(1-176) protein 
encoded by nucleotides from 2992 to 211 (rPreS1), recombinant WHcAg coded 
by nucleotides from 2021 to 2584 (rWHcAg), recombinant truncated WHcAg (1-
149) encoded by nucleotides 2021 to 2467 (rtWHcAg), and recombinant X 
protein encoded by nucleotides 1503-1928 (rWHxAg). All nucleotide positions 
refer to WHV/tm3 sequence (Genbank AY334075) (Michalak et a/., 2004). In 
addition, the recombinant mature form of woodchuck IFNy (ec-rwiFNy) and the 
recombinant mature form of woodchuck TN Fa (ec-rwTNFa) were expressed (see 
Chapter 4). Briefly, each gene sequence of interest was directionally inserted 
into the pET 41 b vector at Ndel and Xhol restriction enzyme sites by a PCR-
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based strategy similar to that described in Chapter 4. Final constructs were 
engineered to have an 8-mer poly-histidine (His) tag at the carboxyl-end to 
facilitate their purification. After transforming with the pET41 plasmid containing 
the exogenous gene of interest into E. coli cells BL21 (DE3) or BL21 (DE3/PiysS), 
which encodes T7 lysozyme for a tighter control of protein expression, individual 
colonies were grown in LB medium supplemented with 50 IJg/ml kanamycin and 
1% glucose at 37 oc with shaking (see Section 2.8.2). When the E. coli culture 
reached a density reading of 0.4-1 at ODsoo nm, it was split into two parts. 
lsopropyl-beta-0-thiogalactopyranoside (IPTG) (Appendix A), the induction 
reagent for pET system, was added to one part at the final concentration of 1 mM. 
The other tube was left as un-induced control. Both cultures were incubated for 
an additional 2-3 h at 37 oc with shaking. Bacteria were pelleted by 
centrifugation at 15,000 x g for 1 min and lysed with BugBuster (Novagen) 
reagent in the presence of 25 U/ml benzonase (Novagen). Following 10-20 min 
lysing, insoluble inclusion bodies (IB) were separated from the soluble proteins 
by centrifugation at 16,000 x g for 20 min at 4 °C. Subsequently, IB was treated 
with lysozyme at a final concentration of 200 IJg/ml for 5 min at room temperature, 
followed by three washings with 1:10 diluted Bug Buster reagent. Finally, the 18 
were suspended in a denaturing buffer containing 8 M urea (Appendix A). All the 
samples, soluble and IB from both IPTG-induced and non-induced controls, were 
then examined by SDS-PAGE to determine the presence of the recombinant 
proteins (see Section 2.12). 
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2.1 0.2 Affinity purification of recombinant proteins 
Due to the presence of 8 consecutive histidine residues at the carboxyl-
end of the recombinant proteins produced, their purification was achieved by 
nickel-charged resin, as proposed in the supplier's instruction. Briefly, His-Bind 
resin (Novagen) was washed 2 times with binding buffer (Appendix A) and then 
incubated with bacterial lysate in BugBuster reagent for 20-60 min at room 
temperature. Subsequently, the resin was washed 2 times with binding buffer 
and the resulting washout buffer saved for later SDS-PAGE analysis. After 
another two washings with washing buffer (Appendix A), 5-times resin bed 
volume elution buffer (Appendix A) was added. Then, 1 00-1-JI fractions were 
collected. For the purification of recombinant protein from IB, a similar procedure 
was employed except that urea at a final concentration of 8 M was added into 
each buffer used in the process. Finally, the purity of the recombinant protein 
was determined by SDS-PAGE gel analysis 
2.11 Antibodies 
2.11.1 Production of polyclonal antibodies against recombinant proteins 
Antisera against purified recombinant proteins, such as WHV rpreS1 and 
ec-rwiFNy were raised in rabbits and guinea pigs. Animals were subcutaneously 
injected at multiple sites with 10-50 1-Jg of recombinant protein emulsified in 
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complete Freund's adjuvant (Sigma Chemical Co.). Four weeks later, each 
animal was boosted with a subcutaneous injection of 10-50 ~g of the respective 
protein with incomplete Freund's adjuvant (Sigma Chemical Co.). Blood samples 
were collected before the first immunization (pre-immune serum) and 2 weeks 
after booster injection. Anti-sera were analysed by Western immunoblotting (see 
Section 2.12) using recombinant proteins as substrates. Pre-immune sera as 
well as non-related recombinant proteins were used as negative controls. In 
some cases, where animals did not produce high-titer antibodies, a second or 
even third booster injection with 1 0-50 ~g purified recombinant protein was given 
intramuscularly at 4-5 weeks intervals until a satisfactory level of antibodies was 
generated. 
2.11.2 Monoclonal antibody to woodchuck class I MHC heavy chain 
Mouse monoclonal antibody (81b.B9 mAb) against a nonpolymorphic 
epitope of the woodchuck MHC class I heavy chain was generated and 
characterized in detail in a previous study from this laboratory (Michalak et a/., 
1995). This antibody recognizes two polypeptide species of woodchuck class I 
heavy chains with molecular masses of 43- and 39-kDa. This mAb was used 
previously to document that chronic WHV hepatitis is associated with an inhibited 
display of class I MHC antigen on infected hepatocytes (Michalak eta/., 2000). 
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2.12 Western blotting 
A 12% acrylamide gel in 37.5 mM Tris-HCI buffer, pH 8.8, with 0.1% 
(wt/vol) SDS along with a 3% acrylamide upper gel in 12.5 mM Tris-HCI buffer, 
pH 6.8, with 0.1% (wt/vol) SDS were prepared in a mini-gel apparatus (Mini-
Protean II dual slab cell; Bio-Rad Laboratories, Hercules, CA). Before analysis, 
test samples were denatured for 5 min at 95 oc in buffer containing 3% SDS, 5% 
2-mercaptothanol, 10% glycerol in 62.5 mM Tris-HC buffer, pH 6.8. After 
electrophoresis at constant voltage (200 V) for about 45 min in reservoir buffer 
(20 mM glycine, 2.5 mM Tris base), the proteins were electrotransferred to 
nitrocellulose (NC) membrane (Amersham) by semi-dry transfer using a Bio-
Trans unit (Gelman Inc., Ann Arbor, Ml) with semi-dry transfer buffer (Appendix 
A). In parallel, gels containing the same electrophorectically separated proteins 
were directly stained with 0.5% Coomassie blue for identification of the complete 
protein band pattern. Efficiency of protein transfer was determined using pre-
stained molecular weight marker (Invitrogen). The same markers were used to 
estimate molecular mass of the separated proteins. To perform Western blot 
analysis, the NC blots were soaked with PBS containing 3% bovine serum 
albumin (BSA) and 0.05% Tween-20 for 2 h at ambient temperature. The blots 
were then incubated overnight at 4 oc with antibodies specific for the target 
protein at pre-tested dilutions in PBST (Appendix A). After 3 times washing with 
PBST, NC blots were incubated with affinity-purified goat anti-rabbit lgG or goat 
anti-guinea pig lgG antibodies conjugated with alkaline phosphatase (Jackson 
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lmmunoresearch Labs Inc., West Grove, PA) for 2 h at room temperature. This 
was followed by an other 3 washes with TBST (Appendix A). Then, the reaction 
was developed in a solution containing nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate, as described in supplier's instructions (Sigma 
Chemical Co.) (Michalak eta/., 1994). 
2.13 lmmunoflorescent methods 
2.13.1 lmmunostaining for class I MHC antigen 
Cultured WCM-260 hepatocytes (see Section 2.3) were harvested by 
trypsinization, divided into 100-1-11 aliquots and placed in 12 x 75 mm tubes 
(Fisher Scientific Ltd.) on ice. B1b.B9 mAb specific for woodchuck class I MHC 
heavy chain (Section 2.11.2) was added at 1:10 dilution and cells left on ice for 
45 min. Cells were then washed twice with 1 ml of PBS by pelleting at 45 x g for 
5 min. The washed cell pellets were resuspended in 100 1-11 of PBS containing 
goat anti-mouse lgG conjugated with fluorescein isothiocyanate (FITC; Jackson 
lmmunoreserach Laboratories Inc.) and kept on ice for 30 min. As controls, 
unstained cells and cells incubated in the first instance with PBS and then FITC-
conjugated anti-mouse lgG were included. Subsequently, hepatocytes were 
washed twice by centrifugation and the cell pellets were fixed in 200 1-11 of 1% 
(wt/vol) paraformaldehyde (Marivac Ltd, Halifax, NS) in PBS for 15 min at room 
temperature in the dark. 
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2.13.2 lmmunoflurescence microscopy 
Stained cells (Section 2.13.1) were mounted in 50% glycerol buffered in 
PBS and examined using a Leitz-Diaplan epifluorescence microscope equipped 
with a mercury lamp. In each set of experiments, unstained cells and cells 
incubated with a relevant secondary antibody were included to determine the 
background fluorescence. 
2.12.3 Confocal microcopy 
Cells grown on clover slips were subjected to immune-staining and then 
mounted in 50% glycerol buffered in PBS. Nail polish was applied to seal the 
edge of the cover slip for long-term storage or left unsealed for immediate 
examination. An Olympus FluoView FV300 confocal system (Olympus America 
Inc. Melville, NY) equipped with a 488-nm blue argon laser, a 543-nm green 
helium neon laser and a 633-nm red helium neon laser and Olympus BX50WI 
microscope (Olympus America Inc) were used for the confocal fluorescent 
microscopy analysis. Digital images were obtained with FluoView application 
software (Ver. 3.0; Olympus America Inc.). Dual channel scanning was applied 
when samples were stained with two different fluorescent dyes (see Chapter 5). 
In each set of experiments, unstained cells, cells stained with secondary antibody 
alone, and cells exposed to preimmune sera and then incubated with the second 
layer antibodies were routinely included to determine the background and 
specificity of fluorescence. 
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2.13.4 Flow cytometry 
Stained cells were examined with a FACS Star™-Pius flow cytometer 
(Becton Dickinson). The FACS data were analysed using the CeiiQuest software 
(Becton Dickinson) or Win MDI (version 2.8) software (The Scripps Research 
Institute, La Jolla, CA). In each experiment, unstained and cells stained with 
secondary antibody were included as controls. The geometrical mean 
fluorescence intensity was calculated by the software to compare the level of 
expression between different samples. 
2.14 Statistic analysis 
Data were analyzed, when required, with GraphPad Prism software 
(GraphPad Software, Inc. San Diego, CA). Appropriate statistical analyses were 
performed where applicable. 
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CHAPTER 3. PURPOSE OF THE STUDY 
Chronic infection with HBV is an important cause of mortality due to the 
induction of severe liver diseases, including chronic active hepatitis, cirrhosis and 
HCC. Both virus and host factors are involved in the pathogenesis of liver 
damage and, most likely, in the establishment of long-term hepadnavirus 
persistence. These processes remain only partially elucidated. WHV infection in 
woodchucks (Marmota monax) closely resembles HBV infection in humans with 
respect to virological, immunological and pathological characteristics, as well as 
the features and outcomes of liver disease. In the present studies, the 
woodchuck model of HBV infection was applied to investigate the nature of 
selected molecular mechanisms potentially utilized by hepadnavirus to persist 
and to examine how antiviral cytokines, particularly IFNy, may reverse a 
hepadnavirus-caused hindrance relevant to its escape from immunological 
surveillance. We also tested the adjuvant action of IFNy in induction of 
preventive, hepadnavirus-specific immunoresponse using combined 
immunization with viral gene and IFNy DNA. To perform these studies, a number 
of woodchuck cellular genes, biologically active recombinant cytokines and 
WHV-specific assays, which were not previously available, were identified, 
produced or developed. 
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The specific objectives of the studies were as follows: 
1. To produce functionally active recombinant woodchuck IFNy and TNFa 
in the baculovirus expression system and compare their biophysical features, 
antiviral or cytolytic properties, and class I MHC inducing activities with those of 
the same cytokines generated in the E. coli expression system. 
2. To investigate the molecular nature of the previously made in vivo 
observation that chronic WHV infection is invariably associated with a severe 
suppression of the class I MHC antigen on infected hepatocytes. For this 
purpose, create a hepatocyte culture system in which the effect of the expression 
of the complete WHV genome, WHV genes encoding individual viral proteins or 
WHV DNA mutants on the surface display of class I MHC antigen can be 
analyzed. Further, to establish which one of the WHV proteins exerts the class I 
MHC inhibitory effect and what could be a possible underlying mechanism. Also, 
to examine whether treatment with an exogenous IFNy can restore the virus-
induced suppressed class I MHC antigen presentation on hepatocytes in vitro. 
3. To study whether IFNy DNA can act as an adjuvant and enhance 
protection against hepadnavirus in the woodchuck model of hepatitis 8 when 
administered as a component of a bicistronic DNA vaccine carrying virus 
nucleocapisd and IFNy gene encoding sequences. To investigate the nature of 
immunological responses induced by this DNA vaccine, examine whether this 
vaccination strategy can protect from the development of serologically and 
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histologically evident hepatitis, and whether it can establish complete (sterilizing) 
immunity against hepadnavirus. 
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CHAPTER 4. COMPARISON OF BIOLOGICAL ACTIVITY OF RECOMBINANT 
WOODCHUCK INTERFERON GAMMA AND TUMOR NECROSIS FACTOR 
ALPHA PRODUCED IN BACULOVIRUS AND E. COLI EXPRESSION 
SYSTEMS* 
4.1 Summary 
To create biologically active recombinant woodchuck interferon gamma 
(rwiFNy) and woodchuck tumor necrosis factor alpha (rwTNFa), the full-length 
cDNAs of these cytokine genes were cloned into baculovirus transfer vectors and 
expressed in insect Sf9 cells. The recombinant proteins secreted by the insect 
cells, bac-rwiFNy and bac-rwTNFa, were found to be functionally competent. 
Their biological activities were compared to those of rwiFNy and rwTNFa 
produced in the E. coli. expression system. The bac-rwiFNy demonstrated a 4.5-
fold greater protective activity against encephalomyocarditis virus (ECMV)-
induced cytolysis of woodchuck hepatocytes and that of class I MHC antigen 
presentation on the hepatocytes than rwiFNy derived from E. coli (ec-rwiFNy). 
The bac-rwTNFa was cytotoxic towards murine fibroblasts and able to upregulate 
class I MHC antigen display and these effects were about 18-fold greater that 
those triggered by rwTNFa from E. coli (ec-TNFa) at a comparable protein level. 
In addition, the antiviral activity of bac-rwiFNy was inhibited by anti-wiFNy 
• This study has been published in Cytokine Jan. 2005, volume 77(2), pp. 970-979. 
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antibodies and the cytotoxicity of bac-rwTNFa neutralized by cross-reactive 
antibodies to murine TNFa. The study showed that expression of rwiFNy and 
rwTNFa in the baculovirus system generated biologically active cytokines whose 
potency was considerably greater than those produced in E. coli. 
4.2 Introduction 
IFNy and TNFcx are potent regulators of both systemic and local immune 
responses, which also inhibit replication of a number of viruses (Rosenblum and 
Donato, 1989; Beutler and Cerami, 1989; Rook eta!., 1991; Baron and Dianzani, 
1994; Landolfo eta/., 1995; Benedict, 2003). In the liver, they are secreted by 
the residing lymphoid cells and by the cells infiltrating hepatic tissue due to 
inflammatory processes. An upregulated intrahepatic transcription of IFNy and 
TNFa is a hallmark of hepadnaviral hepatitis, particularly in patients and animals 
who ultimately recover from acute disease (Guidotti eta/., 1999; Guo eta/., 2000; 
Nakamura eta/., 2001; Hodgson and Michalak, 2001). 
IFNy is a pleiotropic cytokine produced by activated T lymphocytes, NK 
cells and NK T cells. It favors T helper type 1 lymphocyte immune responses 
and exerts a potent antiviral action against certain viruses, including HBV and 
HCV (Baron and Oianzani, 1994; Landolfo eta/., 1995; Chisari, 2000; Frese eta/., 
2002). IFNy also plays a main role in augmentation of immunoproteosome 
formation (Van den Eynde and Morel, 2001; Kloetzel and Ossendorp, 2004) and 
presentation of class I and class II MHC (Boehm et a/., 1997) leading to 
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enhancement in the cell surface display of antigenic epitopes recognized by 
specific effector T cells. Due to its important immunomodulatory functions and 
direct antiviral activity, IFNy is considered to be a suitable vaccine adjuvant and 
as a possible modality in viral infections (Chow eta/., 1998; Kim eta/., 2000). 
IFNy activity is highly species specific and studies in animal or cell culture 
models require its homologous origin. 
TNFa is mainly secreted by activated macrophages and T cells. It 
performs a wide range of functions, including modulation of host immune 
responses, mediation of inflammation, induction of tumor cell death, and 
interference with virus replication (Rosenblum and Donato, 1989; Beutler and 
Cerami, 1989; Rook eta/., 1991; Benedict, 2003). TNFa appears to be highly 
conserved between different species. Nevertheless, the availability of a species-
specific TNFa is required to unambiguously define its biological functions in test 
animal or culture systems. 
It has been demonstrated that both IFNy and TNFa have potent anti-HBV 
action in in vivo models of hepatitis B (see Section 1.9). Briefly, these cytokines, 
particularly IFNy, can reduce HBV gene expression in the liver prior to the 
appearance of the virus-specific CTL and destruction of hepatocytes, implying 
that the cytokine-mediated, non-cytolytic inhibition of virus replication may occur 
in the pre-acute phase of hepatitis B (Guidotti eta/., 1999). The mechanism of 
this direct antiviral action remains unrecognized (Guidotti and Chisari, 2001; 
Wieland eta/., 2003). The release of these cytokines by HBV-specific CTL also 
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is important in activation of other immune effector cells which contribute to 
recovery from hepatitis and their high intrahepatic levels are strongly connected 
with cessation of the acute disease (Guidotti eta/., 1999; Nakamura eta/., 2001; 
Hodgson and Michalak, 2001 ). However, a precise role of these cytokines in the 
development and resolution of hepadnaviral infection is not yet solved. 
The baculovirus system is one of the most powerful expression tools by 
virtue of its high efficiency, eukaryotic processing of recombinant proteins and 
availability of abundant vectors (Luckow and Summers, 1988). Various 
biologically active cytokines (Smith et a/., 1983; Maeda et a/., 1985) and growth 
factors (Chiou and Wu, 1990) have been successfully produced in this system. 
Interestingly, insect cells seem able to recognize and cleave human (Chiou and 
Wu, 1990; Churgay et a/., 1997), equine (Wu et a/., 2002) and bovine (Murakami 
et a/., 2001; Nagata et a/., 2003) signal peptides. The matured form of 
recombinant polypeptides was therefore released into the culture supernatant 
and this makes it easy for downstream purification, especially in serum free 
insect cell cultures. Although post translational modification of recombinant 
proteins in insects is not identical to its in human counterpart, certain strategies 
have been used to engineer insects cells as well as transfer vectors to produce 
humanized glycoproteins (Jarvis, 2003). 
The production of rwiFNy and rwTNFa in the E. coli expression system 
has been recently reported (Lohrengel et a/., 2000; Lu et a/., 2002). However, 
the commonly acknowledged difficulties in the removal of bacterial 
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contaminations, especially traces of a highly pathogenic lipopolysaccharide (Gao 
and Tsan, 2003), make the use of the E. coli-derived rwiFNy and rwTNFa not 
well suitable for in vivo and cell culture experimentations. To overcome this 
problem and, at the same time, to generate cytokines which structurally and 
functionally should be more compatible with those of the woodchuck, we 
expressed the full-length rwiFNy and rwTNFa cDNAs in the baculovirus system. 
We have found that the insect cells infected with the respective baculoviral 
constructs were able to secrete the woodchuck cytokines and that the cytokines 
were functionally competent. Further, we compared the biological activities of 
rwiFNy and rwTNF~ produced in the baculovirus and E. coli expression systems. 
4.3 Materials and Methods 
4.3.1 Cloning of full-length rwiF~y and rwTNFg. eDNA 
PBMCs isolated from healthy adult woodchucks (see Section 2.2.3) were 
cultured in the presence of 10 1..1-g/ml concanavalin A (ConA; Sigma Chemical Co.) 
for 72 h in RPMI 1640 medium with 50 U/ml penicillin, 50 1..1-g/ml streptomycin 
sulfate and 10% heat-inactivated fetal calf serum (HI-FCS) (all from Invitrog-en). 
Then, the cells were collected and RNA extracted with Trizol reagent (Section 
2.4.2). Approximately 2 1-'-9 of total RNA was treated with 2 U of DNase (DNA-
free kit, Ambion) for 30 min at 37 oc to remove potential DNA contaminations. 
The enzyme was inactivated with a chelating reagent from the DNA-free kit 
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(Ambion). eDNA was generated using Moloney murine leukemia virus reverse 
transcriptase (Invitrogen) and hexamer random primers, as described before 
(Hodgson and Michalak, 2001). 
Specific primers, spanning the full-length of wiFNy and wTNFa cDNAs, 
were designed based on homology in the woodchuck sequences reported 
previously by this and other laboratories (Michalak et at., 2000; Lohrengel et at., 
2000; Guo et at., 2000). The GenBank accession numbers for the sequences 
used were: AF08152, Y14138 and AF232728 forwiFNy, and AF082491, Y14137 
and AF333967 for wTNFa. For PCR amplification of wiFNy, the sense primer 
IFNp 5'-GGCCTAACTCTCTCTGAAACG and antisense primer IFNm 5'-
GAGGACTGTTATTTGGATGC were applied. wTNFa was amplified with sense 
TNFp 5'-ATGAGCACTGAAAGYATGATCCG and antisense TNFm 5'-
CCATTCCCTTCACAGAGCAATGAC primers. PCR was performed using 50 ng 
eDNA from GenA-stimulated PBMC under cycling conditions established before 
(Michalak et a/., 2000). After purification of the PCR products from low-melting 
point agarose using Wizard PCR Preps DNA purification system (Promega 
Corp.), the amplicons were cloned into TOPO-PCRII vector using a TA cloning kit 
as described in Section 2.8.2. The specificity and orientation of the sequences 
cloned were confirmed by DNA sequencing, as described previously in Section 
2.9. 
4.3.2 Baculovirus vectors and rwiFNy and rwTNFcx production in insect 
cells 
102 
To directionally insert rwiFNy and rwTNFcx sequences into the baculovirus 
transfer vector pBiueBac 4.5 (Invitrogen), specific PCR primers with introduced 
BamHI and EcoRI restriction sites (marked by low case letters) were designed 
and synthesized (see Figure 4.1 ). Primers for the insertion of rwiFNy eDNA were 
IP2, 5'-GCGCggatccATGAAATACACAAGTTATTT and IP3, 5'-
GCGCgaattcTTATTTGGATGCTCTCCGAC, whereas those for rwTNFcx eDNA 
were TP2, 5'-GCGCggatccATGAGCACTGAAAGTATGAT' and TP3, 5'-
GCGCgaattcTCACAGAGCAATGACCCCAA. The PCR, gel purification, and 
subcloning were carried out as outlined before (see Sections 2.6 and 2.8). 
Spodoptera frugiperda cells (Sf9; Invitrogen) were maintained in complete 
Grace's insect medium (Invitrogen) supplemented with 10% HI-FCS, 50 U/ml 
penicillin and 50 11g/ml streptomycin sulfate at 27 °C. Following the Bac-N-Biue 
transfection kit's procedure (Invitrogen), Autographa califomica Multiple-
embedded Nuclear Polyhedrosis Virus (AcMNPV) DNA (0.5 11g) and the 
baculovirus vector containing rwiFNy or rwTNFcx (4 IJ.g) were co-transfected into 
Sf9 cells using a cationic liposome reagent (lnsectinPius Liposome; Invitrog-en). 
Four days later, the culture supernatant was collected and a plaque assay 
performed. 
Figure 4.1. Vector construction and screening strategies. 
(A) Schematic presentation of the baculoviral constructs containing rwiFNy or 
rwTNFa eDNA, showing relative locations of the vector primers P1 :P4 flanking 
the inserted cytokine cDNAs and IP2:1P3 and TP2:TP3 primer pairs used for 
identification of rwiFNy and rwTNFa eDNA inserts, respectively. (B) Identification 
and purity screening of three randomly selected Sf9 cell plaques transfected with 
recombinant baculovirus carrying either rwiFNy or rwTNFa eDNA. Lanes: culture 
supernantants from plaques1 to 3; WT, supernatant form Sf9 cells infected with 
wild-type baculovirus; M, molecular marker ladder. Molecular sizes (bp) of PCR 
amplicons indicated on sides of the panels. 
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The plaque positivity and discrimination between colonies carrying the 
recombinant vectors and those expressing the recombinant and the wild type 
(WT) baculovirus were determined by a PCR assay with primers P1 and P4 
complementary to the baculovirus vector sequences flanking the cytokine eDNA 
inserts (see Fig. 4.1 ). To produce large amounts of the recombinant virus, 
infected Sf9 cells were cultured for 10 days post-infection. Based on the results 
of the plaque assay with serial 1 0-fold dilutions of the final supernatants, the titer 
of the recombinant virus carrying rwiFNy or rwTNFa: was 8 x 1 as or 6 x 1 as 
plaque forming units (PFU)/ml, respectively. 
For protein production, Sf9 cells were infected with rwiFNy or rwTNFa: 
recombinant baculovirus at multiplicity of infection of 1-2. Since sequences 
encoding both a secretion signal or a membrane binding domain and leader 
peptides were included in the cytokine cDNAs, the secretion of their proteins was 
expected. After 7-10 day culture at 27 °C, the cell supernatant was collected and 
biological activity of wiFNy or rwTNFa:, designated as bac-rwiFNy or bac-rwTNFa:, 
was tested without further purification. In parallel, supernatant from Sf9 cells 
infected with a WT baculovirus (bac-WT) was prepared. 
4.3.3 Expression of rwiFNy and rwTNF« in E. coli 
A fragment of eDNA encoding the mature form of wiFNy was subcloned 
into pET41b E.. coli expression vector (Novagen, Darmstadt, Germany) by PCR 
using primers 5'-ATAGCGCcatatgCAGGACACAGTTAATAAGG and 5'-
GCGCctcgagTTTGGATGCTCTCCGACC with introduced Ndel and Xhol 
restriction sites, respectively. Similarly, eDNA encoding wTNFa fragment 
spanning nucleotides 232 and 699 (GenBank accession number AF333967) 
(Hodgson and Michalak, 2001) and likely representing the mature protein of 
wTNFa for which size was deduced based on the location of the cleavage site 
predicted through interspecies comparison of available human, mouse and rat 
TNFa sequences, was subcloned into pET41b vector using primers 5'-
A TAGCGCcatatgCTCAGATCATCTTCTCAAA and 5'-
GCGCctcgagCAGAGCAA TGACCCCAAAG. 
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E. coli strain BL21 (DE3)plysS was transformed with the above constructs 
following the procedure suggested by the supplier (Novagen) and outlined in 
Section 2.8.2. A single colony of the transformed cells was inoculated into LB 
medium containing 50 J..Lg/ml kanamycin and cells incubated at 200 rpm at 37 oc 
until the 00600 reached 0.6. Then, 1 mM isopropyl-beta-0-thiogalactopyranoside 
(IPTG) was added and the incubation continued for an additional 3 h. In parallel, 
an aliquot of the same cell suspension was incubated in the absence of IPTG, as 
an un-induced cell control. Subsequently, culture medium was removed by 
centrifugation and the cell pellet immediately frozen at -70 °C. The next day, the 
cells were lysed with BugBuster reagent (Novagen) with 20 Ulml benzonase 
(Novagen). Both the soluble fraction and the inclusion bodies (insoluble fraction) 
suspended in 8 M urea were examined by SDS-PAGE to verify the presence of 
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the cytokine proteins by comparing lysates from IPTG-induced and not induced 
cells. 
Since a polyhistidine was tagged to the carboxy-terminus of each cytokine 
protein, the final purification of the E. coli-derived rwiFNy and rwTNFa:, 
designated as ec-rwiFNy and ec-rwTNFa:, was done by I MAC. For this purpose, 
crude ec-rwiFNy and ec-rwTNFa: preparations denatured with 8 M urea were 
incubated for 30 min with pre-charged, pre-washed TALON cell-thru resin 
(Ciontech, Palo Alto, CA). After centrifugation at 700 x g for 2 min, supernatant 
was removed and the resin washed 3 times with 8 M urea buffer. The protein 
bound was eluted with 5-bed volumes of elution buffer and examined by 80S-
PAGE. The proteins were extensively dialyzed against phosphate-buffered 
saline, pH 7.4 (PBS) and stored at 4 °C. Using the same approach, unrelated 
recombinant proteins, i.e., WHV e antigen (ec-rWHe) and recombinant 
woodchuck CD3 (ec-rwCD3), were produced in E. coli and used as specificity 
controls. 
4.3.4 IFNy antiviral protection and antibody neutralization assays 
An ECMV protection assay was employed to assess antiviral activity of 
bac-rwiFNy and ec-rwiFNy. For this purpose, 3 x 104 woodchuck WCM-260 
hepatocytes cultured in conditioned Hepato-Stim medium (see Section 2.3.1) or 
human HepG2 cells maintained in DMEM (see Section 2.3.2) were seeded 24 h 
prior to the assay at 1 00 t.J.IIwell in a flat-bottom 96-well plate (Fisher Scientific 
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Limited, Nepean, Ontario). Then, the cell supernatant was replaced with 100 Ill 
of fresh medium containing serial 2-fold dilutions of bac-rwiFNy or ec-rwiFNy, or 
with equivalent dilutions of bac-WT supernatant, as a control. Triplicate wells 
were tested for each dilution. After 24-h incubation, an additional 100 Ill of 
medium containing cytopathic ECMV (Jin eta/., 1994) was added and the plate 
incubated for 24 h. 
The number of viable cells was determined by a microculture tetrazolium 
(MTT) assay (Mosmann, 1983; Alley et a/., 1988). Briefly, each well was 
supplemented with 50 Ill of MTT (3-[4-,5-dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide; 1 mg/ml in PBS; Sigma) and the plate incubated for 
4 h at 37 °C. The supernatant was removed and 100 Ill of dimethylsulfoxide 
added to dissolve MTT metabolites. The reaction intensity was read at A57o nm 
and at A630 nm (Mosmann, 1983; Alley et a/., 1988). One unit of wiFNy was 
defined as the ability to protect 50% of WCM-260 cells from cytolysis induced by 
ECMV infection, as deduced from the slope of the 00570-630 vs. rwiFNy dilution 
plots (see Figure 4.4). 
For neutralization of bac-rwiFNy antiviral protective activity, supernatant 
containing the cytokine at 10 or 100 U/ml was pre-incubated with rabbit anti-
rwiFNy (prepared as described below) at 1 :20 or 1:100 dilution for 4 h at 37 oc 
prior to performing the ECMV protection assay. The same dilutions of pre-
immune rabbit serum were used as controls. 00570-630 readings from triplicate 
wells after the MTT assay were used to determine mean values. The percentage 
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of 00 reduction was calculated as the difference between mean 00 from wells 
containing pre-immune serum and those containing anti-rwiFNy divided by mean 
00 from wells containing pre-immune serum. 
4.3.5 TNFa cytopathic and neutralization assays 
A mouse fibroblast line L929 (see Section 2.3.2) was used as target cells 
to measure cytotoxicity of bac-rwTNFa and ec-rwTNFa (Meager et a/., 1989; 
Lohrengel eta/., 2000). After seeding L929 cells at 2 x 104 cells in 50 !J.I/well into 
96-well flat-bottom plates 24 h prior to the assay, two-fold serial dilutions of bac-
rwTNFa or ec-rwTNFa in 50 !J.I of OMEM containing 2 IJ.g/ml Actinomycin 0 
(Sigma Chemical Co.) were added in triplicate. Comparable dilutions of bac-VVT 
supernatant were added to control wells. After incubation for 24 h, cell viability 
was determined by the MTT assay described above. Actinomycin 0 was used to 
increase sensitivity of the assay, as reported by others (Meager et a/., 1989; 
Baarsch eta/., 1991 ). One laboratory unit of rwTNFa was defined as the ability 
to kill 50% of L929 cells in test triplicate wells, as deduced from the 00570_630 vs. 
rwTNFa dilution plots (Meager eta/., 1989). 
For neutralization of bac-rwTNFa-mediated cytotoxicity, the supernatant 
containing 10 or 100 U/ml of bac-rwTNFa was preincubated with affinity-purified 
immunoglobulin G (lgG) fraction of rabbit anti-mouse TNFa serum (Cedarlane 
Laboratory Ltd, Ontario, Canada) at 2, 1 or 0.5 IJ.g/ml for 4 h at 37 oc prior to 
performing the cytotoxicity assay with L929 cells described above. The same 
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concentrations of lgG purified from normal rabbit serum were used as controls. 
The percentage of cell survival was determined by comparing the mean OD 
readings from triplicate test wells to mean OD of control wells without rwTNFa 
from an MTT assay. 
4.3.6 Class I MHC antigen display enhancement assay 
To test the ability of rwiFNy and rwTNFa to upregulate the cell surface 
presentation of class I MHC antigen, 5 x 105 WCM-260 hepatocytes, kept at 2 
ml/well in conditioned Hepato-Stim medium in a 6-well plate (Fisher Scientific 
Ltd.), were exposed for 18 h to predetermined concentrations of the recombinant 
cytokines derived from the baculovirus and E. coli systems. Then, the cells were 
trypsinized, washed twice with PBS, and exposed for 30 min on ice to B1bB9 
mAb against a woodchuck class I MHC heavy chain (Section 2.11.2). After three 
washes with PBS, cells were stained with FITC-conjugated goat anti mouse 
lgG/M (Jackson lmmunoresearch Labs, Inc.) for 30 min on ice, washed, and 
fixed in 2% paraformaldehyde. Cells stained with B1 bB9 but not pre-incubated 
with the cytokines or incubated with bac-WT supernatant, and cells stimulated 
with the cytokines but stained with the secondary layer antibodies only were used 
as controls. The cells were analyzed in a FACScalibur flow cytometer (Becton 
Dickinson) and the data interpreted with appropriate softwares (Section 2.13.4). 
111 
4.3.7 Production of antibodies and Western blot analysis 
Polyclonal antibodies against ec-rwiFNy were raised in rabbits as 
described in Section 2.11.1. Antibody specificity and titer were determined by 
Western blot analysis using 1 0-fold serial dilutions of the I MAC-purified ec-
rwiFNy and unrelated ec-rWHe and ec-rwCD3 proteins as controls (see Section 
2.12). 
To identify rwTNFo: proteins, affinity- purified rabbit lgG against murine 
TNFo: (Cedarlane Laboratory Ltd.) at 0.15 ng/ml were applied in Western blotting 
(see Section 2.12). Reactions were detected with goat anti-rabbit lgG 
conjugated with horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA) 
and a home-made enhanced chemiluminescence (ECL) reagent (Yakunin and 
Hallenbeck, 1998). The optical density of the protein bands was quantified by 
densitometry using ChemiGenius bio-imaging system (SYNGENE, Frederick, 
MD). The bac-rwiFNy or bac-rwTNFo: protein content in the insect cell 
supernatants was estimated by comparing their band densities with those of 
serial dilutions of the !MAC-purified ec-rwiFNy or ec-rwTNFa containing known 
protein concentrations, which were probed in parallel on the same immunoblots. 
4.4 Results 
4.4.1 Expression of recombinant baculovirus-rwiFNy and -rwTNFa 
constructs 
112 
Figure 4.1A shows the relative locations of the PCR primers specific for 
the baculovirus transfer vector and wiFNy or wTNFa which were used to test the 
specificity and purity of the recombinant baculoviruses carrying rwiFNy or 
rwTNFa eDNA, which were propagated in Sf9 cells (see Section 4.3.2). It also 
illustrates detection of the recombinant baculoviral DNA and rwiFNy or rwTNFa 
fragments in the supernatants from culture of three randomly selected insect cell 
plaques infected with the constructs (Figure. 4.1 B). As shown by PCR, all 
supernatants gave a single DNA band with the size which corresponded to that 
of the recombinant virus carrying either rwiFNy (924 bp) or rwTNFa (1124 bp) 
eDNA, in the absence of the WT virus DNA fragment (839 bp). Further, PCR 
with primers specific for wiFNy or wTNFa gave, as expected, products with 
molecular sizes of 522 bp and 722 bp, respectively, while the WT baculovirus 
DNA was not amplified. This screening procedure ensured that only cell plagues 
expressing the recombinant baculovirus were selected for further cytokine 
production. 
113 
4.4.2 505-PAGE and Western blot analyses 
In parallel with production of rwiFNy or rwTNFa in the baculovirus system, 
the sequences encoding matured proteins of the same cytokines were also 
expressed in E. coli. The ec-rwiFNy and ec-rwTNFa amino acid sequences were 
tagged with the octamer polyhistidine at the carboxy-terminus to facilitate 
purification by I MAC, as described in Section 2.1 0.2. Upon induction of the 
transfected E. coli cells with IPTG, ec-rwiFNy protein of 18.1 kDa was detected in 
the cell insoluble fraction by SDS-PAGE (Figure 4.2A). This protein was purified 
by I MAC to more than 99% purity, as assessed by a densitometric analysis of the 
protein bands separated by SDS-PAGE. The estimated concentration of the 
affinity purified ec-rwiFNy was 80 !J.g/ml. This preparation was subsequently 
used to produce anti-rwiFNy antibodies, which in turn were applied to determine 
protein profiles of ec-rwiFNy and bac-rwiFNy by Western blotting (Figure 4.28). 
lmmunoblot analysis of the purified ec-rwiFNy revealed two bands of 18.1 
and 36 kDa, corresponding to a monomer and a dimer of wiFNy, respectively 
(Figure 4.28). The molecular size of the monomer was identical to that predicted 
from the sequence of rwiFNy with a methionine residue attached to the N-
terminus and the Xhol restriction site plus polyhistidine to the C-terminus of the 
recombinant cytokine. Unrelated proteins, such as ec-rWHe and ec- rwCD3, 
produced by the same expression procedure in E. coli, were non-reactive with 
anti-rwiFNy antibodies (Figure 4.28). 
Figure 4.2. SDS-PAGE and Western blot analyses of ec-rwiFNy and bac-
rwiFNy. 
(A) SDS-PAGE monitoring of the expression and affinity purification of ec-rwiFNy. 
Lanes: I, inclusion bodies from E. coli cell lysate after IPTG induction; U, 
uninduced E. coli cell lysate; M, pre-stained protein marker ladder; P, !MAC-
purified ec-rwiFNy of 18.1 kDa. (B) Western blot analysis of ec-rwiFNy and bac-
rwiFNy with rabbit anti-rwiFNy antibodies. Lanes: 1, I MAC-purified ec-rwiFNy 
(100 ng) showing 18.1 and 36-kDa protein bands; 2, !MAC-purified ec-rWHe (100 
ng); 3, !MAC-purified ec-rwCD3 (100 ng); 4 and 5, 5 and 10 1-1-l of bac-rwiFNy 
supernatant showing protein bands of 16.5, 17.4 and 34 kDa; 6 and 7, 5 and 10 
1-1-l of bac-WT supernatant. 
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SDS-PAGE analysis of bac-rwiFNy did not yield protein signals, even 
when a relatively large volume (20 f.LI) of the insect cell supernatant containing 
the cytokine was examined. However, when bac-rwiFNy was analyzed by 
Western blotting, three protein bands of 16.5, 17.4 and 34 kDa were detected 
(Figure 4.28). The 17 .4-kDa protein had a slightly greater molecular size than 
that deduced from the nucleotide sequence of the full-length rwiFNy (i.e., 16.5 
kDa) and most likely represented a glycosylated form of the 16.5-kDa protein. 
The supernatant from Sf9 cells infected with bac-WT was not reactive with anti-
rwiFNy antibodies (Figure 4.28), confirming bac-rwiFNy specificity of the 
identified proteins. 
Upon induction of E. coli with IPTG, the rwTNFcx eDNA fragment gave an 
18.8-kDa protein species, which was subsequently purified to homogeneity (98%) 
by I MAC (Figure 4.3A). The final concentration of the affinity-purified ec-rwTNFcx 
was 60 f.Lg/ml. Western blot analysis of ec-rwTNFcx with cross-reactive anti-
murine TNFcx antibodies (see Section 4.3.7) showed two protein bands, 18.5 and 
37 kDa (Figure 4.38), corresponding to wTNFcx monomer and its dimer, 
respectively. The specificity of this identification was confirmed by probing 
unrelated proteins, ec-rWHe and ec-rwCD3, which did not yield any visible 
signals (Figure 4.38). The same analysis of the bac-rwTNFcx supernatant 
showed a 17-kDa protein band, while an equivalent amount of the bac-WT 
supernatant was nonreactive (Figure 4.38). The 17-kDa protein has a molecular 
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size compatible with that deduced from the nucleotide sequence for mature 
wTNFa (17.3 kDa). 
4.4.3 Antiviral effect of rwiFNy 
Two-fold serial dilutions of the insect cell culture supernatants containing 
bac-rwiFNy and the affinity-purified ec-rwiFNy, starting from 1.6 1-Lg/ml, were 
assayed for antiviral activity using woodchuck WCM-260 hepatocytes and human 
HepG2 cells infected with ECMV, as described in Section 4.3.4. As shown in 
Figure 4.4A, bac-rwiFNy was able to protect woodchuck hepatocytes, but not 
human liver cells from the virus-induced lysis. Similarly, ec-rwiFNy protected 
woodchuck, but not human liver cells (Figure 4.48). Interestingly, this antiviral 
effect was seen only when WCM-260 cells were exposed to bac-rwiFNy or ec-
rwiFNy prior to infection, but not when the cytokine was added at the time or after 
exposure of the cells to ECMV (data not shown). In control experiments, bac-WT 
(Figure 4.4A) and an unrelated protein derived from E. coli (i.e., ec-rWHe) 
(Figure 4.48) did not exert an antiviral effect. 
Figure 4.3. SDS-PAGE and immunoblot analyses of ec-rwTNFa and bac-
rwTNFa. 
(A) SDS-PAGE monitoring of the expression and affinity purification of ec-
rwTNFa. Lanes: M, pre-stained protein marker ladder; I, E. coli cell lysate after 
IPTG induction; U, lysate of uninduced cells; P, !MAC-purified ec-rwTNFa of 18.8 
kDa. (B) Western blot analysis of ec-rwiFNy and bac-rwiFNy with anti-murine 
TN Fa antibodies. Lanes: 1, I MAC-purified ec-rwTNFa (40 ng) showing protein 
bands of 18.5 and 37 kDa; 2, !MAC-purified ec-rWHe (40 ng); 3, !MAC-purified 
ec-rwCD3 (40 ng); 4, 20 111 of bac-rwTNFa supernatant showing 17 -kDa protein 
band; 5. 20 111 of bac-WT supernatant. 
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Based on the definition of an IFNy unit as the ability to protect 50% of cells 
from ECMV-induced lysis, it was calculated that the bac-rwiFNy concentration in 
the insect cell supernatant was 7.5 x 104 U/ml, whereas that of the affinity-
purified ec-rwiFNy was 900 U/~g. As shown in Figure 4.4, bac-rwiFNy and ec-
rwiFNy produced comparable profiles of anti-ECMV activity at tested serial 
dilutions. Taking into account this observation and by estimating the bac-rwiFNy 
protein content from the band densities detected on immunoblots, using serial 
dilutions of the purified ec-rwiFNy as quantitative standards, it was estimated that 
bac-rwiFNy has approximately 4.5-fold greater antiviral potency than ec-rwiFNy 
tested at a comparable protein level. 
Specificity of the bac-rwiFNy antiviral effect was confirmed by 
neutralization with rabbit anti-rwiFNy antibodies which were raised during this 
study using the affinity- purified ec-rwiFNy as an immunogen. As shown in 
Figure 4.4C, inhibition of the ECMV-induced hepatocytolysis by bac-rwiFNy was 
almost completely (90.3%) reversed when the cytokine at 10 U/ml was 
pre incubated with anti-rwiFNy serum at 1:20, but not with preimmune serum at 
the same dilution. However, this inhibitory effect was not observed when bac-
rwiFNy at 100 U/ml or anti-rwiFNy at a dilution greater than 1:20 were tested 
(data not shown), indicating that the antibodies neutralization capacity was 
relatively low. 
Figure 4.4. rwiFNy virus protection assay. 
WCM-260 hepatocytes and human HepG2 cells were incubated 24 h prior to 
infection with ECMV with two-fold serial dilutions of: (A) bac-rwiFNy supernatant 
or (B) !MAC-purified ec-rwiFNy. As controls, bac-WT supernatant (bac-
WT/WCM-260) or !MAC-purified ec-rWHe (ec-rWHe/WCM-260) were added at 
comparable dilutions to WCM-260 cells. (C) Neutralization of bac-rwiFNy-
induced antiviral activity by rabbit anti-rwiFNy antibodies. Supernatant containing 
bac-rwiFNy at 10 U/ml was preincubated with anti-rwiFNy or with preimmune 
rabbit serum, both at 1 :20 dilution, which was then added to woodchuck WCM-
260 hepatocytes and the cells infected with ECMV 24 h later. Anti-rwiFNy 
antibodies inhibited bac-rwiFNy antiviral effect by -90% comparing to preimmune 
serum. In all assays, cell survival was monitored by the MTT test performed 24 h 
post-infection with ECMV. Results shown are mean values of ODs?o -OD63o 
readings from triplicate wells and vertical bars are standard deviations of means. 
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4.4.4 Cell killing by rwTNFa 
The cytotoxicity of rwTNFa was assayed with murine L929 fibroblasts by a 
MTT assay. In this assay, the culture medium was supplemented with 
Actinomycin D, following reports that the presence of this transcription inhibitor 
enhances detection of TNFa-induced cytotoxicity (Ruddle, 1992). As shown in 
Figure 4.5, serial two-fold dilutions of the insect cell culture supernatant 
containing bac-rwTNFa and the affinity-purified ec-rwTNFa, starting from 60 
ng/ml, showed a progressively decreasing ability to kill L929 cells. In contrast, 
bac-WT supernatant (Figure 4.5A) and an unrelated ec-rWHe protein, at 
comparable concentrations, displayed only marginal or no cytotoxicity, 
respectively (Figure 4.58). Based on these results, it was estimated that the 
activity of bac-rwTNFa in the Sf9 cell supernatant was 3.2x1 04 U/ml, whereas 
that of the purified ec-rwTNFa was 5.3x1 03 U/1-1g protein. Testing bac-rwTNFa 
and ec-rwTNFa at concentrations giving comparable cytotoxic results and taking 
under consideration the estimated bac-rwTNFa protein content in the supernatant, 
determined as described for bac-rwiFNy, it was approximated that bac-rwTNFa 
was about 18-fold more cytotoxic than ec-rwTNFa at a comparable protein level. 
The bac-rwTNFa cytopathic effect was neutralized by rabbit anti-murine TNFa 
antibodies. As illustrated in Figure 4.5C, the bac-rwTNFa-induced killing of L929 
cells was progressively blocked when the cytokine at 100 U/ml was preincubated 
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with increasing concentrations of anti-TNFa antibodies. The inhibition of more 
than 80% was achieved when anti-TNFa lgG was used at 2 ~g/ml. 
4.4.5 Cytokine-induced class I MHC upregulation 
As shown in Figure 4.6A, incubation of WCM-260 hepatocytes with the 
supernatant containing 150 U/ml (-30 ng/ml) of bac-rwiFNy led to a display of 
class I MHC antigen on the vast majority (88.1 %) of the cells, indicating that this 
recombinant cytokine was highly potent in inducing MHC expression. Similarly, 
150 U/ml (135 ng/ml) of ec-rwiFNy greatly enhanced (91.5%) the cell surface 
presentation of the antigen (Figure 4.68). Incubation of WCM-260 cells with the 
supernatant containing 320 U/ml (-3.4 ng/ml) of bac-rwTNFa also enhanced 
class I MHC display (Figure 4.6C), although to a lesser extent (17.8%) than the 
test concentration of bac-rwiFNy. The affinity purified ec-rwTNFa, used at 320 
U/ml (60 ng/ml), increased class I MHC presentation to a similar level (21.1 %) as 
bac-rwTNFa (Figure 4.60). 
In summary, the woodchuck cytokines generated in the baculovirus 
expression system demonstrated a biological potency that was superior over that 
displayed by the cytokines produced in the E. coli system. This functional 
potency was to a similar degree greater when either the antiviral or cytotoxic 
activity or the ability to upregulate class I MHC antigen presentation was 
assessed. 
Figure 4.5. rwTNFa cytotoxicity assay. 
L929 cells were incubated in the presence of 1 J..Lg/ml Actinomycin D with serial 
two-fold dilutions of: (A) bac-rwTNFa or bac-WT supernatant or (B) I MAC-purified 
ec-rwTNFa or I MAC-purified ec-rWHe protein. Survival of L929 was measured by 
the MTT assay 24 h later. Mean value of ODs?o -00630 readings from triplicate 
wells with SD were plotted against dilutions of rwTNFa. The dashed line marked 
100% survival of L929 in DMEM medium supplemented with 1 J..Lg/ml Actinomycin 
D. (C) Neutralization of bac-rwTNFa with rabbit anti-murine TNFa antibodies. 
Supernatant containing bac-rwTNFa at 100 U/ml was pre-incubated with anti-
TNFa lgG at 0.5, 1 or 2 llg/ml or with normal rabbit serum lgG at the same 
protein concentrations and then added to L929 cells, as described in Materials 
and Methods. Cell survival was plotted as mean .:t SD from triplicate wells in the 
MTT assay. Percentage values indicate the extent to which a particular 
concentration of anti-TNFa lgG inhibited L929 cytotoxicity compared to normal 
serum lgG. 
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Figure 4.6. Flow cytometric evaluation of class I MHC upregulation. 
Analysis of class I MHC antigen display on woodchuck WCM-260 hepatocytes 
treated for 18 h with: (A) 150 U/ml of bac-rwiFNy (-30 ng/ml); (B) 150 U/ml of 
!MAC-purified ec-rwiFNy (135 ng/ml); (C) 320 Ulml of bac-rwTNFo: (-3.4 ng/ml) 
or (D) 320 U/ml of !MAC-purified ec-TNFo: (60 ng/ml). Cytokine unstimulated 
WCM-260 cells and WCM-260 exposed to bac-WT supernatant or !MAC-purified 
ec-rWHe protein were used as controls. Cells were stained with mouse anti-
woodchuck class I MHC heavy chain 81 bB9 monoclonal antibody. Percentages 
of positive cells (gate M1) are indicated on histograms. 
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4.5 Discussion 
We demonstrated that full-length rwiFNy and rwTNFa cDNAs, encoding 
both the leader proteins and the predicted secretion signal of IFNy or a 
membrane-bound domain of TNFa, were successfully cloned and expressed in 
insect Sf9 cells transfected with recombinant baculovirus constructs. Both 
cytokines were secreted to the cell culture supernatant, suggesting that the 
insect cells correctly recognized and cleaved these woodchuck proteins. The 
deduced mature forms of rwiFNy and rwTNFa: were also expressed in E. coli as 
polyhistidine-tagged proteins and affinity purified. Polyclonal antibodies to 
rwiFNy and to murine TNFa specifically recognized bac-rwiFNy and bac-rwTNFa 
proteins, respectively, confirming their antigenic competence. 
Since bac-rwiFNy was not detectable by SDS-PAGE, Western blot 
analysis was applied to identify the constituent proteins. Using this approach, 
bac-rwiFNy showed three protein bands of 16.4, 17.5 and 34 kDa, suggesting 
that a non-glycosylated monomer, a glycosylated monomer and a dimer of wiFNy 
were secreted by the infected insect cells. This was in contrast to ec-rwiFNy 
which displayed on immunoblots two protein bands with molecular sizes 
corresponding to rwiFNy non-glycosylated monomer and its dimer. It has been 
reported that glycosylation of IFNy is not necessary for its biological activity, but it 
likely influences the cytokine circulatory half-life (Kelker et a/., 1983; Rutenfranz 
and Kirchner, 1988). 
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The functional capacity of bac-rwiFNy and ec-rwiFNy was examined by 
two independent methods, i.e., by measuring the antiviral activity and by 
assessing the capacity of enhancing the cell surface display of class I MHC 
antigen. It was found that both bac-rwiFNy and ec-rwiFNy protected woodchuck, 
but not human, liver cells from lysis with ECMV, indicating that wiFNy may 
function in a species-specific manner, similarly as it has been reported for human 
and murine IFNy (Devos eta/., 1982; Gray and Goeddel, 1983; Celada, 1988). 
Furthermore, bac-rwiFNy was approximately 4.5-fold more effective than ec-
rwiFNy in protecting woodchuck hepatocytes from ECMV lysis, as well as in 
enhancing class I MHC antigen presentation, when the extent of these biological 
effects was adjusted to a comparable concentration of the cytokine protein. 
Overall, it became evident that rwiFNy derived from the baculovirus expression 
system was significantly more potent than that produced in E. coli. This finding 
was not surprising considering that the results from Western blot analysis 
suggested that bac-rwiFNy, not ec-rwiFNy, encompassed a glycoslylated protein. 
It is of note that pre-incubation of hepatocytes with rwiFNy was required to 
render protection against ECMV-induced lysis. Addition of rwiFNy at the time of 
inoculation with ECMV or after ECMV infection did not inhibit virus causing 
hepatocytolysis, even when relatively high amounts {i.e., 5000 U/ml) of the 
cytokine were tested (data not shown). This may suggest that to induce the most 
pronounced antiviral effect in vivo, hepatocytes may have to be exposed to this 
cytokine prior to virus infection. 
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The antiviral activity of bac-rwiFNy was neutralized with antibodies raised 
by immunization of rabbits with the affinity-purified ec-rwiFNy. Although these 
antibodies were inhibitory only under certain experimental conditions, i.e., bac-
rwiFNy at 10 U/ml and the antibody dilution 1:20, the blockage was almost 
complete (90%). This ultimately confirmed specificity of the protective effect 
exerted by bac-rwiFNy. 
The protein profile of bac-rwTNFcx determined by Western blot staining 
showed a single protein band with a molecular size which corresponded to a 
non-glycosylated monomer of mature wTNFcx. This suggested that insect cells 
were able to cleave a membrane-bound domain of rwTNFcx in a manner similar to 
that occurring in mammalian cells (Moss et a/., 1997). 
The biological activity of bac-rwTNFcx was tested and compared to that of 
ec-rwTNFcx using two complementary approaches, i.e., by assessing the 
cytotoxic effect against L929 cells and by measuring the capacity to increase 
presentation of class I MHC antigen on woodchuck hepatocytes. Using murine 
L929 fibroblasts, which are typically applied as targets for assessment of TNFcx 
functionality (Meager et a/., 1989; Ruddle, 1992; Lohrengel et a/., 2000), we 
established that bac-rwTNFcx was at least an 18-fold stronger inducer of cell 
killing and class I MHC upregulation than ec-rwTNFcx when examined at a 
comparable protein level. 
In a separate study, it was established that the deduced amino acid 
sequence of the complete wTNFcx is similar by 83% to mouse, 82% to rat and 
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78% to human (Wang and Michalak, unpublished). Considering this high 
interspecies homology, we used rabbit anti-murine TNFcx antibodies in an attempt 
to inhibit the cytotoxic effect exerted by bac-rwTNFcx. We have found that these 
antibodies were remarkably effective in neutralizing the bac-rwTNFcx-mediated 
cytotoxicity and under optimal conditions, i.e., bac-rwTNFcx at 100 U/ml and anti-
TNFcx lgG concentration of 2 ~g/ml, they inhibited the killing by as much as 80%. 
Recombinant proteins produced in the baculovirus expression system 
have shown a number of advantages over those expressed in the E. coli systems. 
These benefits are now well recognized (Miller, 1988; Luckow and Summers, 
1988; Kidd and Emery, 1993; Geisse eta/., 1996). They are mainly related to the 
ability to create proteins of a superior biological efficacy which are free from 
bacterial endotoxin or mitogen contaminations (Stacey et a/., 1992; Lambrecht et 
a/., 1999). The presence of bacterial impurities is of particular concern due to 
their interference with the experimental outcomes, making correct interpretation 
of the results frequently impossible (Gao and Tsan, 2003). In the present study, 
we have established efficient baculoviral expression systems for production of 
rwiFNy and rwTNFcx and we have documented by different testing approaches 
the functional competence of the recombinant cytokines produced. Their 
availability should facilitate further studies in the woodchuck model of 
hepadnaviral infection on elucidation of their antiviral action and their contribution 
to the immunopathogenesis of liver injury in hepatitis B. 
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CHAPTER 5. WOODCHUCK HEPATITIS VIRUS INHIBITION OF CLASS I 
MAJOR HISTOCOMPATIBILITY COMPLEX PRESENTATION ON 
HEPATOCYTES IS MEDIATED BY VIRUS ENVELOPE PreS2 PROTEIN AND 
CAN BE REVERSED BY TREATMENT WITH GAMMA INTERFERON 
5.1 Summary 
Presentation of class I major histocompatibility complex (MHC) is severely 
down-regulated on hepatocytes in woodchucks chronically infected with 
woodchuck hepatitis virus (WHV), as our previous study documented (Michalak 
et a/., 2000). In an attempt to recognize the underlying mechanism, cultured 
normal woodchuck hepatocytes were transfected with the complete WHV 
genome, sequences encoding for individual viral proteins or with whole virus 
genomes in which transcription of selected proteins was disabled by site-specific 
mutagenesis. Hepatocyte presentation of class I MHC antigen was significantly 
suppressed after cell transfection with complete WHV genome or with virus 
subgenomic fragments encoding for envelope preS2 protein or preS1 protein 
which naturally encompasses the preS2 amino acid sequence. In contrast, 
hepatocytes transfected with WHV X gene alone demonstrated a profound 
enhancement in the class I antigen display, whereas those expressing virus 
major S protein or core protein were not different from naive hepatocytes or 
those transfected with empty vector. Analysis of the mutated WHV sequences 
confirmed that the envelope preS2 protein was responsible for inhibition of the 
class I MHC antigen display. Interestingly, treatment with recombinant 
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woodchuck interferon gamma (rwiFN-y) restored the inhibited presentation of the 
class I antigen on hepatocytes. Moreover, the class I antigen suppression was 
not associated with down-regulation of hepatocyte genes for class I MHC heavy 
chain, r3z-microglobulin, transporters associated with antigen processing (TAP1 
and TAP2) or proteasome subunits. These findings suggest that the defective 
presentation of class I MHC antigen on hepatocytes transcribing WHV is a 
consequence of posttranscriptional suppression exerted by virus preS2 protein 
and that this hindrance can be completely reversed by IFNy. 
5.2 Introduction 
The hepatitis B virus (HBV) is a member of the hepadnavirus family which 
includes, among several mammalian and avian viruses, woodchuck hepatitis 
virus (WHV) naturally infecting eastern North American woodchucks (Marmota 
monax). Woodchucks infected with WHV represent a highly valuable natural 
model of hepatitis B in which molecular, immunological and histological sequella 
of virus-induced liver inflammation closely resemble those encountered in 
humans, including development of chronic hepatitis (Michalak, 1998b; Tennant 
and Gerin, 2001 ). It is now also evident that HBV and WHV not only invade and 
replicate in hepatic tissue but also in the lymphatic system, although under most 
circumstances, less vigorously than in the liver (Michalak eta/., 2004; Michalak et 
a/., 1999; Michalak et a/., 1994). The host cellular immune responses directed 
against hepadnavirus protein epitopes displayed on infected hepatocytes, 
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particularly those mediated by cytotoxic T lymphocytes (CTL), are regarded to be 
crucial in the recovery from acute hepatitis as well as in the induction of 
hepatocellular damage in actively progressing infection (Chisari, 2000). In 
contrast to acute hepatitis, which is characterized by a strong and specific CTL 
response directed towards multiple virus epitopes, a weak and narrowly focused 
CTL antiviral reactivity is associated with chronic hepatitis B. It is assumed that 
this hindrance is one of the main pathogenic factors underlying the development 
of chronic hepadnaviral infection and protracted liver damage. 
Because triggering and strength of antiviral CTL responsiveness depend 
to a significant degree on the efficient presentation of viral peptides by class I 
major histocompatibility complex (MHC) molecules on the surface of infected 
cells, we have previously investigated characteristics of the class I MHC antigen 
display on hepatocytes and lymphoid cells in woodchucks acutely and chronically 
infected with WHV (Michalak et at., 2000). Among others, we have uncovered 
that chronic, but not acute WHV hepatitis is associated with a profound 
suppression in class I antigen on the surface of infected hepatocytes. Thus, 
while acute hepatitis was accompanied by enhanced hepatocyte presentation of 
the class I antigen, inhibition of the antigen was consistently detected on these 
cells in chronic hepatitis. This occurred despite the fact that intrahepatic 
expression of class I MHC-affiliated genes encoding woodchuck class I heavy (a) 
and 132-microglobulin (!32m) chains and transporters associated with antigen 
processing (TAP1 and TAP2), as well as interferon gamma (IFNy), which is one 
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of the most powerful simulators of the class I antigen expression (Boehm et a/., 
1997), was augmented to the same degree in both acute and chronic hepatitis. 
Furthermore, the hepatocyte class I antigen suppression was not linked to the 
histological severity of hepatocellular injury, the extent of lymphocytic infiltrations 
or the hepatic load of WHV. It was concluded that the deficiency in hepatocyte 
class I antigen display is a uniform hallmark of chronic WHV hepatitis and is 
caused by a virus-dependent posttranscriptional interference. However, the 
basis of this interference, particularly which of the WHV genome translation 
products might be responsible for this impediment, was not investigated. 
The presentation of peptides by the class I MHC molecules on the cell 
surface accessible for CTL recognition is a multi-step process involving the 
generation of peptides, their transport, loading onto class I heavy chain-~2m 
complexes in the endoplasmic reticulum (ER), and trafficking the complexes to 
the cell surface via the Golgi apparatus (Shastri eta/., 2002). The generation of 
short length peptides in the cytosol is achieved by the ubiquitin-proteasome 
system. Briefly, the endogenously synthesized proteins are first conjugated with 
poly-ubiquitin by ubiquitin ligase (Jentsch, 1992). Then, the ubiquitin-tagged 
proteins are unfolded by the 19S cap of the proteasome, which is composed of 
proteasome activator 28 alpha (PA28a) and proteasome activator 28 beta 
(PA28p) and subsequently degraded into short peptides within the proteasome 
20S core (Kioetzel, 2001 ). The peptidase activity in the 20S proteasome resides 
in constitutive ~ subunits, termed X, Y and Z, which can be readily substituted by 
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IFNy-inducible ~ subunits, such as multicatalytic endopeptidase complex-like 1 
(MECL-1 ), low molecular mass protein 2 (LMP2) and low molecular mass protein 
7 (LMP7), which display catalytic activity. The generated peptides are either 
further degraded into amino acids for recycling by cytosolic peptidase or 
transported to the ER by TAP1/TAP2 heterodimer complexes (Reits eta/., 2000). 
An interaction between the TAP molecules and class I MHC-~2m is required for 
the assembly of class I MHC-peptide complexes (Sadasivan et a/., 1996). Upon 
loading a peptide, the class I MHC complex is exported from the ER to the Golgi 
apparatus, and finally transported to the cell surface where it can be identified by 
the peptide-specific CTL. 
In the present study, to investigate the nature of the molecular hindrance 
responsible for hepadnavirus-induced inhibition of the class I MHC antigen on 
hepatocytes observed in chronic WHV hepatitis (Michalak et a/., 2000), we 
established a panel of woodchuck hepatocyte transfectants transiently or stably 
expressing the whole genome of WHV, subgenomic fragments encoding 
individual virus proteins, or complete WHV sequences in which expression of 
individual translation products was disabled by premature stop codons 
introduced through site-specific mutagenesis. The display of class I MHC 
antigen on these hepatocytes was measured and compared to the control naive 
hepatocytes and those transfected with empty vector. It was found that the 
expression of the complete WHV genome profoundly downregulated 
presentation of the class I antigen on hepatocytes in vitro and, through the 
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differential analysis of transfected hepatocyte lines, we determined that the virus 
envelope preS2 protein mediated for this effect. In parallel experiments, it was 
also found that the inhibited presentation of the class I antigen can be fully 
restored by exposure of hepatocytes to IFNy, implying that the virus-induced 
suppression was not tenacious but can be reversed by treatment with an 
appropriate exogenous agent. 
5.3 Materials and Methods 
5.3.1 WHV plasmids. 
A plasmid containing approximately 1.1-length (exactly 1.127) of WHV genome 
was constructed by sequentially inserting into the eukaryotic expression vector 
pcDNA3.1 (Invitrogen, Carlsbad, Calif.) two fragments (A and B) derived from a 
wild-type WHV/tm3 DNA sequence (GenBank accession number AY334075) 
(Michalak eta/., 2004). Fragment A encompassed nucleotides (nt) from position 
1 to 2120 (numbers denote the position in relation to the endogenous EcoRI site 
in the WHV/tm3 genome), whereas fragment B encompassed nt 1698 to 3308/1 
(Fig. 5.1 ). Fragment A was generated by PCR with sense primer 5'-
TTCGAAA TCAAACCTGGGCC (3286 to 3305), which was homologous to the 
sequence located upstream from the EcoRI site (3308 to 5) (Fig. 5.1 ), and 
antisense primer 5'-CGCGGTACCCAGTGTCCACCAAAGCATTA (2101 to 2120). 
The produced amplicon had the Kpnl site incorporated at the 3'-end (indicated in 
underlined italic letters) and the EcoRI site at the 5'-terminus to facilitate cloning. 
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Fragment 8 was amplified with primers 5'-CGCCTCGAGTCCGGTCCGTGTTGC 
(1698 to 1712) containing an incorporated Xhol site and 5'-
CGTGGTA TGTCCCGAA TTCC (3307 to 18) that contained the endogenous 
EcoRI site (indicated in underlined letters). The PCR cycling conditions used for 
amplification of both fragments were as follows: denaturation at 94 oc for 3 min, 
30 cycles at 94 oc for 30 seconds, 52 oc for 30 seconds and 72 oc for 2 min at 
each step, and final elongation at 72 oc for 3 min. The reaction was performed in 
a Peltier Thermal Cycler PTC-200 (MJ Research Inc., Waltham, MA) using a 
standard reagent mixture described previously (Michalak eta/., 1 999). The 
resulting amplicons were purified from low-melting-point (LMP) agarose using the 
Wizard PCR Preps DNA purification system (Promega Corp., Madison, WI). 
The construction of the plasmid containing more than full-length WHV 
genome was accomplished by a two-step procedure. In the first step, digestion 
of fragment A amplicon with EcoRI and Kpnl enzymes was performed. In parallel, 
the pcDNA3.1 vector was linearized with the same restriction enzymes. The 
ligation of the excised PCR fragment and the linearized vector was done at an 
estimated molar ratio 2:1 at 14 oc for 16 h in a 10-!JI reaction mixture containing 
1 U T4 DNA ligase (Invitrogen) and 1 X ligation buffer (10 mM MgCb, 1 mM ATP, 
1 mM OTT and 5% (w/v) polyethylene glycol-8000 in 50 mM Tris-HCI buffer, pH 
7.6). TOP1 0 competent Escherichia coli (E. coli) cells (Invitrogen) were 
Figure 5.1. Schematic presentations of p-WHV containing -1.1-length WHV 
genome and expression vectors carrying WHV sequences encoding individual 
virus proteins which were generated and examined in the course of this study. 
The nucleotide 5'-end and 3'-end positions for each WHV ORF and for the p-
WHV construct, as well as location of the endogenous EcoRI site within p-WHV 
are marked. Relative positions for endogenous WHV promoters (Pro) and an 
enhancer (En h) are indicated along the p-WHV sketch, while the location of pC-
DNA3.1-derived cytomegalovirus promotor (CMV Pro) is indicated at the 
beginning of each WHV sequence insert. All numbers denote the nucleotide 
positions according to WHV/tm3 genome sequence (GenBank accession number 
AY334075; (Michalak eta/., 2004 ). 
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transformed following the supplier's instructions. Screening of positive colonies 
was based on a standard alkaline method for mini-preps of recombinant plasmid 
DNA, followed by digestion with EcoRI and Kpnl enzymes, and agarose gel 
analysis of the fragments obtained. The selected positive clone was designated 
as p-WHV(0-2120). 
In the next step, WHV genome fragment 8 was cloned into p-WHV(0-2120) 
using the same strategy as above. Thus, the fragment 8 amplicon and p-
WHV(0-2120) were treated with Xhol and EcoRI enzymes and the resulting 
products ligated. After transformation of E. coli, a positive clone was identified by 
restriction enzyme mapping. The final construct, designated as p-WHV, 
contained approximately 1.1-length WHV genome starting from nt 1698, located 
upstream of the enhancer and preC promoter and direct repeats 1 and 2 regions 
(DR1 and DR2, respectively), and ending at nt position 2120 located downstream 
of the WHV polyadenylation signal sequence (Di eta/., 1997)(Fig. 5.1). The 
assessment of the correct design of the construct was confirmed by restriction 
digest analysis and DNA sequencing (data not shown). 
In order to examine whether expression of individual WHV proteins can 
influence presentation of the class I MHC antigen, plasmids containing WHV 
genomic fragments encoding for the virus envelope preS 1 protein (WHpS1 ), 
envelope preS2 protein (WHpS2), envelope major S protein (WHmS), core 
protein (WHc) or X protein (WHx) were constructed using pcDNA3.1 as 
backbone. Briefly, WHV sequences encoding for the respective full-length 
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proteins were amplified by PCR using the sequence specific oligonucleotide 
primers containing appropriate restriction enzyme recognition sequences. Then, 
the PCR products were treated with restriction enzymes and directionally 
inserted into pcDNA3.1 vector. The integrity of the constructs was confirmed by 
DNA sequencing. The names of the plasmids encoding for individual WHV 
proteins are delineated in Figure 5.1. 
5.3.2 WHV mutants. 
To study the effect of individual WHV proteins expressed in the context of 
the whole WHV genome on hepatocyte transcription of the class I MHC-related 
genes and on the surface display of the class I antigen, a series of mutants 
containing premature stop codons within subgenomic sequences encoding for 
individual WHV proteins were produced by site-directed mutagenesis using p-
WHV as the backbone and an approach reported by others (Ho et a/., 1989). 
Thus, WHV genomic regions encoding for WHpS 1, WHmS, WHc, WHx, and 
WHV polymerase (WHp) were mutated to selectively eliminate expression of a 
given protein without introducing amino acid changes to other translation 
products of the virus genome. For generation of each mutant (Fig. 5.2), a pair of 
specific primers was designed to introduce mutating nucleotide/s at the desired 
position (indicated by underlined italic letters in the primer sequences shown 
below). Thus, the WHpS1 mutant (llWHpS1) was generated using 5'-
CAAAATAGCAGCGTGGTAGCCTGCAGTGGGCACT (3027-3060) and 5'-
AGTGCCCACTGCAGGC IACCACGCTGCTA TTTTG (3060-3027) which 
Figure 5.2. Schematic presentation of the strategy applied for generation of p-
WHV mutated sequences by introducing premature stop codons. Designated 
names of the constructs and the introduced nucleotide modifications are 
identified on the left side of the panel. Relative locations of the stop codons 
inserted into WHV ORFs (open arrows) are marked by crosses. Detailed 
information on the site-specific mutagenesis leading to creation of each mutant 
are shown under respective ORF sketches. The bold numbers at the 5'- and 3'-
ends of the outlined sequences show nucleotide positions in relation to the EcoRI 
site in the WHV/tm3 genome (see legend to Fig. 5.1 ). Bold and blue letters in the 
nucleotide sequences stand for introduced nucleotides, whereas the underlined 
triple nucleotide sequences represent the stop codons created. The amino acid 
(aa) sequences of interest and their relative positions (numbers after aa) within 
respective viral proteins are shown above the nucleotide sequences, while the aa 
sequences naturally overlapping the sequence of interest are depicted under the 
nucleotide sequences to indicate that noaa alterations were introduced. *marks 
termination of amino acid translation. 
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changed TGG to TAG, i.e., from tryptophan to a stop codon at position 18 in 
WHpreS1 amino acid (aa) sequence. The WHmS mutant (~WHmS) was created 
using sense primer 5'-GGTGGTGTATTTCTTGTAGACAAAAATCCTAAC (337 to 
369) and antisense primer 5'-GTTAGGAI II II GTCIACAAGAAATACACCACC 
(369 to 337) which changed TGG to TAG, i.e., from tryptophan to a stop codon at 
aa 20 of WHmS. The WHc mutant (~WHc) was produced with primers 5'-
CTATTAGACAAGCTTGAGTATGCTGGGATGAA (2181-2212) and 5'-
TTCATCCCAGCATACTCAAGCTTGTCTAATAG (2212-2181) which modified 
TTA to TGA, i.e., from leucine to a stop codon at aa position 59. The WHx 
mutant (~WHx).was obtained with primers 5'-
GTTGCCAACTGGATCCTTAGAGGGACGTCCTTCTGC (1519-1554) and 5'-
GCAGAAGGACGTCCC IC TAAGGATCCAGTTGGCAAC ( 1554-151 9) that 
changed ACG to TAG, i.e., from threonine to a stop codon at aa position 12. The 
WHp mutant (~WHp} was created with primers 5'-
CTTCCGGAACATACAGTAATTAGGAGAAGAGGAGG (2447-2481) and 5'-
CCTCCTCTTCTCCT AA TIACTGTATGTTCCGGAAG (2481-244 7) which 
changed TCA to TAA, i.e., from serine to a stop codon at aa position 13. For 
generation of each mutant, two rounds of PCR were performed. The first round 
included two reactions, one with a forward primer and a mutant reverse primer 
and the second a mutant forward primer and a reverse primer. Both reactions 
were carried for 15 cycles of 94 oc for 20 sec, 52 oc for 20 sec and 72 oc for 2 
min using 100 ng of p-WHV as template. PCR products from these two reactions 
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were gel purified, combined at an equal molar ratio, and used as the template for 
the second round PCR. The primers for the second round were the same 
forward and reverse primers as those used in the first round. This amplification 
was carried out at 94 oc for 20 sec, 52 oc for 20 sec and 72 oc for 2 min for 35 
cycles with a final elongation step of 72 oc for 5 min. The product from the 
second round PCR was gel purified and cloned into an appropriate vector. The 
presence of the created stop codons were always verified by DNA sequencing 
(data not shown). 
5.3.3 Hepatocyte cultures. 
Woodchuck hepatocyte line WCM-260 was established from a liver biopsy 
obtained from an adult, healthy animal and was characterized in detail previously 
(Churchill and Michalak, 2004; Diao et a/., 1998; Lew and Michalak, 2001 ). 
WCM-260 were grown in a conditioned hepatocyte culture medium consisting of 
80% (vollvol) Hepato-STIM medium (Becton Dickinson, Bedford, Mass.) and 
20% (vol/vol) culture supernatant from HepG2 cells (ATCC No. HB-8065). The 
medium was supplemented with 10 ng/ml epithelial growth factor, 2 mM L-
glutamine, 50 ~g/ml penicillin, and 50 ~g/ml streptomycin (all from Becton 
Dickinson). The conditions for WCM-260 maintenance, detachment, passage, 
and storage were reported before (Churchill and Michalak, 2004; Diao et a/., 
1998). 
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5.3.4 Hepatocyte transfections. 
The transfection of WCM-260 hepatocytes with p-WHV, plasm ids carrying 
sequences encoding individual WHV proteins or its mutants was done using 
LipofectAMINE 2000 (LF2000) reagent (Gibco BRL), following the supplier's 
instruction. The day before the transfection, cells were seeded at 3 x 105 per 
well in a 12-well culture plate (Fisher Scientific Limited, Nepean, Ontario). 
Immediately before transfection, the attached cells were washed 3 times with 
Dulbecco's modified Eagle's medium (DMEM; Invitrogen) without supplements 
and then 1 ml of the same medium was added to each well. At the same time, 2 
~g of plasmid DNA and 2. 5 ~I of LF2000 per transfection were suspended in 100 
~I of DMEM each, combined, and incubated for 20 min at ambient temperature. 
The plasmid DNA-LF2000 mixture was then added to cells and incubated for 8 h 
at 37 °C. Subsequently, the DMEM medium was replaced with conditioned 
hepatocyte culture medium and cells cultured for time periods indicated. Thus, 
the transient expression of a given transgene was evaluated 48-72 h later. For 
stable transfection, G418 reagent (Invitrogen) was added 3 days post-
transfection at 900 ~g/ml and hepatocytes maintained for at least a 4-week 
period, changing culture medium every 3-4 days. WCM-260 cells transiently or 
stably transfected with pcDNA3.1 vector alone (empty vector) were used as 
controls. 
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5.3.5 Hepatocyte stimulation with IFN-y. 
To assess whether the inhibition of class I MHC presentation on 
hepatocytes found after expression of the complete WHV genome or some of its 
subgenomic fragments was reversible, recombinant woodchuck IFN-y (rwiFNy), 
the cytokine which is one of the most potent naturally occurring class I MHC 
inducers, was produced in the baculovirus expression system, as described 
recently (Wang and Michalak, 2005). Briefly, the full-length IFN-y eDNA derived 
from woodchuck peripheral blood lymphoid cells stimulated with Concanavalin A 
(5 ~g/ml; Sigma Chemical Co., St. Louis, Mo) was cloned and expressed in 
insect Sf9 cells using the MaxBac 2.0 expression system (Invitrogen). The final 
concentration of rwiFNy in Sf9 culture supernatant was 150 U/~1. as determined 
by inhibition of WCM-260 hepatocyte lysis caused by infection with 
encephalomyocarditis virus (ECMV) (Wang and Michalak, 2005). For stimulation 
with rwiFNy of WCM-260 transfected with p-WHV, plasmids encoding for 
individual viral proteins or p-WHV mutants, 150 U/ml of rwiFNy was added to the 
hepatocyte culture medium 18 h prior to examination of the class I MHC 
expression. Naive WCM-260 cells exposed under the same conditions to culture 
supernatant from Sf9 cells infected with wild-type (empty) baculovirus veCtor 
were used as controls. 
5.3.6 RNA isolation and reverse transcription. 
Total cellular RNA was extracted with TRizol reagent (Invitrogen), as 
described previously (Michalak et a/., 2000; Michalak et a/., 1999). Possible 
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genomic DNA contamination was eliminated by treatment with DNAse I using 
DNAse-free kit (Ambion, Austin, TX), as per the supplier's instruction. One to 2 
1-1g of total RNA was reverse transcribed into eDNA with random primers using 
200 U of reverse transcriptase (RT) from Moloney murine leukemia virus (Gibco 
BRL), as reported (Coffin and Michalak, 1999; Michalak et a/., 1999). Each 
reaction was set up in parallel with a negative control that had all ingredients 
except RT. 
5.3. 7 Detection of WHV mRNA. 
RNA extracted from transiently or stably transfected hepatocytes were 
reverse transcribed into eDNA and examined by PCR under conditions 
previously established (Coffin and Michalak, 1999; Michalak eta/., 1999) using 
primers specific for nonoverlapping regions of WHV core (C), surface (S) and X 
genes. Primer sequences of the X gene were reported before (Michalak eta/., 
1999), whereas those for amplification of the C and S gene sequences were as 
follows: sense 5'-CTAACAGGTAGGGAACATTGC and antisense 5'-
GACCTAGAAGCTCTTGCACC for C gene, and a common antisense primer 5'-
GCGAAGCTT AA TGTATACCCAAA TC with sense primer 5'-
GCGCTCGAGGCAACA T AA TGGGCAAC for WHpS 1, or sense primer 5'-
CGCCTCGAGACTA TGAAAAA TCAGACT for WHpS2 or sense primer 5'-
CGCCTCGAGAGATGTCACCATCAAGTC for WHmS. As controls, eDNA 
prepared from WCM-260 transiently or stably transfected with pcDNA3.1 alone 
(empty vector) or from na·ive (nontransfected) WCM-260 hepatocytes were 
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included. In addition, samples of RNA isolated during the same extractions, but 
not reversely transcribed, were used as DNA contamination controls (Coffin and 
Michalak, 1999). Southern blot hybridization analysis of the PCR product with 
32P-Iabeled complete recombinant WHV DNA (rWHV DNA) as a probe was 
routinely used to verify the specificity of viral sequence detected and the validity 
of controls, as described elsewhere (Michalak eta/., 1999). 
5.3.8 Cloning of woodchuck proteasome subunit cDNAs. 
Since sequences of woodchuck genes encoding for immunoproteasome 
subunits were unknown prior to this study, we have made an effort to determine 
their partial sequences to investigate the potential influence of WHV expression 
on transcriptional activity of these genes in WCM-260 hepatocytes. For this 
purpose, total RNA isolated from WCM-260 hepatocytes was treated with DNase 
and then reverse transcribed to eDNA, as described above. Amplification of 
woodchuck LMP2, LMP7 and MECL-1, PA28a, and PA28~ eDNA fragments was 
done using primers deduced by inter-species homology comparison of human, 
mouse and rat eDNA sequences using PC Gene software (lntelliGenetics Inc., 
Mountain View, Calif.). The LMP2 was amplified with primers 5'-
CGGRAGAAGTCCACACCGGG and 5'-CTCATCRTAGAATTTTGGCAG, LMP7 
with 5'-GCCTTCAARTTCCAGCATGG and 5'-
CCTCCAGAATAGYTGTCTCTGTG, MECL 1 with 5'-
CTTCTCYTTCGAGAACTGCC and 5'-TCCACCTCCATRGCCTGCAC, PA28a 
with 5'-GGGAGCTATTTYCCCAAGAA and 5'-GGGCTTCTTGCGCTTCTC, and 
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PA2813 with 5'-ATGGCCAAGCCKTGTGGG and 5'-
GA TGGCTTTTCTICACCCTT. PCR amplification was performed in a PTC-200 
cycler using 50 ng of template eDNA and the standard reagent mixture described 
before (Michalak eta/., 1999). Cycling conditions were: 30 cycles of 94 oc for 20 
sec, 52 oc for 20 sec and 72 oc for 1 min, followed by an elongation step at 72 
oc for 3 min. The DNA amplicons of the expected sizes were purified from LMP 
agarose and cloned into the pCRII vector using a TOPO-TA cloning kit 
(Invitrogen). Plasmids with cloned fragments were examined by DNA 
sequencing. The nucleotide sequences obtained were compared to those of 
human, mouse and rat. This comparison showed that the woodchuck sequences 
were more compatible with those of human (91.5% to 98.5%) than with those of 
mouse (87.1% to 94.2%) or rat (87.9% to 93.9%). 
5.3.9 Quantitation of transcriptional activity of class I MHC- and 
proteasome-affiliated genes. 
The quantitation of transcription of class I MHC heavy chain, 132-microglobulin 
(132m), transporter associated with antigen processing type 1 (TAP1) and type 2 
(TAP2), LMP2, LMP7, MECL-1, PA28a, PA2813, and 13-actin in WHV-transfected 
and control WCM-260 hepatocytes was done by real-time PCR using a Light 
Cycler (Roche, Laval, Quebec, Canada). eDNA samples from WCM-260 
hepatocytes transfected with p-WHV or with plasm ids encoding for individual 
WHV proteins or for p-WHV mutants were prepared as described above. Real-
time PCR was carried out in capillary tubes with 0.2 1-11 of eDNA (equivalent of 25-
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50 ng of total RNA) in a 20-IJI volume using FAST start SYBR reagent kit (Roche 
Diagnostics, Laval, Quebec). Primers designed to specifically amplify the 
sequences of interest are listed in Table 5.1. It is of note that primer sequences 
for woodchuck class I heavy chain, 132m, TAP1 and TAP2 were designed based 
on the partial gene sequences previously determined in this laboratory (Michalak 
eta/., 2000). The copy number of each gene was extrapolated from a standard 
curve generated using 1 0-fold serial dilutions of a relevant cloned gene fragment, 
which were run in parallel in each reaction. Specificity of the products was 
determined by melting curve analysis. Negative controls included water instead 
of eDNA and samples treated exactly as test RNA samples but in the absence of 
RT. The house-keeping gene, 13-actin, was used to standardize the expression of 
the genes tested. 
5.3.10 Flow cytometry and confocal microscopy. 
To determine presence of WHV envelope and core proteins in WCM-260 
hepatocytes transfected with p-WHV or plasmids encoding for WHV proteins and 
selected protein mutants, the cells were grown on cover slips, fixed with cold 
ethyl ether for 3 min, and incubated with the respective specific antibodies. The 
WHs antigenic reactivity was detected with guinea pig anti-preS antibodies raised 
by immunization with a recombinant WHV preS1/preS2 protein produced in an E. 
coli expression system (J. Wang and T.l. Michalak, unpublished data) or 
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Table 5.1. Primer sequences for real-time RT-PCR quantitation of woodchuck 
class I MHC- and proteasome-affiliated genes expression. 
Size of 
Gene Primer sequence amp Iicon (bp) 
Heavy chain Sense AGATGGGGAGGACCAGACC 348 Anti-sense GTGAGAGACACATCAGAGCC 
~2M Sense TTCATGCTACTCTTTCTGACC 181 Anti-sense CGACII I I ICTATCTTCTGTCC 
TAP-1 Sense GGAAATGAAGACACTCAACC 676 Anti-sense TCCAGACTGTATTGCAGC 
TAP-2 Sense TTCCAGGAGATTAAGACAGG 417 Anti-sense TATAAGCAGGTACAGAGCACG 
LMP2 Sense ATAGGGAAGACTTGTCGGC 145 Anti-sense ACATAACCGTAAATGTAAGTGCT 
LMP7 Sense TGCCTCCAAACTGCTCTCC 253 Anti-sense ATGAACAATAGCCCTGCGACC 
MECL1 Sense GGGCTTCGGGTTCCTCATG 203 Anti-sense CGTGTAGTCATTTCGGCGT 
PA28a Sense GGGAATAATTTTGGAGTGGCTGT 207 Anti-sense CCGAATGTCCCGGTACTCT 
PA28~ Sense GGTGCGCCTGAGTGGG 138 Anti-sense AGGGAGTCCTCGTGCAAA 
~-actin Sense CAACCGTGAGAAGATGACC 239-Anti-sense ATCTCCTGCTCGAAGTCC 
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with guinea pig anti-WHs produced by immunization with serum-derived WHsAg 
which recognized all three envelope proteins, i.e., WHpreS1, WHpreS2 and 
WHmS (Michalak and Lin, 1994). WHV core antigen (WHcAg) was detected with 
rabbit anti-WHc antibodies produced by immunization with WHV core particles 
(Michalak eta/., 1989). The reactivity of guinea pig antibodies was identified with 
Cy5-conjugated goat anti-guinea pig lgGs and that of rabbit antisera with 
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit lgGs (both from 
Jackson lmmunoReasearch Laboratories Inc., West Grove, PA). Cells were 
examined using an Olympus FluoView™ FV300 confocal system (Olympus 
America Inc. Melville, NY) equipped with an Olympus BX50WI microscope. 
WCM-260 hepatocytes transfected with empty pcDNA3.1 vector and stained 
exactly as test cells, as well as WCM-260 transfected with p-WHV, plasmids 
encoding for individual WHV proteins or p-WHV mutants incubated with pre-
immune sera were used as controls. 
To evaluate presentation of class I MHC antigen on the transfected and 
control WCM-260 hepatocytes, the unfixed cells were incubated for 45 min on ice 
with mouse monoclonal antibody (mAb) against woodchuck class I MHC heavy 
chain (B 1 b.B9), previously prepared in this laboratory (Michalak et a/., 1995) or 
with phosphate-buffered saline, pH 7.6 (PBS), a negative control. After washing 
with PBS, cells were exposed to FITC-conjugated goat anti-mouse lgG (H+L) 
antibodies (Jackson lmmunoReasearch Laboratories Inc.) for 45 min, followed by 
washing with PBS. Subsequently, the cells were fixed with 4% 
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paraformaldehyde in PBS and analyzed by flow cytometry using a FACS Calibur 
flow cytometer (Becton-Dickinson, Palo Alto, Calif.). Flow cytometry data were 
interpreted with assistance of CeiiQuest software (Becton-Dickinson) or WinMDI 
software (The Scripps Research Institute, La Jolla, Calif.). Geometric mean 
fluorescence intensity (MFI), calculated automatically from the plots of flow 
cytometric histograms, was used to compare the level of class I MHC expression. 
The results from three independent experiments were used to calculate the 
means. WCM-260 cells transfected with empty pC-DNA3.1 vector served as a 
control and their MFI values was taken as 100%. 
Moreover, WCM-260 hepatocytes transfected with p-WHV, plasmids 
encoding for individual WHV proteins or mutated p-WHV sequences with 
disabled expression of the selected viral proteins, as well as naive WCM-260 and 
those stably transfected with empty pC-ONA3.1 vector were examined for class I 
antigen display after treatment with exogenous rwiFNy, as described above, and 
compared to the cells not treated with this cytokine. 
5.3.11 Statistical analysis. 
The statistical analysis was carried out using GraphPad software 
(GraphPad Software Inc., San Diego, Calif.) P values were determined by 
unpaired t test and P <0.05 was considered significant. 
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5.3.12 Nucleotide sequences accession numbers. 
The accession numbers for the woodchuck nucleotide sequences 
established in this study submitted to GenBank are as follows: LMP2, A Y726002; 
LMP7, AY7260023; MECL-1, AY726004; PA28a, AY726005, and PA28r3, 
AY726006. 
5.4 Results 
5.4.1 Validation of p-WHV expression in hepatocytes. 
Expression of p-WHV, carrying more than the full-length WHV genome, 
was driven by the CMV promoter contained in the pC-DNA3.1 vector and most 
likely by WHV genome intrinsic promoter/enhancer sequences, as illustrated in 
Fig. 5.1. After transient transfection of WCM-260 hepatocytes with p-WHV, WHV 
RNA transcripts of the C, Sand X genes were identified by RT-PCR using primer 
pairs specific for non-overlapping regions of the respective open reading frames 
(ORFs) (Fig. 5.3A). The specificity of the mRNA detections was ascertained by 
the absence of DNA signals when the RT step was omitted from the RT-PCR 
and by Southern blot hybridization analysis of the amplified products. In addition, 
total RNA isolated from the liver of a woodchuck with chronic WHV hepatitis 
yielded RT -PCR am pi icons with molecular sizes identical to those detected in the 
transfected WCM-260 cells when amplified with the same primer pairs (Fig. 5.3A). 
WCM-260 cells stably transfected with p-WHV gave the same results (fig. 5.38). 
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The synthesis of WHsAg and WHcAg in the transfected cells was 
examined with specific antibodies by confocal microscopy. As shown in Fig. 
5.3C, both antigens were co-localized in the cytoplasm of WCM-260 cells 
transiently transfected with p-WHV. The cells transfected with empty pC-DNA3.1 
plasmid remained entirely negative (data not shown), confirming specificity of the 
antigen detections. The efficiency of the transfection, estimated based on the 
number of WHsAg or WHcAg-positive cells identifiable by immunostaining was 
between 1 0% and 20%. A comparable result was obtained when WCM-260 cells 
were transiently transfected with a plasmid coding green fluorescent protein 
(pEGFP; Clontech, Mountain View, CA) (data not shown). 
Further, to determine whether WHV virions were produced by WCM-260 
hepatocytes transfected with p-WHV, culture supernatants from these cells 
transiently transfected with this plasmid were concentrated by ultracentrifugation, 
as described elsewhere (Coffin et a/., 2004), and injected intravenously into a 
healthy WHV-naive woodchuck. The animal developed WHV infection 
characterized by the persistent presence of WHV DNA in serum, peripheral 
lymphoid cells and liver tissue when tested at week 57 post inoculation. The 
infection progressed in the absence of serological markers of WHV infection,· i.e., 
WHsAg and anti-WHc, and its pattern was comparable to that of the primary 
Figure 5.3. Expression of WHV genes in WCM-260 hepatocytes transfected 
with p-WHV. WCM-260 hepatocytes (A) transiently transfected (after 48-72 h) or 
(B) stably transfected (after 2-3 mo in the presence of G418) with p-WHV were 
analyzed for expression of individual virus gene mRNAs by RT-PCR using primer 
pairs specific for S, C or X gene. The amplified products were identified by 
Southern blot hybridization by probing with complete rWHV DNA. Total RNA 
isolated from the liver of a woodchuck with chronic WHV hepatitis was examined 
each time as a positive control. RNA samples not transcribed to eDNA (RT -) 
were analyzed in parallel with those subjected to RT reaction (RT +) to exclude 
possible contamination with DNA. The molecular sizes (bp) of the detected PCR 
products are marked on the right side of the panel. In panel C, WHV 
preS1/preS2 and core proteins were visualized by immunostaining in WCM-260 
hepatocytes transiently transfected with p-WHV. Following exposure of the cells 
to anti-WHV preS and anti-WHc antibodies, secondary antibodies conjugated 
with Cy5 or FITC were applied to detect WHV preS (left) and WHcAg (center), 
respectively. The overlayed image (right) is shown to illustrate preS1/preS2 and 
WHcAg co-localization. Bars represent 20 J.lM. 
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occult infection which with time spreads to the liver, as described previously 
(Coffin and Michalak, 1999; Michalak et a/., 2004). Taken together, these 
findings showed that p-WHV was not only transcriptionally active in WCM-260 
hepatocytes but also that infectious virions were produced. However, due to the 
relatively small number of hepatocytes displaying WHV antigens after transient 
transfection (.S 20% by immunofluorescent staining), it was concluded that the 
use of the stably transfected hepatocytes, which all a priori express viral genome, 
would be better to examine WHV influence on class I MHC expression. 
5.4.2 Validation of plasm ids encoding individual WHV proteins. 
To assess which of the translation products of the WHV genome may 
modify class I MHC expression, WCM-260 hepatocytes were transfected with 
plasmids carrying WHV sequences encoding for WHpS1, WHpS2, WHmS, WHc 
or WHx protein. As illustrated in Figure 5.4A, when total RNA extracted from 
WCM-260 transiently transfected with the above plasmids was analyzed with 
appropriate specific primer pairs, the resulting RT -PCR amplicons showed the 
same molecular sizes as those obtained by amplifying eDNA derived from RNA 
extracted from the liver of a woodchuck with chronic WHV hepatitis (Fig. 5.4A). 
The signals were detected only in RNA samples subjected to RT but not in those 
in which the RT step was omitted, as confirmed by Southern blot hybridization 
analysis (Fig. 5.4A). These results showed that the genes encoding for individual 
WHV proteins were successfully transcribed in WCM-260 
Figure 5.4. Validation of the expression of the plasmid constructs carrying WHV 
subgenomic sequences encoding individual virus proteins. WCM-260 
hepatocytes (A) transiently transfected or (B) stably transfected with p-WHpS1, 
p-WHpS2, p-WHmS, p-WHc or p-WHx were analyzed for presence of relevant 
mRNA by RT-PCR using primer pairs specific for preS1 (S1 ), preS2 (S2) or mS 
region of S gene or for C or X gene. The amplicons were identified by Southern 
blot hybridization by probing with rWHV DNA. For other details see the legend to 
Figure 5.3. 
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hepatocytes. The same was found to be true for WCM-260 stably transfected 
with the above plasmids (Fig. 5.48). 
Similarly as it was found for the cells transfected with p-WHV (see Fig. 
5.3C), WCM-260 transiently transfected with p-WHc displayed cytoplamic 
localization of WHcAg in 1 0% to 20% of the cells. WHsAg was detected in a 
similar proportion of the cells after transfection with either p-WHpS 1, p-WHpS2 or 
p-WHmS (data not shown). The display of WHx protein was not examined due 
to the lack of an appropriate antibody. The WCM-260 cells stably transfected 
with the same plasmid constructs were seemingly WHcAg and WHsAg non-
reactive by immunostaining, although they were positive when analyzed by 
Western blotting (data not shown). This suggested that the antigens were 
expressed but at the levels which were below the detection limit of the 
immunofluorescent method applied. In subsequent experiments, it was clearly 
established that these expression levels were sufficient to exert a consistent 
modifying effect on class I MHC antigen presentation. 
5.4.3 Expression of the complete WHV genome and its subgenomic 
sequences encoding for pre51 and pre52 proteins inhibits hepatocyte 
class I MHC antigen display. 
Stable transfection of WCM-260 cells with p-WHV resulted in a very 
significant (20-35%; P = 0.004) suppression of the surface class I MHC antigen 
display, as determined by flow cytometry and compared to the control WCM-260 
cells transfected with empty pC-DNA3.1 vector (Fig. 5.5A) or to naive WCM-260 
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cells (data not shown). Similarly, WCM-260 transfected with WHV sequences 
encoding for WHpS1 or WHpS2 protein showed a meaningful inhibition of the 
surface display of class I antigen (22-36%; P = 0.001 and P = 0.0003, 
respectively). In contrast, WCM-260 cells transfected with p-WHmS or p-WHc 
did not show a noticeable change in the class I antigen expression level (Fig. 
5.5A). Interestingly, transfection with p-WHx led to a dramatic upregulation 
(>50%; P = 0.0001) in the class I antigen presentation (Fig. 5.5A). Figure 5.58 
illustrates the detected shifts in the class I MHC heavy chain fluorescence on 
WCM-260 cells transfected with p-WHV, p-WHpS 1 p-WHpS2 or p-WHx, as well 
as after transfection with other plasm ids when compared to the cells transfected 
with the empty vector. Overall, the data revealed that while the expression of 
whole WHV genome downregulated class I MHC antigen display on WCM-260 
hepatocytes, expression of its individual proteins had a variable modifying effect 
from the inhibition exerted by WHpreS1 and WHpres2, through the lack of a 
noticeable effect in the case of WHmS and WHc, to the considerable 
augmentation in the class I antigen presentation when the cells were transfected 
with p-WHx. 
5.4.4 Effects of WHV genome site-specific mutations on hepatocyte class I 
MHC antigen presentation. 
To determine whether individual WHV translation products which were 
found to be capable of modifying hepatocyte class I MHC antigen display when 
expressed alone would yield a similar effect when expressed in the 
Figure 5.5. Modulation of the class I MHC antigen display on WCM-260 
hepatocytes stably transfected with p-WHV or with plasmid constructs encoding 
individual WHV proteins. (A) The class I antigen presentation on WCM-260 
hepatocytes stably transfected with p-WHV, p-WHpS1, p-WHpS2, p-WHmS, p-
WHc or p-WHx was assessed by flow cytometry by comparing the means 
(horizontal short lines) of MFI values obtained from three independent 
experiments. The data are presented as the percentages where the MFI values 
given by WCM-260 stably transfected with empty pC-DNA3.1 vector (e) were 
taken as 100%. P values were determined as indicated in Materials and 
Methods. (B) A representative example of flow cytometry histograms illustrating 
the display of the class I antigen on WCM-260 hepatocytes from one of three 
experiments shown in panel A. The levels of the class I antigen were determined 
on the hepatocytes prior to (IFNv -)and after (IFNy +)treatment with rwiFNy, as 
described in Materials and Methods. The data are shown as overlayed 
histograms representing the cells transfected with plasmids carrying WHV 
sequences (open) and the cells transfected with empty vector (filled). 
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context of the complete WHV genome, WCM-260 hepatocytes were transfected 
with p-WHV mutants in which transcription of selected genes was blocked by 
premature stop codons (see Fig. 5.2). As far as the availability of specific 
antibodies allowed, transcription of individual WHV proteins or their lack and the 
fact that the introduced mutations did not influence the expression of virus 
envelope and core proteins was confirmed by immunofluorescence staining (Fig. 
5.6). Thus, WCM-260 cells transfected with p-~WHc and stained with anti-WHc 
were WHcAg negative, while those transfected with plasmids carrying mutated 
ORFs other than C ORF were WHcAg reactive (Fig. 5.6), as hepatocytes 
transfected with p-WHc shown in Fig. 5.3C. Similarly, preS1/preS2 antigenic 
reactivity was detected after staining with anti-preS antibodies in WCM-260 
transfected with p-~WHc, p-~WHpS1, p-~WHx and p-b.WHp, but not in those 
transfected with p-~WHmS (Fig. 5.6). It is important to emphasize that anti-preS 
antibodies recognize both WHpreS1 and WHVpre2 proteins, but not WHmS (see 
Materials and Methods). Therefore, WCM-260 transfected with p-b.WHpS1 
should be reactive, as they were, since expression of WHpreS2 was not affected. 
These findings not only verified that WHcAg and WHsAg synthesis was 
abrogated in WCM-260 cells transfected with p-~WHc and p-b.WHmS , but ·also 
implied that the absence of a single protein in the context of expression of the 
whole WHV genome in our system was without a major effect on the synthesis of 
other virus proteins. 
Figure 5.6. Determination of the competence of p-WHV mutants with the 
disabled expression of selected structural or nonstructural proteins for encoding 
of virus envelope and core proteins. WCM-260 hepatocytes transiently 
transfected with p-ll.WHpS1, p-ll.WHmS, p-ll.WHc, p-ll.WHx or p-ll.WHp were 
probed with anti-WHV preS or with anti-WHc by immunostaining, as described in 
Materials and Methods and in the legend to Figure 5.3. Bars represent 20 J..LM. 
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As shown in Figure 5. 7 A, the introduction of the premature stop codon in the 
WHmS-encoding region, which abrogated expression of not only WHmS but also 
WHpS1 and WHpS2 proteins (see Fig. 5.2), resulted in a significant 
enhancement (P < 0.05) in the class I MHC surface presentation over that on 
hepatocytes transfected with p-WHV. On the other hand, blocking of the 
expression of WHx led to a profound suppression in the class I antigen display 
when compared with the control cells transfected with the empty vector (P = 
0.0024). Overall, the above results were in good agreement with the findings 
from WCM-260 hepatocytes transfected with plasm ids encoding for WHpS 1, 
WHpS2 or WHx (see Fig. 5.5A). Furthermore, when WCM-260 cells transfected 
with p-LlWHpS1, which contained the stop codon disabling transcription of 
WHpreS1 but still carried functional intrinsic start codons for WHpreS2 and 
WHmS, were analyzed, it was found there was no change in the class I antigen 
display when compared to the cells transfected with p-WHV (Fig. 5.7A). This 
finding strengthened the notion that WHpreS2 protein was mainly, if not entirely, 
responsible for the observed inhibition of the class I antigen on WCM-260 
transfected with p-WHV. Further, transfection with p-LlWHp was without any -
statistically significant effect on the class I antigen staining. Finally, although the 
mean expression of class I antigen on WCM-260 transfected with p-LlWHc was 
somehow enhanced compared to the cells transfected with p-WHV, the 
difference was not statistically significant and it was likely related to a variation in 
Figure 5.7. The class I MHC antigen display on WCM-260 hepatocytes 
transfected with p-WHV mutants in which expression of selected viral proteins 
was disabled by introduction of appropriate premature stop codons. (A) 
Hepatocytes stably transfected with p-t.WHpS1, p-t.WHmS, p-t.WHc, p-t.WHx or 
p-t.WHp or with p-WHV or empty vector (e), as controls, were assessed for class 
I antigen surface presentation by flow cytometry, as described in the legend to 
Figure 5.5 and in Materials and Methods. (B) A representative example of flow 
cytometry histograms demonstrating the class I antigen display on WCM-260 
hepatocytes transfected with different p-WHV mutants from one of three 
experiments depicted in panel A prior to (IFNy -)and after (IFNy +)treatment with 
rwiFNy. For further details see the legend to Figure 5.5 and Materials and 
Methods. 
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one of the experiments. Figure 5.78 shows examples of the changes in the class 
I antigen surface presentation detected on WCM-260 hepatocytes transfected 
with different p-WHV mutants. 
5.4.5 Inhibition of class I MHC antigen presentation by WHV can be fully 
restored by treatment with IFN-y. 
Exposure of WCM-260 hepatocytes transfected with p-WHV or with either p-
WHpS1 or p-WHpS2 to exogenous rwiFNy led to upregulation in the class I MHC 
antigen to the level compatible with that detected on WCM-260 transfected with 
empty pC-DNA3.1 or on naive WCM-260 cells following their treatment with 
rwiFNy (Figs 5.8A and 5.5C). It is of note that the observed augmentation in the 
class I antigen induced by rwiFNy was significantly greater (11.7 ~ 1.6 fold vs. 
1.6 ~ 0.06 fold; P = 0.01) than that mounted by transfection of hepatocytes with 
p-WHx. Also, treatment with rwiFNy of WCM-260 hepatocytes expressing 
mutated p-WHV sequences, including p-L:lWHx, led to a comparable increase in 
the class I MHC antigen surface display (Figs 5.88 and 5.7C). Taken together, 
the above experiments clearly showed that the inhibition of class I MHC antigen 
on cultured hepatocytes expressing whole WHV genome or its fragments 
encoding particular proteins was not permanent but can be reversed by 
treatment with exogenous IFN-y. 
Figure 5.8. The display of class I MHC antigen on the surface of WCM-260 
hepatocytes transfected with different WHV expression constructs following 
treatment of the cells with IFNy. (A) Hepatocytes stably transfected with p-WHV, 
p-WHpS1, p-WHpS2, p-WHmS, p-WHc or p-WHx or (B) with p-LlWHpS1, p-
LlWHmS, p-LlWHc, p-LlWHx or p-LlWHp and control cells transfected with empty 
pC-DNA3.1 vector (e) or with p-WHV were treated with rwiFNy prior to staining 
for class I antigen with 81 b.B9 mAb, as outlined in Materials and Methods. It is 
of note that the treatment with rwiFNy led to the unified augmentation in the class 
I antigen display to approximately the same level on hepatocytes transfected with 
different WHV DNA constructs and on the control cells. The data should be 
interpreted in the context of those shown in Figures 5.5 and 5.7. 
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5.4.6 WHV-induced inhibition of class I antigen presentation is not due to 
suppressed transcription of class I MHC- or proteasome-linked genes. 
Quantitation of the mRNA levels of the class I MHC-related genes (i.e., class I 
MHC heavy chain, ~2m, TAP1 and TAP2) and the genes encoding subunits of 
immunoproteasome (i.e., LMP2, LMP7, MECL 1, PA28a and PA28~) revealed no 
meaningful differences between WCM-260 hepatocytes transfected with p-WHV 
or with sequences encoding for individual virus proteins of the virus and naive 
WCM-260 cells or those transfected with empty vector (Fig. 5.9). Similarly, there 
was no noticeable variation in the transcription level of these genes between 
WCM-260 cells transfected with p-WHV or p-WHV mutants and the control cells 
(data not shown). Taken together, the results revealed that the inhibited or 
augmented presentation of the class I MHC antigen on WCM-260 cells 
transfected with WHV sequences identified in this study as those capable of 
modifying the class I antigen display was not connected to the transcriptional 
activity of the genes examined. In a supplementary experiment, analysis of the 
class I MHC- and proteasome-linked gene mRNA levels in hepatocytes 
transfected with p-WHV, their mutants or WHV subgenomic fragments and in 
control hepatocytes following treatment with wriFNy showed the genes' 
transcriptional activity was upregulated to approximately the same extent in all 
hepatocytes tested (Fig. 5.9 and data not shown). 
Figure 5.9. Quantitation of the class I MHC- and proteasome-linked genes expression 
in hepatocytes transfected with p-WHV and with constructs encoding for individual WHV 
proteins and subjected or not to treatment with IFNy. The data were generated in 
three independent experiments by real time RT-PCR. They are presented as the 
mean gene copy numbers per reaction which were calculated using serial 1 0-fold 
dilutions of internal plasmid standards and normalized against house-keeping 
woodchuck 13-actin eDNA level. The open bars represent hepatocytes not treated 
with rwiFNy, while the stratified bars those treated with the cytokine. 
-'0 Q) 
.~ 
m 
E 
0 
c: 
'-" 
c: 
0 
u 
m 
~ 
-
(/) 
Q) 
·a. 
0 (.) 
Figure 5.9 
10' 
10° 
10' 
108 
107 
108 
108 
10° 
10' 
Iii 
10' 
107 
10' 
h.c. 
~2M 
TAP2 
LMP7 
n l'i n n n 
PA28u 
10' 
10° 
10' 
In ~ 10' 
102 
107 
108 
10' 
10' 
10' n 
102 n 
107 
10° 
r 
107 
10' 
CJIFNy-
-IFNy+ 
TAP1 
I ~ ~ 
LMP2 
n n n 
MECL1 
PA28~ 
182 
~ r 
n n 
183 
5.5 Discussion 
To investigate the impact of WHV expression on the class I antigen 
presentation on the hepatocyte surface, we generated a panel of woodchuck 
hepatocyte lines transcribing complete WHV genome, subgenomic fragments 
coding individual viral proteins. In addition, we produced WHV genome mutants 
in which transcription of selected products in the context of expression of an 
otherwise complete genome was disabled by site-specific mutagenesis. The 
transcriptional activity of individual virus genes or their fragments was confirmed 
by determining the presence of relevant gene-specific mRNAs and, when the 
availability of specific antibodies allowed, expression of viral proteins. The data 
acquired showed that the stable transfection with complete WHV genome 
consistently resulted in a significant suppression of the class I MHC antigen on 
the hepatocyte surface, although no virus antigens could be visualized by 
immunofluorescence using available antibodies and relatively small amounts of 
virions were apparently assembled when hepatocyte supernatants were 
examined for infectivity by injecting into a naive woodchuck. 
Importantly, the level of class I antigen inhibition on hepatocytes 
transfected with the whole WHV genome was comparable to that identified on 
the cells expressing alone either WHpreS1 or WHpreS2. In contrast, transfection 
with p-WHmS did not alter the antigen display when compared to the intact 
hepatocytes or those stably transfected with empty plasmid vector. Taking under 
consideration that all three envelope proteins are encoded within the single S 
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ORF, which has three in-frame translation initiation codons (see Fig 5.1 ), and 
that all of them share the same C-terminal portion while differing in the N-terminal 
amino acid sequences, the above finding implied that the sequence shared by 
both WHpreS1 and WHpreS2, hence most likely located within WHpreS2, was 
responsible for the inhibitory effect observed. The analysis of hepatocytes 
transfected with the complete WHV genome in which expression of WHpreS1 
was selectively disabled, provided supporting evidence which helped to resolve 
this issue. Thus, transfection with p-.6.WHpS1, which was unable to translate 
WHpreS1 due to the stop codon introduced into the extreme 5'-terminal portion of 
the S gene (see Fig. 5.2), but was still able to translate WHpreS2 from the 
downstream initiation site, did not restore suppressed class I antigen display. 
This indicated again that the preS2 segment of the WHpreS1 protein plays a 
critical role in class I antigen suppression. Furthermore, the data from the 
transfection experiments with p-LlWHmS, which was unable to initiate translation 
of WHmS, showed that the hepatocyte class I antigen display was restored 
almost to the same level as that displayed by hepatocytes transfected with empty 
vector. Because the C-terminal portion of both WHpreS1 and WHpreS2 proteins 
is constituted by WHmS, this suggests that the complete intact sequence of 
WHpreS2 protein is required to act as a class I antigen inhibitor. Taken together, 
this differential analysis provided cumulative evidence that suppression of the 
class I antigen on WCM-260 hepatocytes was mediated by WHpreS2 protein. 
Remarkably, but not unexpectedly, transfection with p-WHx induced a 
dramatic increase in hepatocyte class I antigen display. X protein of 
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hepadnaviruses is known to be a promiscuous transactivator capable of 
promoting expression of a variety of viral and cellular genes, including those 
involved in control of cell growth, and can interact with cellular organelles, such 
as mitochondria and proteasomes, and modify their functions (Bouchard et a/., 
2001; Diao eta/., 2001; Fischer eta/., 1995; Hu eta/., 1999; Zhang eta/., 2000). 
In regard to HBV X and class I MHC expression, it has been reported that 
transfection of the same cells with HBV X gene together with a reporter plasmid 
driven by class I MHC promoter led to augmented expression of luciferase 
reporter, suggesting that X protein was responsible for this event (Zhou et a/., 
1990). This result seems to corroborate with the findings in our study, although 
significantly different experimental approaches were used. It has also been 
shown by employing a two-hybrid system that HBV X protein can interact with 
PSMA7 and PSMA1 of the proteasome complex (Fischer eta/., 1995; Hu eta/., 
1999; Zhang et a/., 2000). It was postulated that this interaction may modify the 
fun,ction of both X protein and immunoproteasome. However, the effect of these 
expected modifications of the class I MHC antigen presentation was not 
characterized in these studies. 
The observed diametrically opposed effects on class I MHC presentation 
following transfection with p-WHpS1 or p-WHpS2 or with p-WHx and the fact that 
the expression of the whole WHV genome strongly inhibited the antigen display 
suggest that a highly complex interplay between individual virus products is 
involved in suppression of the class I antigen. Thus, if we assume that, in the 
context of expression of the complete virus genome, both WHpreS2 and WHx 
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exerted their respective inhibitory or stimulatory action to the same degrees as 
those identified on hepatocytes transfected with the sequences encoding 
WHpreS2 or WHx alone, this may suggest that WHpreS2 is a very potent class 1 
antigen inhibitor which is able not only to counteract the stimulating effect of WHx 
but also to suppress the antigen significantly below the level displayed on intact 
hepatocytes. This intriguing possibility will require further examination, for 
example by co-transfecting cells with both p-WHpS2 and p-WHx. It also remains 
to be established whether the same event occurs in naturally infected 
hepatocytes. 
Exposure to rwiFNy completely restored the class I antigen presentation 
on hepatocytes transfected with the whole WHV genome, with gene sequences 
encoding for WHpreS1 and WHpreS2 or with WHV DNA with an introduced stop 
codon disabling transcription of the preS1 region. These findings demonstrated 
that the inhibition of class I antigen was reversible in all hepatocyte lines in which 
defective class I antigen display was detected. This supports the notion that 
intrahepatic induction of IFNy could not only suppress virus replication, as it has 
been shown for HBV in a transgenic mouse model (Guidotti eta!., 1996b), but 
also enhance class I MHC expression on chronically infected hepatocytes, 
promoting their recognition by virus-specific CTL. This is further supported by the 
results from the present study showing that treatment with IFNy was highly 
effective in augmenting expression of the genes encoding different components 
of the endocytic antigen presentation pathway and proteasome subunits in 
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hepatocytes with suppressed class I antigen display. Therefore, treatment with 
this cytokine or with functionally equivalent agents may enable hepatocytes in 
chronic hepadnaviral infection to process and present viral peptides more 
efficiently in the context of class I antigen and, in consequence, increase their 
accessibility for recognition by specific CTL. Furthermore, as a result of the 
increased expression of IFNy-inducible proteasome subunits, the assembly of 
immunopreoteasomes might also be enhanced, which has been shown to be 
required for the generation of certain HBV-specific CTL epitopes (Sijts et a/., 
2000). 
The precise molecular mechanism of WHpreS2-mediated suppression of 
the class I MHC antigen remains to be determined. However, as the quantitative 
analysis of the mRNA levels of several class I MHC- and proteasome-affiliated 
genes revealed, the class I antigen inhibition was not related to hepatocyte 
downregulated transcription of any of the genes examined. This suggests that 
the suppression has to be due to WHpreS2-dependent posttranscriptional 
interference. This conclusion is consistent with the findings from the previous 
study where, based on the analysis of hepatocytes naturally infected with WHV 
derived from woodchucks with chronic hepatitis, a virus-dependent 
posttranscriptional event was suspected as a reason behind the impaired 
hepatocyte presentation of class I molecules (Michalak eta/., 2000). 
The present study provides experimental evidence that the envelope 
preS2 protein of WHV is functioning as a suppressor of class I MHC antigen in 
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hepatocytes actively transcribing virus genome. Identification of the translation 
product responsible for a defect in class I antigen presentation on hepatocytes, 
which are the main targets of hepadnavirus invasion and the fount of clinical 
symptoms, advances our understanding of how hepadnaviruses may subvert the 
host immune system, persist, and uphold protracted liver damage. Moreover, 
this study demonstrates that IFNy can completely reverse the virus-induced 
defect in the class I antigen presentation. This provides an indication of how the 
host immune system, either intrinsically or due to exogenous stimulation, may 
overcome this deficiency in the course of chronic hepadnaviral infection. 
CHAPTER 6. BICISTRONIC WOODCHUCK HEPATITIS VIRUS CORE AND 
GAMMA INTERFERON DNA VACCINE CAN PROTECT FROM 
SEROLOGICALLY EVIDENT INFECTION AND HEPATITIS BUT DOES NOT 
ELICIT STERILIZING ANTIVIRAL IMMUNITY 
6.1 Summary 
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The immunity elicited against the nucleocapsid of hepatitis B virus (HBV) 
and closely related woodchuck hepatitis virus (WHV) has been shown to be 
important in resolution of hepatitis and protection from infection. Further, the 
activity of gamma interferon (IFN-y), which may directly inhibit hepadnavirus 
replication, promotes antiviral defense and favors T helper cell type 1 (Th1) 
response, which is seemingly a prerequisite for HBV clearance. In this study, to 
enhance induction of protective immunity against hepadnavirus, healthy 
woodchucks were immunized with a bicistronic DNA vaccine carrying WHV core 
(WHc) and woodchuck IFN-y (wiFNy) gene sequences. Three groups, of 3 
animals each, were injected once or twice with 0.5 mg, 0.9 mg or 1.5 mg per 
dose of this DNA vaccine. In addition, 4 animals received twice 0.6 mg or 1 mg 
WHc DNA alone. All animals were challenged with WHV. The results showed 
that 4 of 9 animals injected with the bicistronic vaccine and one of 4 immunized 
with WHc DNA became protected from serologically evident infection and 
hepatitis. This protection was not linked to induction of WHcAg-specific 
antibodies or a T cell proliferative response, and was not associated with 
enhanced transcription of Th1 cytokines or 2',5'-oligoadenylate synthetase. 
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Strikingly, all animals protected from serologically positive infection and hepatitis 
became reactive for WHV DNA and carried low levels of replicating virus in 
hepatic and lymphoid tissues after challenge with WHV. This study shows that 
the bicistronic DNA vaccine encoding for both hepadnavirus core antigen and 
IFN-y was significantly more effective in preventing hepatitis than that encoding 
for virus core alone, but neither of them could mount sterile immunity against the 
virus. 
6.2 Introduction 
Hepatitis B virus (HBV) is one of the most common human pathogens that 
affects as a chronic, serum HBV surface antigen (HBsAg)-positive infection over 
350 million people with an estimated 2 billion individuals exposed to the virus 
during their lifetime (Lee, 1997). The virus is the main causative factor of chronic 
hepatitis that frequently advances to cirrhosis and hepatocellular carcinoma 
(Chisari, 2000). It is now evident that HBV also elicits serologically silent, i.e., 
serum HBsAg-negative, infection which persists indefinitely after resolution of 
acute hepatitis B or due to primary asymptomatic exposure (Brechot eta/., 2001; 
Michalak eta/., 1994). This occult infection is associated with an increased risk 
of developing liver cancer (Pollicino eta/., 2004). It also became evident that 
HBV normally replicates in the lymphatic system, although less vigorously than in 
the liver (Lew and Michalak, 2001; Michalak, 2000; Michalak et a/., 1994 ). 
Studies of woodchucks (Marmota monax) infected with woodchuck hepatitis virus 
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(WHV), which represent the closest pathogenic animal model of hepatitis B, 
significantly contributed to recognition of these and other remarkable 
characteristics of hepadnaviral infection (reviewed in Tennant and Gerin, 2001 ). 
Among others, the woodchuck studies showed that WHV invariably invades the 
lymphatic system and persists for life independent of whether the infection is 
symptomatic or serologically undetectable and that exposure to low virus doses 
(~1 03 virions) induces occult infection restricted to the lymphatic system which 
with time may engage the liver (Coffin and Michalak, 1999; Coffin et a/., 2004; 
Hodgson and Michalak, 2001; Lew and Michalak, 2001; Michalak et at., 2004; 
Michalak eta/., 1999; Mulrooney and Michalak, 2003). 
It is acknowledged that the immune responses play a pivotal role both in 
the pathogenesis and in the control of HBV infection (Chisari, 2000). Polyclonal 
cytotoxic T cell (CTL) and T helper type 1 (Th 1) cell responses directed toward 
multiple antigenic epitopes of HBV are associated with resolution of acute 
hepatitis. This is preceded by intrahepatic upregulated expression of antiviral, 
Th1 cytokines, such as interferon gamma (IFN-y) and tumor necrosis factor alpha 
(TNF-a) (Guidotti et a/., 1996b; Guidotti et a/., 1999). In contrast, chronic 
hepatitis B is accompanied by a weak and narrowly focused HBV-specific T cell 
reactivity. It has been postulated, based on the data from other microbial 
infections (Boehm et at., 1997), as well as chimpanzee and woodchuck models 
of hepatitis B (Guidotti et a/., 1999; Menne et a/., 2002b), that induction of a 
prevailing Th1 response and IFN-y should be advantageous in the control of HBV 
infection. In this context, it has been shown that IFN-y is highly effective in 
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steering T cell response toward Th1 type (Boehm eta/., 1997). In addition, IFN-y 
strongly enhances class I and II major histocompatibility complex (MHC) 
expression, and hence augments antigen presentation by both endocytic and 
exocytic pathways (Boehm eta/., 1997; Fruh and Yang, 1999). 
Purified HBV envelope particles or recombinant proteins carrying HBsAg 
reactivity have been applied as vaccines to prevent HBV infection, with overall 
efficacy of -95% (Margolis eta/., 1995). However, their effectiveness is lower in 
elderly individuals, immunocompromised patients, and infants born to HBV-
infected mothers (Sjogren, 2005), and breakthrough infections have been 
reported (McMahon eta/., 2005). Also, the HBsAg-based vaccines have a very 
limited or no beneficial effect in patients with chronic hepatitis B, who normally 
have poor anti-HBV humoral and cellular immune responses (Dienstag et a/., 
1982; Jung et a/., 2002). Of note is that an attempt to augment an antibody 
response against WHV surface antigen (WHsAg) by inducing T helper type 2 
cells in chronic WHV infection led to severe liver damage, particularly when high 
levels of antibodies to WHsAg (anti-WHs) were produced (Hervas-Stubbs et a/., 
1997). This suggested that a similar approach to treatment of chronic hepatitis B 
would be futile. 
The protective effect of immunization with HBV core antigen (HBcAg), an 
inner structural protein of the Dane particle, was first demonstrated in 
chimpanzees (!warson et a/., 1985; Murray et a/., 1984; Murray et a/., 1987). 
After injections with liver-derived or a recombinant HBcAg, antibodies against 
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HBcAg (anti-HBc) were induced and apparent complete protection from HBV was 
observed in some animals (!warson eta/., 1985; Murray eta/., 1984). A similar 
outcome has been seen in woodchucks immunized with native WHV core 
antigen (WHcAg) or recombinant core protein prior to WHV challenge (Roos et 
a/., 1989; Schadel et a/., 1993). The immunization prevented emergence of 
serologically evident infection in some woodchucks and the results suggested 
that priming of a specific Th1 type response, rather than antibodies to WHcAg 
(anti-WHc), could be important in establishing protective immunity. 
Immunizations with DNA encoding for selected structural or nonstructural 
viral proteins have been shown to induce specific humoral and cellular immune 
responses (reviewed in Donnelly et a/., 2005). This is because the protein 
encoded by the delivered DNA is de novo synthesized and can enter both class I 
and class II MHC presentation pathways and prime CDS+ and CD4+ T cells 
simultaneously. The immune responses elicited by DNA vaccination have been 
shown to be protective against pathogens in a variety of experimental systems 
(Huygen et a/., 1996; Manickan et a/., 1995; Michel et a/., 1995; Sedegah et a/., 
1994; Ulmer eta/., 1993; Wang eta/., 1993; Xiang eta/., 1994). Moreover, it was 
uncovered that increased efficacy of DNA vaccination and skewing toward a 
preferable T helper cell response can be achieved by co-delivery of plasmids 
encoding for molecules acting as adjuvants, such as cytokines, chemokines, and 
co-stimulatory factors (Calarota and Weiner, 2004; Chow eta/., 1998; Kwissa et 
a/., 2003; Lu eta/., 2005). 
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A number of DNA immunization protocols have been tested, with highly 
varying success, in animal models of hepadnaviral infection (Davis et a/., 1996; 
Lu eta/., 1999; Lu eta/., 2005; Michel eta/., 1995; Musacchio eta/., 2001; 
Pancholi et a/., 2001; Roilier et a/., 1999; Sail berg et a/., 1998; Thermet et a/., 
2004; Triyatni eta/., 1998; Wild eta/., 1998). In woodchucks, to boost and to 
shift toward a preferable Th1 antiviral response, co-administration of plasmids 
encoding for WHcAg and IFN-y (Siegel et a/., 2001) or interleukin-12 (IL-12) 
(Garcia-Navarro et a/., 2001 ), a cytokine promoting maturation of Th1 cells and 
production of IFN-y, has been tested. As a result, it was shown that the 
protective immunity against WHV infection could be meaningfully enhanced over 
that induced by WHc DNA alone. However, protection was never achieved in all 
animals vaccinated and it remains unclear whether the protection was complete. 
In the present study, in an attempt to enhance the effectiveness of the 
DNA vaccine encoding for WHcAg by inducing simultaneous production of IFN-y 
to prime Th1 cell response and, at the same time, to fully control the co-delivery 
of the antigen- and the cytokine-encoding sequences, a bicistronic vector 
capable of concomitant expression of WHcAg and woodchuck IFN-y (wiFNy) 
was constructed. This expression vector was investigated in parallel with the 
plasmid encoding for WHcAg alone for the ability to mount complete (sterilizing) 
protection against the hepadnavirus. This was achieved by challenging the 
vaccinated woodchucks with a massive dose of WHV and by applying highly 
sensitive assays to detect WHV genomes and their replication. We also 
examined the ability of the bicistronic plasmid to elicit WHcAg-specific humoral 
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and T cell immune responses, and to upregulate expression of Th1 cytokines 
and IFN-cx responsive 2',5'-oligoadenylate synthetase in peripheral lymphoid cells 
and hepatic tissue. We have found that immunization with the bicistrionic DNA 
was significantly more effective than that with WHc DNA alone in preventing 
WHV infection identifiable by serological assays. However, all animals who were 
free of serologically evident infection and hepatitis after vaccination had acquired 
low levels of replicating virus following challenge with WHV, indicating that the 
protection was not absolute. The reported findings raise a concern about the 
actual prophylactic potency of vaccination with DNA encoding for the internal 
protein of hepadnavirus. They also reveal that prevention against disease and 
protection from infection may not be synonymous in the case of hepadnaviral 
infection. 
6.3 Material and Methods 
6.3.1 Animals. 
Fifteen healthy, adult woodchucks housed in the Woodchuck Hepatitis 
Research Facility at Memorial University, St. John's, Canada were used in this 
study. The possibility of prior exposure of the animals to WHV was excluded 
based on negative serological results for WHV infection markers, i.e., WHsAg 
and anti-WHc, and the absence of WHV DNA tested by a nested PCR/nucleic 
acid hybridization (PCR/NAH) assay (sensitivity, ~1 0 virus genome equivalents 
[vge]/ml) using DNA from randomly selected serum, peripheral blood 
196 
mononuclear cell (PBMC), and liver biopsy samples, as described (Coffin et a/., 
2004; Michalak et a/., 2004; Michalak et a/., 1999). Animal experimental 
protocols were approved by the Institutional Presidents' Committee on Animal 
Bioethics and Care. 
6.3.2 Construction of pC-WHc and pWHc-wiFNy expression vectors. 
Full-length WHV core (WHc) gene sequence (567 bp in length; GenBank 
accession number J02442) (Galibert et a/., 1982) was amplified by PCR and 
inserted into the EcoRI site of the pCI-vector (Promega, Madison, WI). The 
integrity of the resulting plasmid, designated as pC-WHc, was confirmed by 
sequencing. To express simultaneously WHcAg and woodchuck IFN-y (wiFNy), 
a bicistronic vector containing both WHc gene and full-length wiFNy eDNA was 
constructed. Briefly, wiFNy eDNA was amplified with sense primer 5'-
GCGCGGA TCCATGAAA TACACAAGTT A TTT and antisense primer 5'-
GCGCGGTACCTTATTTGGATGCTCTCCGAC with incorporated BamHI and 
Kpnl sites (shown as underlined italics) using recombinant wiFNy as template, 
which was previously generated in this laboratory (Wang and Michalak, 2005). 
Encephalomyocarditis virus internal ribosome entry site (IRES) sequence was 
amplified from piRES2-EGFP vector (Ciontech, Palo Alto, CA) with sense primer 
5'-GGTGGGAGGTCTATATAAGCAGAGC and anti-sense primer 5'-
GCGAGATCTGGTTGTGGCCATATTATCATCG with an inserted Bg/11 site. The 
final construct, designated as pWHc-wiFNy, was generated by sequentially and 
directionally inserting into pcDNA3.1 eukaryotic expression vector (Invitrogen, 
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Carlsbad, CA) full-length wiFNy eDNA, then IRES, and finally WHc sequence 
released from pC-WHc by digestion with EcoRI restriction enzyme. The 
transcription of the WHc insert was driven by a cytomegalovirus immediate early 
promoter (PCMVIE) (see Fig. 6.1A). Large quantities of both pC-WHc and 
pWHc-wiFNy plasmids were prepared using a giga-preps kit (Qiagen, 
Mississauga, Ontario) and re-suspended in phosphate-buffered saline, pH 7.4 
(PBS) at 1 1-Lg/J..LI for injections. 
6.3.3 WHcAg and wiFNy expression in transfected hepatocytes. 
To assess competence of the constructed expression vectors, cultured 
woodchuck WCM-260 hepatocytes, previously derived and characterized in our 
laboratory (Diao et a/., 1998; Lew and Michalak, 2001 ), were transiently 
transfected with pC-WHc or pWHc-wiFNy using Lipofectamine 2000 reagent 
(Invitrogen). Briefly, 1.5 x 105 WCM-260 cells were seeded on an 18-mm round 
glass cover slip in the well of a 12-well culture plate (Nunc, Rochester, NY). Next 
day, 1.6 1-Lg of test plasmid and 4 J.LI of Lipofectamine 2000 reagent were first 
diluted separately in 100 J.LI of serum-free, antibiotics-free Dulbecco's modified 
Eagle medium (DMEM) (GIBCO BRL, Grand Island, NY) and then combined 
together. After incubation for 20 min at ambient temperature, the mixture was 
added to WCM-260 cell culture in which complete hepatocyte culture medium 
(Churchill and Michalak, 2004) had just been replaced with serum-free, 
antibiotics-free DMEM. After incubation in a humidified, 5% C02 atmosphere for 
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8 h at 37 °C, DMEM was substituted with complete hepatocyte culture medium 
and cells maintained for 48-72 h before evaluation. 
WHcAg was detected in WCM-260 transfected with pC-WHc or pWHc-
wiFNy by immunofluorescence after staining with rabbit anti-WHc, produced as 
reported before (Michalak et a/., 1989). For this purpose, WCM-260 cells grown 
on the cover slip were fixed for 3 min with cold ethanol ether (Michalak et a/., 
1989), exposed to rabbit anti-WHc for 30 min on ice, washed, and stained with 
goat anti-rabbit lgG conjugated with rhodamine (Jackson lmmunoresearch Labs, 
Inc., West Grove, PA). Finally, the cover slip was mounted on a slide with 50% 
glycerol in PBS and examined with a Fluoview 300 confocal imaging system 
(Olympus America, Melville, NY). 
Expression of wiFNy was determined by assessing upregulation of the 
class I major MHC antigen in WCM-260 hepatocytes, which normally express 
very low levels of this antigen on their surface (Wang and Michalak, 2005). To 
simultaneously detect WHcAg and class I MHC antigen in WCM-260 hepatocytes 
transfected with the pWHc-wiFNy construct, the cells, prepared and incubated 
with Rb-anti-WHc, as described above, were exposed for 30 min on ice to 81 Bb9 
monoclonal antibody (mAb) specific for the heavy chain of woodchuck class I 
MHC molecule. This mAb was previously prepared and characterized in this 
laboratory (Michalak et a!., 1995; Michalak et a/., 2000). Then, the cells were 
exposed to FITC-conjugated goat anti-mouse lgM/IgGs antibodies (Jackson 
lmmunoresearch Labs, Inc.) for 30 min on ice and examined by confocal 
microscopy. 
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6.3.4 DNA immunization and WHV challenge. 
In the first phase of the study, 4 healthy woodchucks were immunized 
twice with pC-WHc alone (Table 6.1; pC-WHc group). Two of the animals were 
injected with 0.6 mg and two with 1.0 mg of pC-WHc DNA per injection. As a 
control, one woodchuck was injected twice with 1 mg DNA of pCI empty vector. 
For each injection, half of the plasmid DNA was administered subcutaneously at 
1 0-15 sites on the back and another half intramuscularly injected to the 
quadriceps of the hind leg at 3-5 sites under general anesthesia. Approximately 
two mo after the first immunization, a boost DNA injection with the same dose 
was given. 
In a parallel experiment, 9 woodchucks were injected with the pWHc-
wiFNy DNA (Table 6.1; pWHc-wiFNy group). The animals were divided into 
three subgroups each of which received 0.5 mg, 0.9 mg or 1.5 mg of the total 
plasmid DNA using the same mode of DNA administration as for the pC-WHc 
group. The pWHc-wiFNy doses of 0.9 mg and 1.5 mg were calculated to contain 
DNA encoding for WHcAg at equivalent amounts to those contained in pC-WHc 
doses of 0.6 mg and 1.0 mg, respectively. Two months after primary 
immunization, a boost DNA injection with the same dose as the primary injection 
was given to selected woodchucks (see Table 6.1 ). After 2-3 mo, woodchucks 
belonging to pC-WHc and pWHc-wiFNy groups were challenged by intravenous 
injection with WHV/tm2 inoculum at 1.1 x 1010 DNase-protected vge (GenBank 
accession number AY628096) (Coffin eta/., 2004). In addition, one woodchuck 
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received 1.3 mg DNA of wiFNy plasmid (pC-wiFNy) for each of the two injections 
prior to challenge. 
6.3.5 Sample collection. 
Sera were collected biweekly from the time of DNA immunization until 6 
mo after challenge with WHV and then monthly. PBMC were obtained biweekly 
after DNA immunization and weekly following challenge with WHV for 2 months, 
then bi-weekly for 4 months, and monthly thereafter. The cells were isolated by 
density gradient centrifugation on Ficoii-Paque (Pharmacia Biotech, Baie d'Urfe, 
Quebec, Canada) as described elsewhere (Lew and Michalak, 2001 ). Liver 
biopsies were obtained by surgical laparotomy (Michalak eta/., 1999). The first 
biopsy was taken before DNA immunization, the second 6 or 7 weeks after 
challenge with WHV, and the third at autopsy. In some animals, the second 
biopsy was obtained 2 wks after the challenge, a third biopsy 6 wks later and a 
fourth at autopsy. At autopsy, in addition to liver tissue, samples of serum, 
PBMC and lymphatic organs were collected and preserved, following procedures 
described before (Hodgson and Michalak, 2001; Michalak eta/., 1999). 
6.3.6 Serological and WHV DNA, cccDNA and mRNA detection assays. 
Serum WHsAg, anti-WHc and anti-WHs were determined by specific 
enzyme-linked immunosorbent assays as described (Michalak eta/., 1999). For 
detection of WHV DNA in serum, PBMC, liver biopsies and in autopsy lymphatic 
and hepatic tissue samples, DNA was extracted by the proteinase K-phenol-
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chloroform method (Michalak et a/., 1 999). The isolated DNA was subjected to 
direct and, if required, nested PCR using WHV core gene-specific primers, 
conditions, and controls described previously (Michalak et a/., 1 999). For 
detection of WHV cccDNA by specific PCR, mung bean nuclease treatment, 
primers and conditions previously established, were used (Lew and Michalak, 
2001; Michalak eta/., 2004). The presence of WHV mRNA was examined using 
total RNA extracted with Trizol (Invitrogen). Samples were treated with DNase I 
following instructions of a DNA-free kit (Ambion, Austin, TX) before reverse 
transcription (RT) to eDNA (Coffin and Michalak, 1 999; Michalak et a/., 1 999). In 
all instances, DNA and RNA isolations were carried out in parallel with mock 
samples containing water instead of test nucleic acid samples. In addition, DNA 
from serum, or DNA or RNA from PBMC or liver tissue of a healthy animal and 
from a woodchuck with WHsAg-positive chronic hepatitis were included as 
negative and positive controls, respectively. In the case of RT-PCR, test RNA 
not transcribed in RT reaction was used to rule out potential carryover of WHV 
DNA (Hodgson and Michalak, 2001 ). Southern blot hybridization analysis of the 
amplified PCR products with 32P-Iabeled complete recombinant WHV DNA was 
routinely used to verify the specificity and to enhance the sensitivity of the virus 
sequence detection, as described elsewhere (Lew and Michalak, 2001; Michalak 
eta/., 1999). 
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6.3.6 Real-time RT -PCR. 
To quantify expression of wiFNy and woodchuck TN F-a (wTNFa), IFN-a 
responsive 2',5'-oligoadenylate synthetase (wOAS), CD3e (wCD3), p-actin and 
WHV RNA in the liver and PBMC, real-time RT-PCR assays were established 
using Light Cycler Faststart Master SYBR I kit (Roche Diagnostics, Laval, 
Quebec) and a LightCycler (Roche Diagnostics). Briefly, eDNA derived from 
approximately 25 ng of total RNA was used as template for each RT reaction. 
For PCR amplifications the following primer pairs were used: sense primer 5'-
AGGAGCATGGACACCATCA and anti-sense primer 5'-
CCGACCCCGAA TCGAAG for wJFNy, sense primer 5'-
TGAGCACTGAAAGTATGATCC and anti-sense primer 5'-
TGCTACAACATGGGCTACAG for wTNFct, sense primer 5'-
TCAGGCAAAGGCACTACCC and anti-sense primer 5'-
ACTTCTCTTTCGGACATGCT for wOAS, sense primer 5'-
CTGGGACTCTGCCTCTTATC and anti-sense primer 5'-
GCTGGCCTTTCCGGATGGGCTC for wCD3, and sense primer 5'-
CAACCGTGAGAAGATGACC and anti-sense primer 5'-
ATCTCCTGCTCGAAGTCC for woodchuck p-actin. WHV RNA was quantified 
using sense primer 5'-ATGCACCCA TTCTCTCGAC and anti-sense primer 5'-
TCAGGCAAAGGCACTACCC. Upon completion of PCR, a melting curve 
analysis was routinely carried out to determine the specificity of the am pi icons. 
Ten-fold serial dilutions of respective recombinant gene eDNA fragments and 
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Light Cycler-quantification software (Roche Diagnostics) were used for 
enumeration of copy numbers or virus load in test samples. As controls, water 
instead of test nucleic acid and DNase-treated RNA samples not subjected to RT 
were included to rule out contamination or DNA carryover, respectively. 
6.3.7 WHV-specific T cell proliferation assay. 
WHV-specific T cell proliferation response was measured using isolated 
PBMC and [2-3H]-adenine incorporation assay, as previously reported (Gujar and 
Michalak, 2005; Menne et a/., 1997a). As stimulators of WHV-specific T cell 
proliferation, recombinant WHV proteins produced in the pET41 Escherichia coli 
expression system (Novagen, Madison, WI), as previously described (Wang and 
Michalak, 2005), were used. Thus, recombinant WHV core protein (rWHcAg) 
was encoded by the sequence spanning nucleotides 2021 and 2584 of WHV 
genome, recombinant truncated WHcAg (1-149 amino acids) corresponding to 
the predicted partial sequence of WHV e antigen (rWHeAg) was encoded by 
nucleotides 2021 - 2467, and recombinant WHV X protein (rWHxAg) by 
nucleotides 1503 -1928 (numbers denote the positions of the nucleotides in 
WHV/tm3 genome according to Michalak et al. (GenBank accession number 
AY334075; Michalak et a/., 2004). Each protein was tagged with an octamer 
polyhistidine at the C-terminus to facilitate affinity purification (Wang and 
Michalak, 2005). In addition, a synthetic WHV core peptide, encompassing 
amino acids located in positions 97 to 100 of the virus nucleocapsid protein 
(WHc97_110) and containing a WHV core T cell immunodominant epitope (Menne 
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eta/., 1997b), was prepared (Synprep Corp., Dublin, CA). Also, native WHV 
envelope particles carrying WHsAg specificity, which were purified from plasma 
of a woodchuck with chronic hepatitis (Michalak et a/., 1990), were used as a T 
cell stimulator. 
In brief, PBMC (1 x 105/well) were cultured in the presence of a 
recombinant WHV protein or WHsAg at 1 !lg/ml and 2 !lg/ml or with 2-fold serial 
dilutions of WHC91-11o peptide ranging from 10 to 1.2 f.Lg/ml. Five two-fold serial 
dilutions of Concanavalin A (ConA; Pharmacia Fine Chemicals, Uppsala, 
Sweden) ranging from 20 to 1.2 !lg/ml, were included as positive controls and 
indicators of the natural T cell proliferation capacity. PBMC cultured in the 
absence of any stimulating antigen or ConA served as background controls. 
After 96 h culture, the cells were supplemented with 0.5 f.l.Ci of 3H-adenine 
(Amersham Pharmacia Biotech, Piscataway, NJ) and incubated for an additional 
12-18 h. Then, cells were harvested on a glass fibre filter membrane (Wallac Oy, 
Turku, Finland) using an automatic cell harvester (Harvester 96; Tomtec, 
Hamden, CT), and counts per minute (cpm) in each well were determined in a 
Topcount Scintillator (PerkinEimer, MA). All tests were performed in triplicates. 
The average cpm from readings of the triplicates, containing either stimulated or 
control cells, were calculated to define mean cpm values. The stimulation index 
(S.I.) was calculated by dividing mean cpm obtained after stimulation with test 
antigen or mitogen by mean cpm detected in the absence of a stimulant. An S.l. 
value equal to or above 3.1 was considered as positive (Gujar and Michalak, 
2005). 
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6.3.8 Liver histology. 
Histological examination of liver tissue samples was done after routine 
processing to paraffin, sectioning and staining (Michalak et a/., 1990). 
Morphological alterations encountered in hepatocellular, extrahepatocellular 
intralobular and portal compartments of hepatic parenchyma were graded on a 
numerical scale from 0-3, as described in previous works (Diao et a/., 2003; 
Hodgson and Michalak, 2001; Michalak et a/., 1990) and referred to herein as the 
histological degree of hepatitis. 
6.4 Results 
6.4.1 WHcAg and IFN-y expression in cells transfected with pC-WHc or 
pWHc-wiFNy. 
The translational competence of pC-WHc and the bicistronic WHc-wiFNy 
plasmids (Fig. 6.1A) were examined in transient transfection experiments using 
WCM-260 hepatocytes as targets. As shown in Figure 6.1 B, WHcAg was 
detected in the cells transfected with either pC-WHc or pWHc-wiFNy. On the 
other hand, synthesis of wiFNy was monitored indirectly by detection of the 
enhanced expression of class I MHC antigen. The results showed that the 
display of class I antigen was significantly increased on hepatocytes transfected 
with pWHc-wiFNy, but not on those transfected with pC-WHc alone. In addition, 
the cells transfected with a control pC-wiFNy plasmid also showed upregulated 
Figure 6.1 The pWHc-wiFNy construct and the assessment of its expression 
competence in woodchuck WCM-260 hepatocytes. (A) Schematic presentation 
of the bicistronic plasmid pcDNA3.1 containing complete WHc gene, 
encephalomyocarditis-derived IRES sequence, and the whole wiFNy eDNA 
sequence. Expression of WHc was driven by the cytomegalovirus immediate 
early promoter, PCMVIE. BGHpA represents bovine growth hormone 
polyadenylation signal. (B) Staining of WHcAg and class I MHC antigen in 
woodchuck WCM-260 hepatocytes transfected with pC-WHc (A and B), pWHc-
wiFNy (C and D) or with control pC-wiFNy expression vector (E and F). After 72 
h of transfection, cells were incubated with B1 bB9 mAb against woodchuck class 
I MHC heavy chain followed by goat anti-mouse antibodies conjugated with FITC 
(B, D and F) and then with rabbit anti-WHc followed by goat anti-rabbit antibodies 
conjugated with rhodamine (A, C and E). 
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expression of class I MHC antigen, while they remained WHcAg non-reactive. 
These data implied that neither transfection with lipofectamine reagent nor 
expression of WHcAg enhanced class I MHC antigen display. This supported 
the contention that the observed increase in the class I MHC display was a 
specific consequence of synthesis of functionally active IFN-y in cells transfected 
with pWHc-wiFNy or pC-wiFNy. 
6.4.2 WHcAg-specific antibody and T cell responses after immunization 
with WHc DNA. 
In the first phase of the study, 4 naive woodchucks were immunized with 
pC-WHc DNA (Table 6.1; group pC-WHc). Two of the animals (AIM and B/M) 
injected twice with 0.6 mg of pC-WHc did not produce anti-WHc (Fig. 6.2A). 
However, two others (C/M and D/M), which received two 1-mg doses of DNA, 
developed anti-WHc 4 to 5 weeks after the first injection with the plasmid (Fig. 
6.2A). The level of anti-WHc elicited was on average -25% higher in C/M than 
that in D/M. As expected, a control woodchuck injected with empty pCI vector 
was anti-WHc negative (not shown). WHV-specific lymphoproliferative response 
was not measured in these animals. 
In the subsequent experiments, to test whether introduction of wiFNy DNA 
into the WHc DNA construct would strengthen induction of immune responses 
towards WHcAg and augment protection against hepadnavirus, three groups of 
woodchucks, each of which contained 3 animals, were injected with 0.5, 0.9 or 
1.5 mg per dose of pWHc-wiFNy DNA (Table 6.1; group pWHc-wiFNy). Among 
Table 6.1. WHc DNA immunization protocols and features of WHV infection after challenae with WHV 
After DNA After WHV challengec injectionsb Treatment 
group and Plasmid Number Follow-up Duration Degree of hepatitis
8 
DNA of period of Serum animal 
Anti-WHc Serum Anti-WHc Anti-WHs WHV mg/dose injections (wk)" WHsAg No./Sex WHsAg positivity DNAd 2-8 wk p.i. Autopsy 
(wk) 
pC-WHc group 
AIM 0.6 2 50 + 1 + + + 0.5 
8/M 0.6 2 48 + 5 + + + 0.5 1.0 
C/M 1.0 2 51 + 0 + + + 0 0 
D/M 1.0 2 41 + + 39 + n.a. + 0.5 2.0 
pWHc-wiFN:y group 
1/F 0.5 1 45 + 0 + + 0 0 
2/F 0.5 2 22 + 18 + + 1.5 0.5 
3/M 0.5 2 22 + 1 + + + <0.5 <0.5 
4/F 0.9 1 21 + 0 + + + 0 0 
5/F 0.9 1 43 + 17 + + 2.5 0.5 
6/M 0.9 2 22 + 5 + + 3 <0.5 
7/M 1.5 1 27 0 + 
8/M 1.5 2 22 + 0 + 
9/M 1.5 2 15 + 1 + 
Abbreviations: M, male; F, female; p.i., post infection; wk, week; n.a., not applicable. 
a From time of challenge with WHV. 
b Period from first DNA injection untill challenge with WHV. 
+ 0 
+ 0 
+ 0 
c Period between challenge with WHV and the end of follow-up. 
d Serum WHV DNA detected by direct or nested PCR/NAH with WHc gene-specific primers using DNA extracted 
from 100 1-11 of serum. 
e Degree of hepatitis determined on scale from 0-3 based on severity of liver alterations according to the criteria 
described before (Hodgson and Michalak, 2001; Michalak eta/., 1999). 0 indicates normal liver histology and 3 
most severe necroinflammatory lesions. 
0 
0 
0 
N 
0 
CD 
Figure 6.2. Serological markers of WHV infection, WHV DNA detection and liver 
histology in woodchucks immunized with pC-WHc DNA and challenged with 
WHV. Two groups, each consisting of two animals, were injected twice with 
either 0.6 mg/dose (A) or 1 mg/dose (B) of pC-WHc DNA at the time points 
indicated by solid vertical lines. Subsequently, the animals were challenged with 
1.1 x 1010 vge of WHV at week 0. The appearance and duration of serum 
WHsAg, anti-WHc and WHV DNA are indicated as black bars. Liver tissue 
samples were collected at the time points shown by arrows and examined for 
WHV DNA presence (+ or -) and by histology. Morphological alterations 
encountered in liver samples are presented as the histological degree of hepatitis 
ranging from 0 to 3. 
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Figure 6.3. Serological markers of WHV infection, WHV DNA detection and liver 
histology in woodchucks immunized with pWHc-wiFNy DNA. Three groups of 
woodchucks, each consisting of three animals, were immunized with 0.5 
mg/dose (A), 0.9 mg/dose (B) or 1.5 mg/dose (C) of pWHc-wiFNy DNA at the 
time points indicated by solid vertical lines. The animals then were challenged 
with 1.1 x 1010 vge of WHV at week 0. WHsAg, anti-WHc and WHV DNA and 
liver samples were evaluated and the results presented as described in Materials 
and Methods and in the legend to Fig. 6.2. 
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these 9 animals, 3 responded by producing anti-WHc (Fig. 6.3). The antibodies 
appeared at 3 and 5 wks after first immunization in 1/F and 4/F, respectively, and 
in one week after booster injection in 8/M, independently of the dose of pWHc-
wiFNy given. Therefore, in contrast to the pC-WHc group, there was no relation 
between the amount of pWHc-wiFNy given and induction of anti-WHc. A 
woodchuck injected with pC-wiFNy was anti-WHc negative. 
In 4 animals vaccinated with pWHc-wiFNy, WHV-specific T cell 
proliferative response was measured prior to and after challenge with WHV. Two 
of the animals, 2/F immunized twice with 0.5 mg and 8/M injected twice with 1.5 
mg of the plasmid, mounted specific T cell response, as shown in Figure 6.4. As 
expected, this response was directed against proteins encoded by WHV core 
gene, i.e., rWHcAg and rWHeAg, and WHc97_11o peptide, but not toward rWHxAg 
or WHsAg, confirming antigenic- restricted specificity of the T cell response 
induced by pWHc-wiFNy. Also it is of note that a significantly higher magnitude 
of WHc-specific T cell response was detected in 2/F (maximum S.l. 13.7) than in 
8/M (maximum S.l. 4.2). Overall, the results revealed that immunization with 
pWHc-wiFNy DNA was able to elicit WHc-specific T cell response. However, this 
response was not induced uniformly among the animals immunized, suggesting 
that host factors played a decisive role in its development. 
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Figure 6.4. Profiles of WHV-specific cellular immune response in woodchucks 
immunized with pWHc-wiFNy DNA. Animal 2/F was immunized twice with 0.5-
mg doses and 8/M twice with 1.5-mg doses of pWHc-wiFNy DNA at the time 
points indicated by arrows. Then the animals were challenged with 1.1 x 1010 
vge of WHV at week 0. Proliferative T cell response to WHV antigens indicated 
in the inserts was measured by 3H-adenine incorporation assay as described in 
Materials and Methods. The stimulation index was calculated by dividing mean 
cpm obtained after stimulation with test antigen by mean cpm detected in the 
absence of a stimulant. A stimulation index equal to or greater than 3.1, marked 
by the horizontal line, was considered as positive. 
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6.4.3 Immunization with WHc DNA can protect from serologically evident 
WHV infection and hepatitis. 
Animals immunized with pC-WHc or pWHc-wiFNy DNA were challenged 
with a massive dose of WHV to determine protective effectiveness of the 
vaccination strategy tested. Among 4 woodchucks which were injected with pC-
WHc DNA, C/M developed anti-WHc and remained serum WHsAg non-reactive 
during the 12-mo follow-up after inoculation with virus (Fig. 6.28). Liver biopsy 
obtained at 6 wks after challenge showed entirely normal histology, whereas that 
obtained 12 mo later displayed minimal nonspecific parenchymal alterations with 
sparse lymphocytic infiltrations in a few portal areas. In contrast, DIM which also 
developed anti-WHc following DNA vaccination established serum WHsAg-
positive, histologically evident chronic hepatitis lasting until the end of the 12-mo 
observation period. Two remaining woodchucks, AIM and 8/M, immunized with 
0.6-mg doses of pC-WHc each developed transiently serum WHsAg-positive 
infection and self-limited acute hepatitis (Fig. 6.2A). Anti-WHc antibodies 
appeared in these two animals after WHV challenge and remained at high levels 
throughout the 12-mo observation period. Liver samples collected after acute 
phase of infection showed residual minimal inflammatory alterations persisting in 
both animals to the end of follow-up. These features were similar to those found 
in remote resolved hepatitis, as previously described (Coffin et a/., 2004; 
Hodgson and Michalak, 2001; Michalak et a/., 1999). A control animal 
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immunized twice with 1 mg of empty pCI vector and infected with WHV 
developed classical serum WHsAg-positive, self-limited hepatitis which was 
followed by persistent minimal inflammatory alterations in liver parenchyma. 
As shown in Figure 6.3 and summarized in Table 6.1, 4 of 9 animals 
immunized with pWHc-wiFNy remained serum WHsAg negative after challenge 
with WHV. Three of them (1/F, 4/F and 8/M) acquired anti-WHc due to DNA 
vaccination, while one (7/M) remained anti-WHc negative and produced the 
antibodies shortly after challenge with WHV. In addition, a very brief episode of 
WHs antigenemia, identifiable only in a single serum sample, was detected in 
3/M and 9/M. The remaining 3 animals (2/F, 5/F and 6/M) developed serum 
WHsAg-positive infection lasting between 3 and 20 weeks (Fig. 6.3). All of these 
5 animals became anti-WHc reactive in one to 4 wks after inoculation with WHV. 
Anti-WHs reactivity was detected in 2 of the woodchucks (Table 6.1). 
Importantly, histological examination of 2 or 3 liver tissue samples 
collected from each animal during follow-up lasting for up to 45 weeks after 
inoculation with WHV showed consistently normal morphology in 5 of 9 
woodchucks (Table 6.1). Among them were 4 animals (1/F, 4/F, 7/M and 8/M) 
which remained serum WHsAg nonreactive after inoculation with WHV and one 
(9/M) which had a one-week long episode of borderline WHs antigenemia (Fig. 
6.3C). Three (7/M, 8/M and 9/M) of those 5 woodchucks were immunized once 
or twice with 1.5 mg of pWHc-wiFNy (Table 6.1 ). Contrastingly, animals which 
established serum WHsAg-positive infection (2/F, 3/M, 5/F and 6/M) developed, 
as expected, acute hepatitis which subsided to minimal residual inflammatory 
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changes persisting to the end of the observation period. A control animal 
immunized twice with 1.3 mg of pC-wiFNy DNA and then inoculated with WHV 
had classical serum WHsAg-positive self-limiting acute hepatitis (not shown). 
It is of note that 2/F woodchuck, which developed a robust WHc-specific T 
cell proliferative response but no anti-WHc antibodies after DNA vaccination and 
displayed a swift and strong lymphoproliferative response to WHcAg and related 
antigens following challenge with WHV (maximum S.l. of 29) (Fig. 6.4), failed to 
be protected (Fig. 6.3A). In this animal, T cell proliferation response against 
multiple WHV antigens, including rWHxAg and WHsAg, was detected around 7 
week post-infection, as well as in several other woodchucks infected with the 
same WHV inoculum but not immunized with WHc DNA which were investigated 
in parallel (Gujar and Michalak, manuscript in preparation). In contrast to 2/F, 
animal 8/M which developed a relatively weak WHc-specific T cell response and 
anti-WHc following vaccination, was free from WHs antigenemia and protected 
from hepatitis. 
6.4.4 Transcription of IFN-y, TNF-a, OAS in livers and lymphoid cells after 
vaccination with pWHc-wiFNy. 
To recognize whether induction of antiviral and Th1 cytokines may play a 
role in protection against WHV infection and hepatitis, the levels of wiFNy, 
wTNFcx and wOAS mRNAs were quantified by real-time RT -PCR in hepatic 
tissue and PBMC samples collected before DNA immunization and after 
challenge with WHV. As shown in Fig. 6.5A, intrahepatic transcription of wiFNy 
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and wTNFcx was not noticeably different prior to and after exposure to virus in any 
of the 4 animals protected from serologically evident infection and hepatitis, 
except 7/M which had an unexplained increase in wTNFa mRNA prior to WHV 
challenge. This was accompanied by relatively stable levels of wOAS and C03 
mRNA in individual animals, except 7/M (Fig. 6.5A). In contrast, an enhanced 
transcription of intrahepatic wiFNy (2.5 to 5.7-fold increase) and wTNFcx (4.2 to 
6.3-fold increase) in comparison to the levels prior to WHV challenge was seen in 
woodchucks not protected from WHV infection (2/F, 5/F and 6/M) (Fig. 6.58). 
These increases were observed in the acute phase of infection and were 
accompanied by upregulated expression of wOAS and C03. In 3/M and 9/M 
which showed a brief episode of WHs antigenemia, the mRNA levels tested 
between 2 and 8 weeks post-infection were only moderately elevated or 
remained at the pre-challenge values. Analysis of the expression of the same 
genes in serial PBMC samples did not reveal measurable differences between 
the protected and non-protected animals or between the pre- and post-challenge 
phases (not shown). Overall, the data implied that protection from WHV infection 
and hepatitis induced by pWHc-wiFNy was not correlated with measurable 
changes in the expression of Th1 cytokines or IFN-a in either peripheral lymphoid 
cells or hepatic tissue. However, this does not exclude a contribution of other 
anti-viral cytokines or immune mechanisms which were not tested in this study. 
Figure 6.5. Profiles of relative expression of wiFNy, wTNFa, wOAS, and CD3 
genes in liver biopsy samples collected prior to and after challenge with WHV 
from woodchucks protected (A) and non-protected (B) from WHV infection after 
immunization with pWHc-wiFNy DNA and challenge with WHV. The time of 
challenge with 1.1 x 1010 vge of WHV is indicated by arrow and corresponds to 
week 0. The mRNA levels of indicated woodchuck genes were quantified by 
specific real-time RT-PCR. The results are shown as the number of copies of a 
given gene per reaction after normalization against -3 x 104 copies of woodchuck 
p-actin, which was quantified in parallel with each test sample. 
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6.4.5 Woodchucks otherwise successfully immunized with pWHc-wiFNy 
vaccine acquire traces of replicating WHV after challenge. 
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Although 5 of the 13 animals immunized with pC-WHc or pWHc-wiFNy 
were protected from serologically apparent WHV infection and hepatitis, their 
serial serum sample collected after inoculation with WHV revealed low levels of 
WHV DNA when analyzed by sensitive PCR/NAH assays. This unexpected 
finding was investigated in detail using approaches previously established for 
identification of occult hepadnavirus persistence (Coffin and Michalak, 1999; 
Coffin et a/., 2004; Hodgson and Michalak, 2001; Lew and Michalak, 2001; 
Michalak et a/., 2004; Michalak et a/., 1999). Thus, the analysis of serial serum 
samples obtained after inoculation with WHV and at autopsy demonstrated WHV 
DNA at levels usually not exceeding 102 vge/ml. In all 5 animals apparently 
protected, WHV DNA was also detected in sequential PBMC samples collected 
after challenge and in lymphatic organs gathered at autopsy (not shown). The 
estimated levels of WHV genomes ranged between 0.005 and 0.5 vge/1 04 
lymphoid cells, calculated as described previously (Michalak eta/., 1999). 
In the animals protected from serologically evident infection, less than 2 x 
1 03 WHV vge per 1-Lg of total DNA was detected in liver samples collected after 
challenge and at the time of autopsy, compared to an estimate of up to 2 x 107 
vge per 1-Lg of total DNA detected in acute phase of hepatitis in the non-protected 
animals. At the end of follow-up of the non-protected woodchucks, WHV DNA in 
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the liver dropped to the loads comparable to those found in the protected animals, 
i.e., about 103 vge per ~g of total DNA, with the exception of 0/M which 
developed serum WHsAg-positive chronic hepatitis. Importantly, WHV cccDNA 
was also identified in autopsy liver tissue samples (not shown). Further, to 
determine the magnitude of WHV replication in the livers of the protected 
woodchucks, WHV pre-genomic RNA was quantified by real time RT -PCR in liver 
biopsies collected from 1/F, 4/F, 7/M and 8/M between 2 and 8 weeks after 
challenge and at autopsy. As shown in Figure 6.6A, less than 100 copies of 
WHV mRNA per 3 x 1 04 copies of p-actin mRNA was found in these liver 
samples. The WHV mRNA levels remained stable (in one log1o range) for up to 
45 weeks after challenge. In woodchucks not protected from infection, i.e., 2/F, 
3/M, 5/F, 6/M and 9/M, one to four log higher WHV RNA levels than those 
occurring in the livers of the protected animals were identified at 2 to 8 weeks 
post-infection, except 3/M. These hepatic loads progressively declined reaching 
less than 100 copies of WHV RNA per 3 x 104 copies of p-actin mRNA at the end 
of the observation period. Interestingly, 9/M animal, which showed unaltered 
liver histology after inoculation with WHV (Fig. 6.3C), carried WHV RNA at a high 
level at week 7 after challenge and this level declined to less than 1 00 copies at 
week 15 after challenge with WHV. 
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Figure 6.6. Detection of WHV RNA in liver tissue samples collected from 
woodchucks protected (A) and non-protected (B) from WHV infection after 
vaccination with pWHc-wiFNy DNA The time of challenge with WHV is indicated 
by arrow and corresponds to week 0. The WHV RNA levels were quantified by 
real-time RT-PCR and normalized against p-actin, as described in the legend to 
Figure 6.5. It is of note that WHV RNA was consistently detected, although at 
levels below 100 copies per -3 x 104 copies of p-actin, in all liver samples 
acquired from animals which were otherwise protected from WHV infection and 
hepatitis after immunization with pWHc-wiFNy DNA. 
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6.5 Discussion 
In previous reports, it has been shown that immunizations of WHV-naive 
woodchucks with native or recombinant WHcAg or with plasmids encoding for 
this antigen were able to protect individual animals against experimental WHV 
infection, as determined by the absence of serum WHsAg and WHV DNA by 
PCR assays with detection limits of 5 x 102 to 103 vge/ml (lu et a/., 1999; Lu et 
a/., 2005; Roos eta/., 1989; Schadel eta/., 1993). It was also demonstrated that 
co-administration of plasmids encoding for WHcAg and woodchuck IFN-y or IL-
12, enhanced the efficacy of the protection when compared to that elicited by 
WHc DNA alone (Garcia-Navarro eta/., 2001; Siegel eta/., 2001 ). In the present 
work, we confirmed that vaccination with WHc DNA can, although only 
occasionally, prevent animals from acquiring serologically detectable WHV 
infection and hepatitis. We also showed that the protective efficacy of this 
vaccine can be improved by delivery of DNA encoding for WHcAg and wiFNy 
incorporated into a single plasmid vector. This result indicates that the bicistronic 
vector approach, in which the expression of the cytokine-encoding sequence is 
translated via IRES, represents a valid strategy for cytokine-facilitated 
enhancement of protective immunity against hepadnavirus. In other studies, the 
bicistronic plasmids encoding for HBV preS2 and IL-2 elicited a stronger Th1 
response than HBV preS2 DNA alone when given to mice (Chow eta/., 1997). 
Similarly, immunization with HIV gp120/granulocyte-monocyte colony-stimulating 
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factor (GM-CSF) bicistronic DNA was able to enhance gp120-specific CD4+ T 
cell response in mice in comparison with co-application of plasmids encoding for 
each of these two molecules separately (Barouch et a/., 2002). An increased T 
cell response was also observed when a bicistronic plasmid encoding for HCV 
NS 3, 4 and 5 proteins and GM-CSF were injected to rats (Cho et a/., 1 999). 
Therefore, the current data support the view that immunization with the DNA 
constructs encoding for viral antigen and an adjuvant acting cytokine can 
significantly enhance specific immune response to the antigen of interest. 
In the present study, immunization with the bicistronic pWHc-wiFNy DNA 
vaccine protected 4 of 9 (44.5%) animals from serologically detectable WHV 
infection. The protection was not related to the number of the DNA injections 
given, since a single dose was just as effective as two injections. However, 
among three woodchucks which received the greatest amount of the bicistronic 
DNA, two animals did not develop serologically evident infection and all three 
were free from hepatitis after inoculation with the virus (see Table 6.1 and Fig. 
6.3C). Among the remaining 6 woodchucks injected with the intermediate or the 
low doses of pWHc-wiFNy, two animals receiving a single injection with 0.9 mg 
or 0.5 mg of DNA became protected (see Table 6.1; pWHc-wiFNy group).- In 
contrast, among 4 animals immunized with pC-WHc alone, only C/M injected 
twice with 1 mg of the plasmid remained serologically negative and free from 
hepatitis after challenge (see Table 6.1; WHc group). These data showed that 
the protection induced by pWHc-wiFNy was related to the amount of the DNA 
administered but not to the number of injections given, and that pWHc-wiFNy 
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was clearly more potent than pC-WHc in preventing serologically evident 
infection. 
Among woodchucks immunized with pWHc-wiFNy who acquired 
protection, three animals produced anti-WHc prior to challenge (see Table 6.1 ). 
However, 7/M, which did not develop anti-WHc, was also protected from 
serologically positive infection. An even stronger indication that anti-WHc had 
little or no contribution to the protective immunity in our study, came from the 
experiment with woodchucks immunized with pC-WHc. Specifically, two animals 
injected twice each with 1-mg doses of pC-WHc produced anti-WHc. However, 
while C/M was protected from WHsAg-positive infection and liver injury, 0/M 
established serum WHsAg-positive, histologically evident chronic hepatitis (Fig. 
6.28). This is a rare outcome of WHV infection in adult animals which is 
observed in no more than 15% of woodchucks infected during adulthood with a 
massive dose of the virus in our laboratory (Michalak, 1998b; Michalak, 2000). 
Overall, we did not observe an interdependence between the induction of anti-
WHc and protection from experimental infection. This finding is consistent with 
the data from other studies in which a relation between humoral response to 
WHcAg and the outcome after challenge with WHV was investigated (Garcia-
Navarro eta/., 2001; Lu eta/., 2005; Siegel eta/., 2001). 
There was also no evident relation between WHcAg-specific T cell 
proliferative response induced by vaccination with pWHc-wiFNy and protection 
from infection. Specifically, 2/F woodchuck which mounted a readily detectable T 
cell proliferation following stimulation with WHV nucleocapsid-related antigens 
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and a very strong specific T cell memory response within 1-2 wk of WHV 
inoculation (see Fig. 6.4A), developed WHs antigenemia and hepatitis (see Fig. 
6.3A). In contrast, 8/M animal which showed borderline WHcAg-specific 
lymphoproliferation after vaccination and no memory response after challenge 
(see Fig. 6.48), was protected from serologically positive infection and hepatitis 
(see Fig. 6.3C). These results differ from those reported by others for 
woodchucks immunized by co-administration of WHc and IFN-y plasm ids, where 
all three animals examined showed lymphoproliferative response to WHcAg and 
were protected from infection, as determined by assessing serum WHV DNA by 
PCR with the detection limit of -103 vge/ml (Siegel eta/., 2001). However, in the 
same study, another animal, which had been injected with WHc DNA and not 
produced measurable T cell response to WHcAg, was also protected. Taken 
together, we tend to believe that immune responses other than those 
meaningfully involving specific T cells, for which activity is measured after ex vivo 
stimulation with WHV nucleocapsid-related antigens, play a prevailing role in the 
protection elicited by vaccination with WHV core encoding DNA in the presence 
of IFN-y as a vaccine adjuvant. In this regard, a contribution of specific CTL or 
innate immunity primed by vaccination could be considered. However,- this 
hypothesis can not be easily tested, since there are no assays measuring these 
types of immune responses in woodchucks available at the present time. 
Vaccinated animals which mounted WHcAg-specific lymphoproliferative 
response or those which became protected from serologically evident infection 
and hepatitis did not show any measurable differences in expression of wiFNy or 
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wTNFa, as well as wOAS, in serial samples of circulating lymphoid cells, when 
compared to those in the non-protected animals. Similarly, quantification of the 
mRNA levels of these cytokines in liver samples from the protected and the 
unprotected animals did not provide a lead to a possible mechanism underlying 
the elicited protection. 
Liver tissue from the woodchucks protected from serologically positive 
WHV infection was free from inflammatory alterations, as evidenced by 
histological examinations. The lack of lymphocytic infiltrations and inflammation 
was confirmed by unaltered expression of intrahepatic C03, IFN-y and TNF-a 
(Hodgson and Michalak, 2001 ). Although the nature of the protection elicited by 
pWHc-wiFNy vaccine remains uncertain, these findings convincingly showed that 
when this protective response was successfully induced it was sufficient to 
prevent entirely histological and molecular signs of hepatitis. In addition, the data 
from 9/M woodchuck, which developed a brief episode of WHsAg-positive 
infection but no hepatitis (see Table 6.1 and Fig. 6.3C), suggested that this 
response was robust, since no residual inflammatory changes were found in liver 
samples of this animal after challenge with WHV, although such alterations are 
frequently encountered even years after resolution of WHsAg-positive infection 
(Coffin eta/., 2004; Michalak eta/., 2004; Michalak eta/., 1999). In contrast, liver 
samples from woodchucks developing serum WHsAg-positive infection displayed 
typical histological features of hepatitis which subsided to minimal inflammatory 
changes persisting throughout the entire observation period, as reported before 
(Coffin eta/., 2004; Hodgson and Michalak, 2001; Michalak eta/., 1999). The 
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temporal upregulation in hepatic expression of C03 and IFN-y and, in some 
animals, TN F-a coincided with the acute phase of liver inflammation, as observed 
previously (Hodgson and Michalak, 2001; Nakamura eta/., 2001). 
Despite the fact that vaccination with pWHc-wl FNy was able to prevent 
hepatitis, all animals protected acquired low levels of WHV after challenge and 
trace virus replication persisted to the end of the experiment. This showed that 
the immunity elicited by vaccination with DNA encoding for hepadnavirus core 
antigen was unable to provide a sterile protection against the virus. Accordingly, 
our data argue for a possibility that the mechanisms governing protection from 
hepadnaviral infection and prevention of liver disease caused by this infection 
may not be identical. 
The lack of sterile protection against hepadnavirus found in our study 
could be a consequence of at least two coinciding events. Firstly, since WHcAg 
is an inner structural antigen, immunity raised against this antigen may not be as 
effective as that directed towards virus envelope epitopes in preventing the initial 
attachment and entry of the virus to hepatocytes and lymphoid cells, which both 
are naturally targeted by the virus (Lew and Michalak, 2001; Michalak eta/., 2004; 
Michalak eta/., 1999). Therefore, virus replication can be established, at least at 
a low level, and virus can persistently propagate in the liver and lymphatic 
system, as shown by our study. On the other hand, the immunity raised against 
the core antigen, particularly in the presence of IFN-y, can be highly effective in 
suppressing virus replication, possibly by a noncytopathic pathway (Guidotti eta/., 
1996b), and in limiting virus spread to uninfected cells. This mechanism can 
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keep the virus under control. i.e., at the levels which are not pathogenic to the 
liver (see below) (Michalak, 2000; Michalak et a/., 1999). It has been 
documented in a series of previous studies that once WHV replication is 
established it can be suppressed but never completely eradicated (Coffin and 
Michalak, 1999; Hodgson and Michalak, 2001; Michalak eta/., 1999). The same 
appears to be true for humans who recovered from HBsAg-positive acute 
hepatitis B (Michalak et a/., 1994; Rehermann et a/., 1996a). The data from the 
present work are in full agreement with this previously established fact. Based 
on this, it can be conclusively stated that the protection against experimental 
WHV infection observed in our study was not complete. 
Secondly, all animals vaccinated in our study were challenged with a 
massive dose of WHV normally causing hepatitis in naive animals and the 
woodchucks otherwise protected from infection and hepatitis carried low levels of 
virus in both lymphoid cells and their livers after challenge. We have previously 
uncovered that there is a significant difference in the threshold level of WHV 
required to infect lymphoid cells and that to infect hepatocytes (presumably 1 00-
to 1000-fold) (Michalak eta/., 2004). We have found that WHV doses lower than 
or equal to 1 03 virions cause serologically concealed infection restricted to the 
lymphatic system, termed primary occult infection (POl). Contrastingly, WHV at 
higher doses induces serologically evident infection, involving both the lymphatic 
system and the liver, and causes hepatitis, which when resolved is followed by 
indefinitely long residual infection in the liver and lymphoid tissues, termed as 
secondary occult infection (SOl) (Coffin eta/., 2004; Michalak, 2000; Michalak et 
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a/., 2004). Therefore, detection of low levels of WHV in the liver of the otherwise 
protected animals suggests that hepatocytes were initially exposed to a high 
dose of virus (greater than 103 virions) and infected, but the infection was most 
likely swiftly suppressed leaving behind residual WHV replication, which always 
escapes elimination by immunological and intracellular antiviral mechanisms. 
Hence, it is possible that the pWHc-IFNy vaccine tested, as well as other 
vaccines based on immunization against hepadnavirus nucleocapsid antigens, 
can protect the liver, but unlikely the immune system, from infection with low 
virus doses. 
In conclusion, our findings indicate that delivering simultaneously to the 
same location both WHcAg and IFN-y encoding sequences has a potency to 
suppress virus replication and prevent development of hepatitis in woodchucks 
experimentally exposed to a massive virus dose. However, this vaccination 
strategy is unable to induce sterile protection against the virus. It is expected this 
approach might be of value in therapeutic treatment of hepatitis B, but unlikely in 
prophylaxis against HBV infection. 
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CHAPTER 7. GENERAL DISCUSSIONS 
The aims of these studies were to investigate selected aspects of viral-
host interactions which could be involved in the establishment of WHV 
persistence and to design experimental approaches to reverse the virus-caused 
cellular defects possibly supporting protracted virus infection in the liver, as well 
as to promote the host anti-viral immune responses. In particular, our studies 
focused on identifying how WHV can modify class I MHC antigen presentation on 
hepatocytes. Further, we attempted to discover whether an antiviral and 
immunoregulatory cytokine, such as IFNy, could restore the inhibitory effect 
exerted by hepadnavirus on class I MHC antigen expression. Finally, we 
explored whether the DNA vaccine aiming at promoting anti-viral Th type 1 cell 
response by incorporating IFNy DNA as the adjuvant could be used to prevent 
hepadnaviral infection in the woodchuck model of hepatitis B. 
In order to address these issues, we first generated recombinant IFNy and 
rwTNFa using both baculoviral and E. coli expression systems. The biological 
activities of the cytokines produced were confirmed not only by conventional 
virus protective or cytotoxic assays, but also by examining their 
immunoregulatory ability to enhance expression of class I MHC antigen on 
woodchuck hepatocytes. In subsequent studies, we have established an in vitro 
model to investigate whether WHV could interfere with the expression of class I 
MHC, a key molecule for recognition of infected cells by cytotoxic T cells. We 
have found that more than one of the WHV proteins is involved in modulating 
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hepatocyte class I MHC antigen display and that WHV envelope preS2 and X 
proteins act in diametrically opposing ways in this regard. The data revealed that 
the preS2 protein is a dominant class I MHC inhibitor when the hepatocyte 
transcribes the complete virus genome. Although the precise molecular 
mechanism of this event remains to be established, our data suggested the 
preS2 protein-induced posttranscriptional mechanism is responsible for this 
defect. Importantly, we have shown that rwiFNy treatment of hepatocytes 
transcribing either whole WHV DNA or the preS2 encoding sequences negated 
the WHV-caused class I MHC antigen suppression and restored its presentation 
to the same level as that observed on control cells. 
In another study, we designed a bicistronic plasmid containing DNA 
sequences coding for WHc and IFNy and tested the efficacy of the construct as a 
vaccine in preventing WHV infection in woodchucks. We have found that a 
significant proportion of the vaccinated animals was protected from hepatitis, as 
revealed by the absence of serological markers of WHV infection and normal 
liver histology. The protection was accompanied by a dramatic decrease in liver 
WHV RNA, the intermediate of WHV replication, when compared to the non-
protected animals. This inhibition of WHV replication is mediated by a 
mechanism which does not appear to involve intrahepatic activation of IFNy, 
TNFa and 2' -5' OAS. However, in spite of the disease-free state, residual WHV 
infection was detected in all the animals, indicating that sterile immunity against 
hepadnavirus is unlikely to be achieved by this approach. Nevertheless, our 
findings do not exclude a possibility that the same approach might be effective as 
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a therapeutic vaccine against chronic hepatitis. It is now recognized that 
hepadnavirus replication once established never can be totally eliminated, even 
in cases in which apparently successful response to antiviral therapy with IFNcx 
or nucleoside analogues is achieved. Therefore, the approach tested in our 
current study should be further investigated in animals chronically infected with 
WHV, both alone and in combination with the presently available antiviral agents, 
to determine its efficacy in suppressing liver disease in chronic infection. 
The complexity of the hepadnavirus-host interactions, influenced by the 
host's individual variability in the range and strength of its antiviral immune 
responses and by variations in the intrahepatic cytokine milieu, makes it 
exceedingly difficult to inspect the viral influence on hepatocyte class I MHC 
expression in in vivo conditions. This is further complicated by a very low 
efficiency of HBV and WHV infections in cultured hepatocytes, which impedes 
the dissection of this issue in vitro. In the current studies, we have circumvented 
these difficulties by establishing a woodchuck hepatocyte line stably transfected 
with more than the full-length WHV genome to mimic the situation occurring in 
chronic infection. In addition, we created hepatocyte lines transcribing genes 
encoding individual WHV proteins and complete WHV DNA knock-out mutants 
generated by the site-specific mutagenesis. We have found that WHV 
suppresses class I MHC presentation on hepatocytes in our model, as we have 
earlier observed for naturally infected hepatocytes in the course of chronic WHV 
hepatitis (Michalak et a/., 2000). In addition to the significance of these data 
summarized and discussed in Sections 5.5 and 8, the results obtained suggest 
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that the WHV preS2 protein may act as a viral transactivator, in addition to WHV 
X protein (Murakami, 1999). In this regard, it has been reported that HBV 
preS1/2 protein may play a role in regulating host gene transcription (Hildt eta/., 
2002; Hildt et a/., 1996). Moreover, such an interference with the host gene 
transcription has been suggested to result in the development of HCC, a 
common consequence of chronic HBV infection (Kekule eta/., 1990). In order to 
avoid recognition by host CDS+ CTL, one of the strategies shared by both 
malignant tumors and viral infections is suppression of cell surface class I MHC 
display to abrogate class I MHC-TCR CTL interaction. Our data indicate that 
hepadnavirus preS2 protein inhibits expression of class I MHC antigen, which 
may greatly enhance the chance of virus to persist in infected hepatocytes. 
These data offer an alternative explanation for the reported association between 
integration of the HBV sequence encoding preS1/preS2 proteins and HCC 
development. 
The data from our in vitro hepatocyte-WHV system do not allow for 
comment on whether suppression of the class I MHC presentation could promote 
the activation of innate cellular responses, particularly of NK cells whose activity 
is triggered by the decreased class I MHC display on the surface of targeted cells 
(Karre, 2002). The answer may rely on several factors, among which in vivo 
accessibility of hepatocytes to NK cells, generally low levels of class I MHC 
expression on na'ive hepatocytes, and massive amounts of virus envelope 
material circulating in chronic infection, which has been shown to compromise 
NK cell activity (de Martino eta/., 1985), need to be considered. 
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Our data also revealed that IFNy could reverse WHV-caused inhibition of 
hepatocyte class I MHC expression. This suggests that the host's immune 
system can potentially overcome the virus-induced inhibitory effect. Analysis of 
the class I MHC-affiliated gene transcription also indicated that the endocytic 
presentation pathway was activated upon IFNy stimulation, including cells 
actively transcribing WHV genome. The class I MHC-Iinked genes investigated 
in our study are all known to be involved in processing, transporting or loading of 
endogenously generated peptides to class I MHC molecules. The enhanced 
expression of these genes by IFNy would lead to a more efficient presentation of 
viral peptides by class I MHC to virus-specific CTL. Therefore, treatment with 
IFNy could make virally infected cells more recognizable by the immune system. 
Overall, our results support the notion that induction of intrahepatic IFNy can 
contribute to the clearance of HBV not only by directly inhibiting virus replication, 
as suggested by others (Guidotti and Chisari, 2001 ), but also by promoting virus-
specific immune responses. Understanding of how, when and to what extent 
such intrahepatic IFNy should be induced would add another dimension to the 
possibility of successful management of chronic hepatitis B. 
It has been well established that anti-viral T cell responses play a critical 
role in eliminating hepadnavirus infection. Therefore, induction of this response 
should be highly favorable to the host. One of the strategies is to use DNA 
immunization, which has been shown to have superior advantages by eliciting 
not only B cell but also T cell immune responses (Donnelly eta/., 2005). In our 
DNA vaccine design, introduction of DNA encoding for IFNy, which is a Th type 1 
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polarizing cytokine, should skew the immune response toward the generation of 
viral-specific COB+ CTL reactivity. Moreover, providing IFNy should also 
enhance antigen processing and antigenic epitope presentation via stimulation of 
the endocytic presentation pathway, as our data confirmed. Taking this into 
consideration, there is a significant difference in the principle of operation 
between the currently available HBV vaccine and our DNA vaccine. Unlike the 
current HBsAg-based vaccine, which presumably blocks virus cell entry via 
induction of neutralizing anti-HBs and enhance virus clearance by the monocyte-
macrophage system, the virus-specific COB+ CTL induced by DNA immunization 
recognize target cells which have already been infected. In other words, virus-
specific COB+ CTL cannot block the entry of infectious virions and they can act 
only when the infection and synthesis of viral proteins have been established. 
Therefore, this type of vaccine should be of value in controlling already 
progressing infection, as it is in the case in chronic hepatitis B. On the other 
hand, as the data from our and other laboratories indicated, this type of vaccine 
can prevent hepatitis. Therefore, the question is how this can happen, especially 
since the DNA sequence coding for the internal virus antigen was used. 
Our data revealed that the introduction of IFNy DNA to the WHc DNA 
vaccine gave a significant advantage over administration of WHc DNA alone in 
protecting woodchucks from serologically evident infection and liver necro-
inflammation. Although residual WHV DNA and RNA were detectable in the liver 
and the lymphatic system by sensitive PCR-based techniques, the response 
primed by the WHc-IFNy DNA was able to keep the virus replication under tight 
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control. The detection of small quantities of WHV DNA was not completely 
surprising since persistence of viral genomes and their replicative intermediates, 
as we now know, universally continues years after apparent complete resolution 
of AH, which is normally accompanied by a strong, multivalent virus-specific CTL 
and T helper cell response (Penna et a/., 1 996; Rehermann et a/., 1 996a). 
Nevertheless, our findings provided. conclusive data indicating that sterilizing 
immunity against hepadnavirus cannot be achieved using immunization with 
DNA encoding for the virus nucleocapsid antigen. This is entirely new 
information which contradicts the majority of the previous studies in which less 
sensitive techniques were applied for hepadnavirus detection. 
Considering the fact that very close contact is required between virus-
specific T cells and infected hepatocytes, it was rather surprising to find that none 
of the protected animals developed any sign of intrahepatic lymphomononuclear 
infiltrations, as judged by liver histology at the time corresponding to pre-acute 
phase (2 weeks p.i.) or acute infection (6-8 weeks p.i.). This suggests that the 
bicistronic WHc-IFNy DNA vaccine was able to protect or induce almost 
complete virus clearance by a non-inflammatory pathway. This finding may 
suggest that controlling hepadnavirus replication can be achieved without 
damaging or compromising the liver function. In our study, there was also no 
relation between protection and the production of core antigen specific antibodies. 
Furthermore, the data obtained showed that there was also no association 
between protection and elevated intrahepatic expression of IFNy, TNFa or 2'-
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5'0AS, which has been suggested to contribute to HBV clearance from the liver 
in the HBV transgenic mouse model (Guidotti and Chisari, 2001 ). One potential 
explanation could be that enhanced IFNy, TNFa and/or 2'-5'0AS expression 
occurred at a very early stage, i.e., between 0 and 2 weeks after challenge with 
WHV. Alternatively, our data cannot rule out involvement of another not yet 
identified anti-viral molecule. If a similar anti-viral state can be elicited in chronic 
hepatitis B, the resolution of HBV infection would probably happen without 
severe liver inflammation, which is a side effect of the activation of antiviral 
immunity. Further investigation of the underlying mechanisms may contribute to 
the development of novel therapies against chronic HBV infection. 
One of the issues which was not investigated in our study was to what 
extent the innate immunity could be involved in defending against infection 
following vaccination with WHc-IFNy DNA. As one of the first lines of host 
defense, innate immunity has been shown to be very potent in elimination of a 
variety of pathogens (Kawai and Akira, 2006; Portnoy, 2005). Activation of NK 
and NK T cells, as well as administration or induction of IFNa has been reported 
to be able to limit HBV infection (Baronet a/., 2002; Kakimi eta/., 2000; Kakimi et 
a/., 2001). Recruitment of neutrophils to the liver was also found to participate in 
the immunopathogenesis of liver injury in chronic HBV infection (Sitia et a/., 
2002). Therefore, limited activation of the innate immune responses in 
hepadnaviral infection may have a significant potential in limiting the virus spread, 
especially at the early stage of infection. We believe that in our model, the 
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observed protection from challenge with a massive virus dose was probably a 
consequence of the synergistic effect exerted by both the innate immunity and 
very early activation ofT cell anti-viral response. 
Hepadnavirus-host interaction is a highly dynamic and complex process. 
In this infection, the virus would replicate, produce an excess of envelope 
(surface) antigens, which most likely have immunomodulatory properties, and 
interfere on different levels with the host's immune defense machinery. On the 
other hand, the immune system, with its innate and adaptive branches of 
immunity, is set up to fight pathogens. The outcome of the infection is, therefore, 
determined by who is winning the battle, the virus or the host. In the case of 
chronic hepadnaviral infection, an effective therapy should act on both sides, i.e., 
by inhibiting virus replication and by promoting host anti-viral immunity. At the 
present time, suppression of virus replication can be achieved by nucleoside 
analogs capable of inhibiting the activity of viral DNA polymerase. With the 
exception of the drug resistant infections, this kind of treatment can dramatically 
reduce the total virus load. Ideally, such a treatment can be combined with 
activation of both innate and virus-specific adaptive immunities. We believe that 
the sustained virological response can be eventually achieved in chronic HBV 
infection by such a combination of antiviral and immune-based therapy. As our 
data suggest. application of IFNy or. more likely, functionally compatible synthetic 
analogs, could be a viable option to reverse HBV evasion. The effectiveness of 
this approach can be further enhanced by inducing or delivering the cytokine or 
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its functional equivalent to the site of infection to minimize the side effects seen in 
systemic administration of IFNy. The ultimate goal would be to elicit virus-
specific T cell and B cell responses. The former should combat the intracellular 
infection, while the latter should neutralize infectious virus outside the cell and 
limit spread of infection. However, one of the major challenges of this strategy 
will be to break the virus-specific immune tolerance which normally accompanies 
chronic hepatitis B. The introduction of IFNy DNA into a therapeutic HBV DNA 
vaccine might be a valid approach. 
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CHAPTER 8. SUMMARY AND CONCLUSIONS 
In the series of studies presented, we explored the woodchuck model of 
hepatitis B and the woodchuck hepatocyte culture system to investigate the 
nature of hepadnavirus-cell interactions potentially underlying the hepadnavirus 
ability to escape from immunological surveillance and the role of antiviral 
cytokines, predominantly IFNy, in reversing a virus-caused defect and in 
modulating an anti-hepadnavirus immune response mounted by preventive DNA 
vaccine. For the purpose of our studies, several relevant woodchuck genes were 
identified and biologically active woodchuck cytokines, IFNy and TNFa., were 
produced. In addition, an in vitro hepatocyte culture model was established to 
analyse WHV interference with the hepatocyte presentation of class I MHC 
molecules. Real-time RT-PCR quantification assays measuring transcriptional 
activity of WHV genes, as well as expression of woodchuck genes encoding 
components of the class I MHC presentation pathway and subunits of the 
proteasome were also developed. The results obtained can be summarized as 
follows: 
1. The full-length woodchuck IFNy and TNFa. cDNAs have been successfully 
cloned and both cytokines were produced in the baculovirus-insect cell 
and the E. coli expression systems. The rwiFNy derived from the 
baculoviral system was found to be biologically active, as determined by 
protection of woodchuck hepatocytes against ECMV-induced cytolysis, 
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inhibition of the cytolysis protection by specific antibodies raised against 
rwiFNy, and by augmentation of the presentation of class I MHC antigen 
on woodchuck hepatocytes but not human HepG2 liver cells. In contrast, 
while rwiFNy produced in E. coli was immunogenic, it was functionally less 
active. 
The rwTNFa generated in the baculovirus system showed a classical 
ability to kill murine fibroblasts, which was specifically inhibited by cross-
reactive antibodies to murine TNFa. The recombinant cytokine also 
upregulated class I MHC antigen display on woodchuck hepatocytes. The 
rwTNFa from E. coli. displayed substantially lower biologically activity. 
Overall, the study demonstrated that the expression of rwiFNy and 
rwTNFa in the baculovirus system generated biologically active cytokines 
whose potency was considerably greater than those produced in E. coli. 
2. To investigate the mechanism of WHV interference with the hepatocyte 
class I MHC antigen presentation, which has been identified as an 
unvarying feature of chronic WHV infection in the previous studies from 
this laboratory, we established a hepatocyte culture model stably 
transfected with the whole WHV genome, with sequences encoding for 
individual WHV proteins or with whole virus genomes in which 
transcription of selected proteins was disabled by site-specific 
mutagenesis. We discovered that the surface display of class I MHC 
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antigen was suppressed on hepatocytes transcribing the complete WHV 
genome or its subgenomic fragments encoding for the virus envelope 
preS2 protein or preS1 protein, which naturally encompasses preS2 
amino acid sequence. Analysis of the mutated WHV genomes confirmed 
that the envelope preS2 protein was responsible for inhibition of the class I 
antigen display. Importantly, the class I antigen suppression was not 
associated with down-regulation of the genes encoding class I MHC heavy 
chain, [3 2m, TAP1 and TAP2 or proteasome subunits. This suggested that 
it is unlikely that the interference occurred at the level of gene transcription. 
The results obtained imply that the defective presentation of class I MHC 
antigen on hepatocytes transcribing WHV is a consequence of intracellular 
posttranscriptional suppression exerted by the virus envelope preS2 
protein. 
3. In contrast to the inhibition of class I MHC presentation in hepatocytes 
expressing the complete WHV genome or subgenomic fragments 
encoding for the virus envelope preS2 and preS1 proteins, hepatocytes 
transcribing WHV X gene alone demonstrated a profound enhancement in 
class I antigen display. These remarkable contradictory findings indicate 
that different sequences of the hepadnavirus genome exert diametrically 
opposed effects on the class I MHC antigen presentation. This suggests 
that in the context of transcription of the complete WHV genome, a highly 
complex interplay between individual virus translation products is 
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responsible for inhibition of the hepatocyte class I MHC display and that 
the virus envelope preS2 protein acts as a dominant inhibitor of class 1 
MHC expression. 
4. WHV-induced class I MHC antigen suppression was completely reversed 
by exposure of cultured hepatocytes to IFNy, which is known to be a 
potent stimulator of class I antigen expression. This may suggest that 
treatment with this cytokine or with functionally equivalent agents or 
promotion of the local (intrahepatic) production of the cytokine may enable 
hepatocytes in chronic hepadnaviral infection to overcome an inhibitory 
effect exerted by the virus preS2 protein on the class I antigen expression. 
This may allow for processing and effective presentation of viral peptides 
in the context of class I antigen, leading to their increased accessibility for 
recognition by specific CTL and, in consequence, enhance elimination of 
virally infected cells and clearance of the virus from the liver. Therefore, 
our study suggests that the induction of IFNy, in addition to enhancing the 
host's innate immunity, might have a beneficial effect on the virus-specific 
immune response. 
5. To examine the immunoregulatory function of IFNy in promoting anti-viral 
immunity, we designed a bicistronic DNA vaccine encoding WHV core and 
woodchuck IFNy within a single plasmid construct and investigated the 
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efficacy of this DNA vaccine in protecting woodchucks from experimental 
WHV challenge. We found that almost half (4 of 9) of the woodchucks 
immunized with the bicistronic vaccine became protected from 
serologically evident infection and hepatitis after challenge with WHV. In 
contrast, only one of four animals injected with WHc DNA alone was 
similarly protected. This protection was not linked to induction of WHcAg-
specific antibodies or WHV-specific T cell proliferative response, and was 
not associated with enhanced intrahepatic transcription of Th 1 cytokines 
or 2',5'-oligoadenylate synthetase, an indicator of IFNcx activation. 
Strikingly, all animals protected from serologically detectable 
infection and histologically evident hepatitis became reactive for WHV 
DNA and carried persistently low levels of replicating virus in hepatic and 
lymphoid tissues after challenge with a massive dose of WHV. Our data 
shows that the bicistronic DNA vaccine encoding for both hepadnavirus 
core antigen and IFNy was significantly more effective in preventing 
hepatitis than that encoding for virus core alone, but neither of them could 
mount sterilizing immunity against the virus. Our findings indicate that 
immunization with DNA encoding for a hepadnavirus internal antigen is 
unlikely to be of value in prophylaxis against HBV infection, but they do 
not exclude that this approach might be applicable in therapeutic 
treatment of chronic hepatitis B. 
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CHAPTER 9. FUTURE DIRECTIONS: 
The results obtained during the course of these studies have raised several 
important questions which are worthy of further investigation. Some of them are 
as follows: 
1) Does inhibition of hepatocyte class I MHC expression by hepadnavirus 
compromise the host's immune defense against other intracellular 
pathogens infecting the liver? Since it is well known that the class I MHC-
CTL interaction plays a critical role in clearing intracellular pathogens, the 
hepadnavirus-induced class I MHC suppression may not only promote 
persistence of HBV infection, but also prevent immune recognition of other 
viruses or parasites infecting hepatocytes. For example, when a liver is 
co-infected with HBV and HCV, the HBV-induced deficiency in the class I 
MHC antigen presentation may hinder the clearance of both viruses from 
the liver. 
2) Would an induction of either intra or extrahepatic IFNy promote the 
immune recognition of hepadnavirus in the liver in chronic hepatitis? Our 
in vitro data clearly showed that IFNy can reverse the hepadnavirus-
induced suppression of class I MHC antigen presentation on hepatocytes. 
It is a valid assumption that in vivo stimulation of the local (hepatic) or the 
extrahepatic production of IFNy or providing the exogenous cytokine can 
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also restore the class I MHC inhibition on hepatocytes in chronically 
infected livers. Consequently, this could augment the recognition of 
infected cells by virus-specific CTL and, possibly, lead to the clearance of 
virus and termination or at least a decrease in the protracted liver injury 
which typically accompanies chronic hepadnaviral infection. 
3) Since we have established the in vitro model of WHV infection in 
hepatocytes after their stable transfection with the complete WHV DNA, it 
would be feasible to examine whether IFNy and/or TN Fa directly suppress 
WHV replication, as it was reported for HBV in transgenic mice (Guidotti 
and Chisari, 2001 ). Our in vitro model offers a significant advantage by 
allowing for convenient, well-controlled manipulations and for a precise 
analysis of hepadnavirus replication status. In addition, woodchuck 
hepatocyte lines stably expressing IFNy or TNFa and the availability of 
biologically active rwiFNy and rwTNFa generated in the course of our 
study provide unique tools for these further investigations. Therefore, the 
system established can contribute to identification of the pathways by 
which the cytokines exert their postulated direct anti-viral action. This may 
subsequently aid in designing novel anti-viral agents. 
4) In order to enhance the efficacy of DNA vaccination in preventing 
hepadnaviral infection, some further optimization procedures should be 
tested, particularly since we have found that immunization with DNA 
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encoding hepadnavirus core protein, even when supplemented by IFNy 
DNA as an adjuvant, does not mount complete sterilizing immunity against 
the virus. For example, immunization via ex vivo manipulated DC can be 
tested. As professional antigen presenting cells, DCs express high levels 
of class I and class II MHC antigens as well as co-stimulatory molecules, 
and secrete numerous cytokines promoting cellular immune responses. 
Therefore, anti-hepadnaviral immunity could be greatly enhanced by using 
autologous DC transfected with DNA encoding the selected virus gene 
and transferring the cells back to the recipient. The availability of the 
woodchuck model of hepatitis 8 in this laboratory makes such testing 
highly feasible. Similar strategies have been successfully applied in 
eliciting anti-tumor immunity (Nestle eta/., 2005). 
5) It will be highly valuable to establish a technique for evaluation of the 
WHV-specific CTL responses in the woodchuck model of hepatitis B. This 
is important because the aim of both the restoration of class I MHC 
antigen presentation in chronically infected livers and the anti-viral DNA 
vaccination is to ultimately induce effective CTL response against WHV 
epitopes. The currently available assays measure WHV antigen-specific T 
cell proliferative response, which detects CD4+ T helper but not CDS+ 
CTL reactivity. The development of CTL assays will help to better 
characterize the efficacy of the approaches enhancing the class I MHC 
expression on hepatocytes and DNA immunization protocols. 
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6) It would be important to understand how the immunization with WHV core 
DNA in fact protects the animals from WHV infection and hepatitis. Unlike 
conventional immunizations with HBsAg, which presumably block the 
infectivity by inducing specific antibodies inhibiting virus envelope-target 
cell interactions, T cell responses directed against hepadnavirus internal 
nucleocapsid epitopes are considered to be involved in the induction of 
protective immunity. However, since the nature of class I MHC 
presentation and class I MHC-CTL interactions is such that anti-viral T cell 
responses are induced after the virus invades the target cell and virus 
protein synthesis has been initiated, it is difficult to reconcile these 
opposing facts. Based on the above, we were rather surprised to see the 
lack of lymphocyte infiltrations in the livers of the protected woodchucks. 
Understanding the underlying mechanism will contribute to better 
recognition of the role of T cell response in the pathogenesis of hepatitis 
and may help in designing immunotherapy directed against chronic 
infection. 
7) Although the DNA vaccination approach tested was successful in 
preventing experimental hepatitis only in some of the animals vaccinated 
and did not induce sterilizing protective immunity, its efficacy should be 
tested in chronic hepadnaviral infection to examine whether it can elicit 
curative virus-specific immune responses at least in some cases of 
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chronic hepatitis. The regimen may include pre-treatment of chronically 
infected patients or animals with a known anti-viral agent, such as 
lamivudine or adefovir, to reduce the virus load. This could be followed by 
DNA immunization to activate virus-specific T cell responses, which are 
generally weak and narrowly focused on singular virus epitopes in chronic 
infection. The addition of a Th1-type cytokine, such as IFNy, may help to 
augment anti-viral T cell immune responses to a therapeutically 
meaningful level. The activated responses should keep the v1rus 
replication under tight control, but is unlikely to eliminate the virus 
completely, as the data from our and other studies indicate (Brechot eta/., 
2001; Michalak eta/., 1999; Michalak eta/., 1994). 
8) Why does the anti-viral immune response fail to completely eradicate 
hepadnavirus infection? Persistence of low levels of HBV and WHV 
replication after spontaneous or therapeutically induced recovery from 
hepatitis or, as the current study showed, after challenge of animals 
otherwise successfully protected by DNA vaccination, appears to be a 
common consequence of exposure to these viruses. The residual or 
secondary occult infection (SOl) is associated with a high risk of 
development of HCC in both humans (Pollicino eta/., 2004) and 
woodchucks (Michalak eta/., 1999). It might also be followed by there-
occurrence of symptomatic infection if the host's immune system became 
compromised by certain factors, for example, immunosuppressive therapy, 
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cancer, or co-infection with another virus. Therefore, the understanding of 
the mechanism of virus escape even from frequently very strong, 
polyvalent and epitope multispecific immune response, as is normally 
seen in self-limited acute hepatitis, would represent a significant 
advancement 
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APPENDIX A: FREQUENTLY USED MOLECULAR BIOLOGY BUFFERS AND 
REAGENTS 
ACK buffer: 0.15 M NH4CI, 1 mM KHC03, pH 7.3, with 0.1 mM EDTA 
Binding buffer: 50 mM Sodium Phosphate (pH 8.0), 300 mM NaCI, 8 M Urea 
Denaturing buffer: 50 mM Sodium Phosphate (pH 7.0), 300 mM NaCI, 8 M 
Urea 
Elution buffer: 45 mM Sodium Phosphate (pH 7.0), 8 M Urea, 270 mM NaCI, 
150 mM Imidazole 
Formamide stop solution: 10 mM NaOH, 95% formamide, 0.05% bromophenol 
blue, and 0.05% xylene cyanole. 
Forward reaction buffer (5X): 350 mM Tris pH 7.6, 50 mM MgCI2 , 500 mM KCI, 
5 mM ~-mercaptoethanol 
GTE (glucose/Tris/EDTA): 50 mM glucose, 10 mM EDTA in 10 mM Tris-HCI 
buffer, pH 8.0 
lsopropyl-beta-0-thiogalactopyranoside (IPTG): 1 OOmM (1 OOx stock) 
Lysis buffer (DNA): 1 00 mM NaCI, 10 mM Tris-HCI buffer (pH 8.0), 25 mM 
EDTA, (pH 8.0), 0.5 % SDS and 0.1 mg/ml proteinase K (prepared fresh) 
P1 solution: 50 mM Tris·CI (pH 8.0), 10 mM EDTA, 100 ~g/ml RNase A 
P2 solution: 200 mM NaOH, 1% SDS (w/v) 
P3 solution: 3.0 M potassium acetate (pH 5.5) 
PBS-EDTA: 20 mM Phosphate buffer (pH 7.4), 150 mM NaCI, 5 mM EDTA 
PBST: 20 mM Phosphate buffer (pH 7.4), 150 mM NaCI, 0.1% Tween 20 
QBT buffer: 750 mM NaCI, 50 mM MOPS (pH 7.0),15% isopropanol (v/v), 
0.15% Triton X-1 00 (v/v) 
QC buffer: 1.0 M NaCI, 50 mM MOPS, pH 7.0;15% isopropanol (v/v) 
QF buffer: 1.25 M NaCI, 50 mM Tris·CI (pH 8.5), 15% isopropanol (v/v) 
Semi-dry transfer buffer: 39 mM Glycine, 48 mM Tris, 0.03% w/v SDS, 20% 
Methanol 
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SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCI, 2.5 mM 
KCI, 10 mM MgC12 , 1 OmM MgS04 and 20 mM glucose. 
TBST: 10 mM Tris (pH 7.5), 150 mM NaCI, 0.1% Tween 20. 
Washing buffer: 50 mM Sodium Phosphate (pH 7.0), 300 mM NaCI, 8 M Urea, 
7.5 mM Imidazole 
X-Gal: 40 mg of 5-bromo-4-chloro-3-indolyl ~-0-galacto-pyranoside resuspended 
in 1 ml of dimethylformamide (DMF) 
All reagents were obtained from Sigma Chemical Co. unless otherwise noted. 
APPENDIX 8: WOODCHUCK SEQUENCES CLONED DURING THE 
PRESENT STUDY. 
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The following appendices document woodchuck sequences that were cloned in 
this laboratory during the course of the present study. These sequences are also 
available by their respective GenBank accession number in a similar format at 
National Institute of Health GenBank, accessible at www.ncbi.nlm.nih.gov. 
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APPENDIX 8.1 
LOCUS A Y726002 576 bp mRNA linear ROD 28-SEP-2004 
DEFINITION Marmota monax low molecular mass protein 2 mRNA, partial cds. 
ACCESSION A Y726002 
VERSION AY726002.1 Gl:52547777 
SOURCE Marmota monax (woodchuck) 
FEATURES Location/Qualifiers 
source 1 .. 576 
/organism="Marmota monax" 
/mol_type="mRNA" 
/db_xref="taxon:9995" 
CDS <1 .. >576 
/note="LMP2; proteasome subunit" 
/codon_start=1 
/product="low molecular mass protein 2" 
/protein_id="AAU81924.1" 
/db xref="GI:52547778" 
/translation="TTIMAVEFDGGWVGSDSRVSAGEAWNRVFDKLSPLHHRIYCAL 
SGSAAOAQAVADMAA YQLELHGLELEEPPL VLAAANVI RN ITYKYREDLSAHLM 
VAGWDQREGGQVYGTLGGML TRQPFAIGGSGSTYIYGYVDAA YKPGMTPEEC 
RRFTTDAITLAMNRDGSSGGVIYLVTVTAAGVDHRVILGNE" 
ORIGIN 
1 acaaccatca tggcagtgga gtttgatggg ggtgtcgtgg tgggttctga ttcccgggtg 
61 tctgcaggag aggcagtggt caaccgggtg tttgacaagc tgtcccctct acaccatcgc 
121 atctactgtg ccctctctgg ttcagccgct gatgcccaag ccgttgcgga catggccgcc 
181 taccagctgg agttgcatgg gttggaactg gaagaacctc cactggttct ggctgctgca 
241 aatgtgataa ggaatatcac ctacaaatat agggaagact tgtcggcaca cctcatggta 
301 gctggctggg accaacgtga agggggccag gtatatggaa ccctgggagg aatgctgact 
361 cgacagccct ttgccattgg tggatctggc agcacttaca tttacggtta tgtggatgca 
421 gcatataaac caggcatgac ccctgaggag tgcaggcgct tcaccacaga tgctatcact 
481 ctggccatga accgggatgg ctccagtgga ggtgtcatct acctggtcac tgtcaccgct 
541 gctggtgtgg atcatcgagt aatcttgggg aatgag 
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APPENDIX 8.2 
LOCUS AY726003 471 bp mRNA linear ROD 28-SEP-2004 
DEFINITION Marmota monax low molecular mass protein 7 mRNA, partial cds. 
ACCESSION A Y726003 
VERSION AY726003.1 Gl:52547779 
SOURCE Marmota monax (woodchuck) 
FEATURES Location/Qualifiers 
source 1 . .471 
/organism="Marmota monax" 
/mol_ type="mRNA" 
/db_xref="taxon:9995" 
CDS <1 .. >471 
/note="LMP7; proteasome subunit" 
/codon_start=2 
/product="low molecular mass protein 7" 
/protein_id="AAU81925.1" 
/db xref="GI:52547780" 
/translation="VIVAVDSRASAGSYIATLRMNKVI El NPYLLGTMSGCAADCQYWE 
RLLAKECRL YYLRNGERISVSAASKLLSNMMCQYRGMGLSMGSMICGWDKKG 
PGLYYVDHNGTRLSGCMFSTGSGNSYAYGVMDSGYLPNLSPEEAYDLGRRAI 
VHATHRD" 
ORIGIN 
1 agttattgta gcagtggatt cccgggcctc ggctggaagt tacattgcca ccttaaggat 
61 gaacaaggtg attgagatta atccctacct gcttggcacc atgtctggct gtgcagcaga 
121 ctgtcagtac tgggagcgcc tgttggccaa agaatgcagg ctgtactact tgcggaatgg 
181 ggagcggatc tcagtgtcag ctgcctccaa actgctctcc aacatgatgt gtcagtaccg 
241 gggcatgggc ctctccatgg gcagtatgat ctgtggctgg gacaagaagg gtccaggact 
301 ttactatgtg gatcacaatg ggactcggct ctcaggatgt atgttctcca ccggtagtgg 
361 gaacagttat gcctacgggg ttatggacag tggctatctg cccaatctta gtcctgaaga 
421 agcttatgac cttggtcgca gggctattgt tcatgccact cacagagaca a 
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APPENDIX 8.3 
LOCUS AY726004 746 bp mRNA linear ROD 28-SEP-2004 
DEFINITION Marmota monax multicatalytic endopeptidase complex-like 1 
mRNA, partial cds. 
ACCESSION A Y726004 
VERSION AY726004.1 Gl:52547781 
SOURCE Marmota monax (woodchuck) 
FEATURES Location/Qualifiers 
source 1 .. 7 46 
/organism="Marmota monax" 
/mol_type="mRNA" 
/db _xref="taxon: 9995" 
CDS <1 .. >746 
/note="MECL-1; proteasome subunit" 
/codon start=3 
/prod uct="multicatalytic endopeptidase complex-like 1" 
/protein_id="AAU81926.1" 
/db xref="G1:52547782" 
/translation="RNASLERVLPGLRVPHARKTGTTIAGLVFRDGVILGADTRATNDS 
WADKNCEKIHFIAPKIYCCGAGV AADAEMTTRMAASNMELHAMSTGREPRVA 
TVTRLLRQTLFRYQGHVGASLIVGGVDL TGPQL YGVHPHGSYSRLPFTALGSG 
QDAALA VLEDRFQPNMTLEAAQGLLVEAITAGILGDLGSGGSVDACVITASGAQ 
LLRTLSSPTEPIKRPDSYCFAPGTTAIL TQTVKPLNLELLEET" 
ORIGIN 
1 agagaaacgc atccttggaa cgtgtccttc ccgggcttcg ggttcctcat gcgcgcaaga 
61 ctggcaccac catcgcaggc cttgtattcc gagacggggt catcctgggc gcggatacga 
121 gggccactaa cgattcagtc gtggcagaca agaattgcga gaagatccac ttcattgccc 
181 ccaaaatcta ctgctgtggg gctggagtag ccgcagacgc cgaaatgact acacggatgg 
241 ctgcatccaa catggagcta cacgcaatgt ccactggacg cgagcctcgc gtggccacgg 
301 tcactcgcct cctacgccag acgctattcc ggtaccaggg acacgtgggc gcatcgctga 
361 tcgtgggcgg agtagatctg accggaccgc aactctatgg cgtgcacccc cacggttcct 
421 acagccgact gccctttacg gctctgggct ccgggcagga cgcggccctg gcagtgctgg 
481 aggaccggtt ccagccaaac atgacgctgg aggctgcaca ggggctgctg gtggaagcta 
541 ttaccgcagg gatcctgggt gacttgggct ctgggggcag cgtggatgca tgtgtgatca 
601 ccgcatcagg tgcccagctg ctgcggacac tgagctcgcc cacagagcct ataaagaggc 
661 ctgatagcta ctgctttgca cctggaacca cagccattct gacccagaca gtgaagccat 
721 tgaacttgga gctcctagaa gaaact 
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APPENDIX 8.4 
LOCUS A Y726005 595 bp mRNA linear ROD 28-SEP-2004 
DEFINITION Marmota monax proteasome activator 28-alpha mRNA, partial cds. 
ACCESSION A Y726005 
VERSION AY726005.1 Gl:52547783 
SOURCE Marmota monax (woodchuck) 
FEATURES Location/Qualifiers 
source 1 .. 595 
/organism="Marmota monax" 
/mol_ type="mRNA" 
/db_xref="taxon:9995" 
CDS <1 .. >595 
/note="PA28a; proteasome subunit" 
/codon_ start=2 
/product="proteasome activator 28-alpha" 
/protein_id="AAU81927 .1" 
/db xref="GI:52547784" 
/translation="ISELDAFLKEPALNEVNLSNLKAPLDIPVPDPVKDKEKEDRKKQQE 
KEDKDEKKKGEDEDKGPPCGPVNCNEKIWLLQRLKPEIKDVIEQLNLVTTWLQ 
LQIPRIEDGNNFGVAVQEKVFELMTSLHTKLEGFHTQISKYFSERGDAVTKAAK 
QPHVGDYRQLVHELDEAEYRDIRLMVMEIRNAYAVLYDIILKNF" 
ORIGIN 
1 gatttctgag ttggatgcat ttttaaagga accagctctc aatgaagtca acctgagcaa 
61 tttgaaggcc cctttggaca tcccagtgcc tgatccagtc aaggacaaag agaaggagga 
121 tcggaagaaa cagcaggaga aggaagataa ggatgagaag aagaaagggg aagatgaaga 
181 caaaggtcct ccctgtggcc cagtgaactg caatgagaag attgtggtcc tcctgcaacg 
241 tctgaaacct gaaatcaagg atgtcatcga gcaactcaac ctggtcacta catggttgca 
301 gctacagata cctcggattg aggatgggaa taattttgga gtggctgtcc aggagaaggt 
361 atttgagctg atgactagcc ttcacaccaa gctggaaggc ttccacactc aaatctctaa 
421 gtatttctct gagcgtggtg atgcagttac caaagcagct aaacagcccc atgtgggtga 
481 ttatcggcag ctggtccatg agttggatga agcagagtac cgggacattc ggctgatggt 
541 catggagatc cgcaacgctt atgctgtgtt atatgacatc atcctgaaga acttt 
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APPENDIX 8.4 
LOCUS A Y726006 672 bp mRNA linear ROD 28-SEP-2004 
DEFINITION Marmota monax proteasome activator 28-beta mRNA, partial cds. 
ACCESSION A Y726006 
VERSION AY726006.1 Gl:52547785 
SOURCE Marmota monax (woodchuck) 
FEATURES Location/Qualifiers 
source 1 .. 672 
/organism="Marmota monax" 
/mol_ type="mRNA" 
/db_xref="taxon:9995" 
CDS <1 .. >672 
/note="PA28b; proteasome subunit" 
/codon start= 1 
/product="proteasome activator 28-beta" 
/protein_id="AAU81928.1" 
/db xref="GI:52547786" 
/translation="VRLSGEARKQVDVFRQNLFQEAEEFL YRFLPQKIMYLSQLLHEDS 
LNVADLTSLRAPLDIPIPDPPPKDDEMETDKQEKKEVPKCGFLPGNEKVLALLAL 
VKPEVWTLKEKCILVITWIQHLIPKIEDGNDFGVAIQEKVLERVNAVKTKVEAFQT 
TISKYFSERGDAVAKASKETHVMDYRALVHERDEAAYGELRAMVLDLRAFYAE 
L YHIISSNLEKIVNP" 
ORIGIN 
1 gtgcgcctga gtggggaggc ccgaaaacag gtggatgtct tcagacaaaa tcttttccag 
61 gaggctgagg aattcctcta cagattcttg ccacagaaaa tcatgtacct gagtcagctt 
121 ttgcacgagg actccctcaa tgtggctgac ctgacctccc tccgggcccc tctggacata 
181 cccatcccag accccccacc caaggatgat gagatggaaa cagataagca ggagaagaaa 
241 gaagtaccca agtgtggctt tctccccggg aatgagaagg tcctggccct gcttgctcta 
301 gttaagccag aagtctggac tctcaaagag aaatgtattc tggtgatcac ttggatccag 
361 catctgatcc ctaagattga ggatggaaat gattttgggg tggcaatcca ggagaaggtg 
421 ctggagaggg tgaatgctgt gaagacgaaa gtggaagcct ttcagacaac catttccaag 
481 tacttctcag aacgtgggga tgctgtggct aaggcctcca aggagaccca tgtaatggat · 
541 taccgggc-ct tagtgcatga gagagatgag gcagcctatg gggagctcag ggccatggtt 
601 ctggacctca gggccttcta tgctgagctt tatcatatca tcagcagcaa cctagagaaa 
661 attgtcaacc ca 




